

WO2006136823

Publication Title:

HETEROCYCLIC CONTAINING AMINES AS KINASE B INHIBITORS

Abstract:

Courtesy of <http://worldwide.espacenet.com>

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 December 2006 (28.12.2006)

PCT

(10) International Publication Number
WO 2006/136823 A1

(51) International Patent Classification:

C07D 333/20 (2006.01) **A61K 31/341** (2006.01)
C07D 401/10 (2006.01) **C07D 249/08** (2006.01)
A61K 31/381 (2006.01) **A61K 31/4196** (2006.01)
A61K 31/4409 (2006.01) **C07D 213/38** (2006.01)
A61K 31/506 (2006.01) **A61P 35/00** (2006.01)
C07D 307/52 (2006.01)

Road, Slough SL1 3WE (GB). **HAMLETT, Christopher** [GB/GB]; 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA (GB). **SORE, Hannah, Fiona** [GB/GB]; 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA (GB).

(21) International Application Number:

PCT/GB2006/002278

(22) International Filing Date: 21 June 2006 (21.06.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0512681.8 21 June 2005 (21.06.2005) GB
60/692,483 21 June 2005 (21.06.2005) US

(71) Applicants (for all designated States except US): **ASTEX THERAPEUTICS LIMITED** [GB/GB]; 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA (GB). **THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL** [GB/GB]; 123 Old Brompton Road, London SW7 3RP (GB). **CANCER RESEARCH TECHNOLOGY LIMITED** [GB/GB]; Sardinia House, 52 Sardinia Street, London WC2A 3NL (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BOYLE, Robert, George** [GB/GB]; 30 Catharine Street, Cambridge CB1 3AW (GB). **SAXTY, Gordon** [GB/GB]; 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA (GB). **VERDONK, Marinus, Leendert** [NL/GB]; 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA (GB). **TAYLOR, Richard, David** [GB/GB]; 208 Bath

(74) Agent: **HUTCHINS, Michael, Richard**; M. R. Hutchins & Co., 23 Mount Sion, Tunbridge Wells, Kent TN1 1TZ (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HETEROCYCLIC CONTAINING AMINES AS KINASE B INHIBITORS



(I)

(57) Abstract: The invention provides a compound of the formula (I) or a salt, solvate, tautomer or N-oxide thereof; for use as a PKB kinase inhibitor or PKA kinase inhibitor. In formula (I), A is a saturated hydrocarbon linker group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; HET is a monocyclic heterocyclic group; R¹ is an aryl or heteroaryl group; n is 0 to 4; and R², R³ and R⁴ are as defined in the claims, provided that HET is other than an unsubstituted or substituted pyrazole-4-yl group.

WO 2006/136823 A1

HETEROCYCLIC CONTAINING AMINES AS KINASE B INHIBITORS

This invention relates to aryl- and heteroaryl-alkylamine compounds that inhibit or modulate the activity of protein kinase B (PKB) and protein kinase A (PKA), to the use of the compounds in the treatment or prophylaxis of disease states or conditions mediated by PKB and PKA, and to novel compounds having PKB and PKA inhibitory or modulating activity. Also provided are pharmaceutical compositions containing the compounds and novel chemical intermediates.

Background of the Invention

Protein kinases constitute a large family of structurally related enzymes that are responsible for the control of a wide variety of signal transduction processes within the cell (Hardie, G. and Hanks, S. (1995) *The Protein Kinase Facts Book. I and II*, Academic Press, San Diego, CA). The kinases may be categorized into families by the substrates they phosphorylate (e.g., protein-tyrosine, protein-serine/threonine, lipids, etc.). Sequence motifs have been identified that generally correspond to each of these kinase families (e.g., Hanks, S.K., Hunter, T., *FASEB J.*, 9:576-596 (1995); Knighton, *et al.*, *Science*, 253:407-414 (1991); Hiles, *et al.*, *Cell*, 70:419-429 (1992); Kunz, *et al.*, *Cell*, 73:585-596 (1993); Garcia-Bustos, *et al.*, *EMBO J.*, 13:2352-2361 (1994)).

Protein kinases may be characterized by their regulation mechanisms. These mechanisms include, for example, autophosphorylation, transphosphorylation by other kinases, protein-protein interactions, protein-lipid interactions, and protein-polynucleotide interactions. An individual protein kinase may be regulated by more than one mechanism.

Kinases regulate many different cell processes including, but not limited to, proliferation, differentiation, apoptosis, motility, transcription, translation and other signalling processes, by adding phosphate groups to target proteins. These phosphorylation events act as molecular on/off switches that can modulate or regulate the target protein biological function. Phosphorylation of target proteins occurs in response to a variety of extracellular signals (hormones, neurotransmitters, growth and differentiation factors, etc.), cell cycle events, environmental or nutritional stresses, etc. The appropriate protein kinase functions in signalling pathways to activate or inactivate (either directly or indirectly), for example, a metabolic enzyme, regulatory protein, receptor, cytoskeletal protein, ion channel or pump, or transcription factor. Uncontrolled signalling due to defective control of protein

phosphorylation has been implicated in a number of diseases, including, for example, inflammation, cancer, allergy/asthma, diseases and conditions of the immune system, diseases and conditions of the central nervous system, and angiogenesis.

- Apoptosis or programmed cell death is an important physiological process which removes cells no longer required by an organism. The process is important in early embryonic growth and development allowing the non-necrotic controlled breakdown, removal and recovery of cellular components. The removal of cells by apoptosis is also important in the maintenance of chromosomal and genomic integrity of growing cell populations. There are several known checkpoints in the cell growth cycle at which DNA damage and genomic integrity are carefully monitored. The response to the detection of anomalies at such checkpoints is to arrest the growth of such cells and initiate repair processes. If the damage or anomalies cannot be repaired then apoptosis is initiated by the damaged cell in order to prevent the propagation of faults and errors. Cancerous cells consistently contain numerous mutations, errors or rearrangements in their chromosomal DNA. It is widely believed that this occurs in part because the majority of tumours have a defect in one or more of the processes responsible for initiation of the apoptotic process. Normal control mechanisms cannot kill the cancerous cells and the chromosomal or DNA coding errors continue to be propagated. As a consequence restoring these pro-apoptotic signals or suppressing unregulated survival signals is an attractive means of treating cancer.
- The signal transduction pathway containing the enzymes phosphatidylinositol 3-kinase (PI3K), PDK1 and PKB amongst others, has long been known to mediate increased resistance to apoptosis or survival responses in many cells. There is a substantial amount of data to indicate that this pathway is an important survival pathway used by many growth factors to suppress apoptosis. The enzyme PI3K is activated by a range of growth and survival factors e.g. EGF, PDGF and through the generation of polyphosphatidylinositols, initiates the activation of the downstream signalling events including the activity of the kinases PDK1 and protein kinase B (PKB) also known as Akt. This is also true in host tissues, e.g. vascular endothelial cells as well as neoplasias. PKB is a protein ser/thr kinase consisting of a kinase domain together with an N-terminal PH domain and C-terminal regulatory domain. The enzyme PKB itself is phosphorylated on Thr 308 by PDK1 and on Ser 473 by an as yet unidentified kinase. Full activation requires phosphorylation at both sites whilst association between PIP3 and the PH domain is required for anchoring of the

enzyme to the cytoplasmic face of the lipid membrane providing optimal access to substrates.

Activated PKB in turn phosphorylates a range of substrates contributing to the overall survival response. Whilst we cannot be certain that we understand all of the factors responsible for mediating the PKB dependent survival response, some important actions are believed to be phosphorylation and inactivation of the pro-apoptotic factor BAD and caspase 9, phosphorylation of Forkhead transcription factors e.g. FKHR leading to their exclusion from the nucleus, and activation of the NfκappaB pathway by phosphorylation of upstream kinases in the cascade.

- 10 In addition to the anti-apoptotic and pro-survival actions of the PKB pathway, the enzyme also plays an important role in promoting cell proliferation. This action is again likely to be mediated via several actions, some of which are thought to be phosphorylation and inactivation of the cyclin dependent kinase inhibitor of p21^{Cip1/WAF1}, and phosphorylation and activation of mTOR, a kinase controlling several aspects of cell growth.
- 15 The phosphatase PTEN which dephosphorylates and inactivates polyphosphatidyl-inositols is a key tumour suppressor protein which normally acts to regulate the PI3K/PKB survival pathway. The significance of the PI3K/PKB pathway in tumourigenesis can be judged from the observation that PTEN is one of the most common targets of mutation in human tumours, with mutations in this phosphatase having been found in ~50% or more of
- 20 melanomas (Guldberg et al 1997, Cancer Research 57, 3660-3663) and advanced prostate cancers (Cairns et al 1997 Cancer Research 57, 4997). These observations and others suggest that a wide range of tumour types are dependent on the enhanced PKB activity for growth and survival and would respond therapeutically to appropriate inhibitors of PKB.

- There are 3 closely related isoforms of PKB called alpha, beta and gamma, which genetic studies suggest have distinct but overlapping functions. Evidence suggests that they can all independently play a role in cancer. For example PKB beta has been found to be over-expressed or activated in 10 – 40% of ovarian and pancreatic cancers (Bellacosa et al 1995, Int. J. Cancer 64, 280 – 285; Cheng et al 1996, PNAS 93, 3636-3641; Yuan et al 2000, Oncogene 19, 2324 – 2330), PKB alpha is amplified in human gastric, prostate and breast cancer (Staal 1987, PNAS 84, 5034 – 5037; Sun et al 2001, Am. J. Pathol. 159, 431 – 437) and increased PKB gamma activity has been observed in steroid independent breast and prostate cell lines (Nakatani et al 1999, J. Biol. Chem. 274, 21528 – 21532).
- 25
- 30

The PKB pathway also functions in the growth and survival of normal tissues and may be regulated during normal physiology to control cell and tissue function. Thus disorders associated with undesirable proliferation and survival of normal cells and tissues may also benefit therapeutically from treatment with a PKB inhibitor. Examples of such disorders are disorders of immune cells associated with prolonged expansion and survival of cell population leading to a prolonged or up regulated immune response. For example, T and B lymphocyte response to cognate antigens or growth factors such as interleukin-2 activates the PI3K/PKB pathway and is responsible for maintaining the survival of the antigen specific lymphocyte clones during the immune response. Under conditions in which lymphocytes and other immune cells are responding to inappropriate self or foreign antigens, or in which other abnormalities lead to prolonged activation, the PKB pathway contributes an important survival signal preventing the normal mechanisms by which the immune response is terminated via apoptosis of the activated cell population. There is a considerable amount of evidence demonstrating the expansion of lymphocyte populations responding to self antigens in autoimmune conditions such as multiple sclerosis and arthritis. Expansion of lymphocyte populations responding inappropriately to foreign antigens is a feature of another set of conditions such as allergic responses and asthma. In summary inhibition of PKB could provide a beneficial treatment for immune disorders.

Other examples of inappropriate expansion, growth, proliferation, hyperplasia and survival of normal cells in which PKB may play a role include but are not limited to atherosclerosis, cardiac myopathy and glomerulonephritis.

In addition to the role in cell growth and survival, the PKB pathway functions in the control of glucose metabolism by insulin. Available evidence from mice deficient in the alpha and beta isoforms of PKB suggests that this action is mediated by the beta isoform. As a consequence, modulators of PKB activity may also find utility in diseases in which there is a dysfunction of glucose metabolism and energy storage such as diabetes, metabolic disease and obesity.

Cyclic AMP-dependent protein kinase (PKA) is a serine/threonine protein kinase that phosphorylates a wide range of substrates and is involved in the regulation of many cellular processes including cell growth, cell differentiation, ion-channel conductivity, gene transcription and synaptic release of neurotransmitters. In its inactive form, the PKA holoenzyme is a tetramer comprising two regulatory subunits and two catalytic subunits.

PKA acts as a link between G-protein mediated signal transduction events and the cellular processes that they regulate. Binding of a hormone ligand such as glucagon to a transmembrane receptor activates a receptor-coupled G-protein (GTP-binding and hydrolyzing protein). Upon activation, the alpha subunit of the G protein dissociates and binds to and activates adenylate cyclase, which in turn converts ATP to cyclic-AMP (cAMP). The cAMP thus produced then binds to the regulatory subunits of PKA leading to dissociation of the associated catalytic subunits. The catalytic subunits of PKA, which are inactive when associated with the regulatory sub-units, become active upon dissociation and take part in the phosphorylation of other regulatory proteins.

For example, the catalytic sub-unit of PKA phosphorylates the kinase Phosphorylase Kinase which is involved in the phosphorylation of Phosphorylase, the enzyme responsible for breaking down glycogen to release glucose. PKA is also involved in the regulation of glucose levels by phosphorylating and deactivating glycogen synthase. Thus, modulators of PKA activity (which modulators may increase or decrease PKA activity) may be useful in the treatment or management of diseases in which there is a dysfunction of glucose metabolism and energy storage such as diabetes, metabolic disease and obesity.

PKA has also been established as an acute inhibitor of T cell activation. Anndahl *et al*, have investigated the possible role of PKA type I in HIV-induced T cell dysfunction on the basis that T cells from HIV-infected patients have increased levels of cAMP and are more sensitive to inhibition by cAMP analogues than are normal T cells. From their studies, they concluded that increased activation of PKA type I may contribute to progressive T cell dysfunction in HIV infection and that PKA type I may therefore be a potential target for immunomodulating therapy.-Aandahl, E. M., Aukrust, P., Skålhegg, B. S., Müller, F., Frøland, S. S., Hansson, V., Taskén, K. *Protein kinase A type I antagonist restores immune responses of T cells from HIV-infected patients. FASEB J.* 12, 855--862 (1998).

It has also been recognised that mutations in the regulatory sub-unit of PKA can lead to hyperactivation in endocrine tissue.

Because of the diversity and importance of PKA as a messenger in cell regulation, abnormal responses of cAMP can lead to a variety of human diseases such as irregular cell growth and proliferation (Stratakis, C.A.; Cho-Chung, Y.S.; Protein Kinase A and human diseases. *Trends Endrocri. Metab.* 2002, 13, 50-52). Over-expression of PKA has been observed in a variety of human cancer cells including those from ovarian, breast and colon

patients. Inhibition of PKA would therefore be an approach to treatment of cancer (Li, Q.; Zhu, G-D.; *Current Topics in Medicinal Chemistry*, 2002, 2, 939-971).

For a review of the role of PKA in human disease, see for example, *Protein Kinase A and Human Disease*, Edited by Constantine A. Stratakis, Annals of the New York Academy of Sciences, Volume 968, 2002, ISBN 1-57331-412-9.

hERG

In the late 1990s a number of drugs, approved by the US FDA, had to be withdrawn from sale in the US when it was discovered they were implicated in deaths caused by heart malfunction. It was subsequently found that a side effect of these drugs was the development of arrhythmias caused by the blocking of hERG channels in heart cells. The hERG channel is one of a family of potassium ion channels the first member of which was identified in the late 1980s in a mutant *Drosophila melanogaster* fruitfly (see Jan, L.Y. and Jan, Y.N. (1990). A Superfamily of Ion Channels. *Nature*, 345(6277):672). The biophysical properties of the hERG potassium ion channel are described in Sanguinetti, M.C., Jiang, C., Curran, M.E., and Keating, M.T. (1995). A Mechanistic Link Between an Inherited and an Acquired Cardiac Arrhythmia: HERG encodes the I_{Kr} potassium channel. *Cell*, 81:299-307, and Trudeau, M.C., Warmke, J.W., Ganetzky, B., and Robertson, G.A. (1995). HERG, a Human Inward Rectifier in the Voltage-Gated Potassium Channel Family. *Science*, 269:92-95.

The elimination of hERG blocking activity remains an important consideration in the development of any new drug.

Prior Art

Several classes of compounds have been disclosed as having PKA and PKB inhibitory activity.

For example, a class of isoquinolinyl-sulphonamido-diamines having PKB inhibitory activity is disclosed in WO 01/91754 (Yissum).

WO 00/07996 (Chiron) discloses substituted pyrazoles having estrogen receptor agonist activity. The compounds are described as being useful in treating or preventing *inter alia* estrogen-receptor mediated breast cancer. PKB inhibitory activity is not disclosed.

WO 00/31063 (Searle) discloses substituted pyrazole compounds as p38 kinase inhibitors.

WO 01/32653 (Cephalon) discloses a class of pyrazolone kinase inhibitors. WO 03/059884 (X-Ceptor Therapeutics) discloses N-substituted pyridine compounds as modulators of nuclear receptors.

- 5 WO 03/068230 (Pharmacia) discloses substituted pyridones as p38 MAP kinase modulators.

WO 00/66562 (Dr Reddy's Research Foundation) discloses a class of 1-phenyl-substituted pyrazoles for use as anti-inflammatory agents. The 1-phenyl group is substituted by a sulphur-containing substituent as a sulphonamide or sulphonyl group.

- 10 Simig *et al.*, *Acta Chimica Hungarica*, 118 (4), pp 309-314 (1985) describes the preparation of several morpholinyl-substituted diphenylacetamide compounds from 2-bromo-*N,N*-dimethyl-2,2-diphenylacetamide. No therapeutic uses or biological activities are described for the compounds.

- 15 Nagarajan *et al.*, *Tetrahedron Letters*, No. 22, pp 2717-2720 (1968) describes the preparation of N-methylpiperazinyl-substituted diphenylacetamide compounds from 2-chloro-*N,N*-dimethyl-2,2-diphenylacetamide but no therapeutic uses or biological activities are disclosed.


- 20 WO 00/14066 (Pfizer) and WO 00/39091 (Pfizer) each disclose a class of 4,4-diphenylpiperidine compounds having opioid receptor activity which are stated to be useful in treating neurological and gastrointestinal disorders, and various other diseases including inflammatory conditions such as psoriasis.

WO 91/11445 (Dupont Merck) discloses a class of pyridylphenol carbinols as anti-inflammatory agents.

Summary of the Invention

- 25 The invention provides compounds that have protein kinase B (PKB) and protein kinase A (PKA) inhibiting or modulating activity, and which it is envisaged will be useful in preventing or treating disease states or conditions mediated by PKB or PKA.

In a first aspect, the invention provides a compound for use in the prophylaxis or treatment of a disease state or condition mediated by protein kinase B, the compound being a compound of the formula (I):



- 5 or a salt, solvate, tautomer or N-oxide thereof;
 wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R¹ and NR²R³ and a maximum chain length of 4 atoms extending between E and NR²R³, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen
 10 atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom α with respect to the NR²R³ group and provided that the oxo group when present is located at a carbon atom α with respect to the NR²R³ group;
- 15 E is a monocyclic or bicyclic carbocyclic or heterocyclic group;
 HET is a monocyclic heterocyclic group having 4 to 7 ring members of which up to 4 are heteroatoms selected from O, N and S;
 R¹ is an aryl or heteroaryl group;
 R² and R³ are independently selected from hydrogen, C₁₋₄ hydrocarbyl and C₁₋₄ acyl
 20 wherein the hydrocarbyl and acyl moieties are optionally substituted by one or more substituents selected from fluorine, hydroxy, amino, methylamino, dimethylamino and methoxy;
 or R² and R³ together with the nitrogen atom to which they are attached form a cyclic group selected from an imidazole group and a saturated monocyclic heterocyclic
 25 group having 4-7 ring members and optionally containing a second heteroatom ring member selected from O and N;
 or one of R² and R³ together with the nitrogen atom to which they are attached and one or more atoms from the linker group A form a saturated monocyclic heterocyclic group

having 4-7 ring members and optionally containing a second heteroatom ring member selected from O and N;

or NR^2R^3 and the carbon atom of linker group A to which it is attached together form a cyano group;

5 n is 0 to 4;

each R^4 is independently selected from oxo; halogen; C_{1-6} hydrocarbyl optionally substituted by halogen, hydroxy or C_{1-2} alkoxy; cyano; C_{1-6} hydrocarbyloxy optionally substituted by halogen, hydroxy or C_{1-2} alkoxy; CONH_2 ; CONHR^9 ; CF_3 ; NH_2 ; NHCOR^9 ; NHCONHR^9 ; and NHR^9 ;

10 R^9 is a group R^{9a} or $(\text{CH}_2)\text{R}^{9a}$, wherein R^{9a} is a monocyclic or bicyclic group which may be carbocyclic or heterocyclic;

the carbocyclic group or heterocyclic group R^{9a} being optionally substituted by one or more substituents selected from halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, mono- or di- C_{1-4} hydrocarbylamino; a group $\text{R}^a\text{-R}^b$ wherein R^a is a bond,
15 O, CO, $\text{X}^1\text{C}(\text{X}^2)$, $\text{C}(\text{X}^2)\text{X}^1$, $\text{X}^1\text{C}(\text{X}^2)\text{X}^1$, S, SO, SO_2 , NR^c , SO_2NR^c or NR^cSO_2 ; and R^b is selected from hydrogen, heterocyclic groups having from 3 to 12 ring members, and a C_{1-8} hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, carboxy, amino, mono- or di- C_{1-4} hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or
20 more carbon atoms of the C_{1-8} hydrocarbyl group may optionally be replaced by O, S, SO, SO_2 , NR^c , $\text{X}^1\text{C}(\text{X}^2)$, $\text{C}(\text{X}^2)\text{X}^1$ or $\text{X}^1\text{C}(\text{X}^2)\text{X}^1$;


R^c is selected from hydrogen and C_{1-4} hydrocarbyl; and

X^1 is O, S or NR^c and X^2 is =O, =S or = NR^c ;

provided that:

25 (a-1) HET is other than a substituted or unsubstituted pyrazole-4-yl group.

In another aspect, the invention provides a compound for use in medicine having the formula (Ia):



or a salt, solvate, tautomer or N-oxide thereof;

wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R^1 and NR^2R^3 and a maximum chain length of 4 atoms extending between E and NR^2R^3 , wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom α with respect to the NR^2R^3 group and provided that the oxo group when present is located at a carbon atom α with respect to the NR^2R^3 group;

E is a monocyclic or bicyclic carbocyclic or heterocyclic group;

HET is a monocyclic heterocyclic group having 4 to 7 ring members of which up to 4 are heteroatoms selected from O, N and S;

R^1 is an aryl or heteroaryl group;

R^2 and R^3 are independently selected from hydrogen, C_{1-4} hydrocarbyl and C_{1-4} acyl wherein the hydrocarbyl and acyl moieties are optionally substituted by one or more substituents selected from fluorine, hydroxy, amino, methylamino, dimethylamino and methoxy;

or R^2 and R^3 together with the nitrogen atom to which they are attached form a cyclic group selected from an imidazole group and a saturated monocyclic heterocyclic group having 4-7 ring members and optionally containing a second heteroatom ring member selected from O and N;

or one of R^2 and R^3 together with the nitrogen atom to which they are attached and one or more atoms from the linker group A form a saturated monocyclic heterocyclic group having 4-7 ring members and optionally containing a second heteroatom ring member selected from O and N;

or NR^2R^3 and the carbon atom of linker group A to which it is attached together form a cyano group;

n is 0 to 4;

each R^4 is independently selected from oxo; halogen; C_{1-6} hydrocarbyl optionally substituted by halogen, hydroxy or C_{1-2} alkoxy; cyano; C_{1-6} hydrocarbyloxy optionally substituted by halogen, hydroxy or C_{1-2} alkoxy; $CONH_2$; $CONHR^9$; CF_3 ; NH_2 ; $NHCOR^9$; $NHCONHR^9$; and NHR^9 ;

R^9 is a group R^{9a} or $(CH_2)R^{9a}$, wherein R^{9a} is a monocyclic or bicyclic group which may be carbocyclic or heterocyclic;

the carbocyclic group or heterocyclic group R^{9a} being optionally substituted by one or more substituents selected from halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, mono- or di- C_{1-4} hydrocarbylamino; a group R^a-R^b wherein R^a is a bond, O, CO, $X^1C(X^2)$, $C(X^2)X^1$, $X^1C(X^2)X^1$, S, SO, SO_2 , NR^c , SO_2NR^c or NR^cSO_2 ; and R^b is selected from hydrogen, heterocyclic groups having from 3 to 12 ring members, and a C_{1-8} hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, carboxy, amino, mono- or di- C_{1-4} hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C_{1-8} hydrocarbyl group may optionally be replaced by O, S, SO, SO_2 , NR^c , $X^1C(X^2)$, $C(X^2)X^1$ or $X^1C(X^2)X^1$;


R^c is selected from hydrogen and C_{1-4} hydrocarbyl; and

X^1 is O, S or NR^c and X^2 is =O, =S or = NR^c ;

provided that:

- (a-1) HET is other than a substituted or unsubstituted pyrazole-4-yl group;
- (b-1) when E is phenyl, A is a saturated hydrocarbyl group bearing a hydroxy substituent and NR^2R^3 forms an imidazolyl group, then HET is other than a pyridyl group; and
- (b-2) when HET is a thienyl group, E is an optionally substituted phenyl group and the moiety ANR^2R^3 forms an optionally substituted piperidine group, then R^1 is other than a phenyl group bearing a substituent at the *meta* position thereof and optionally a second substituent.

In a further aspect, the invention provides a compound of the formula (Ib):



or a salt, solvate, tautomer or N-oxide thereof;

wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R^1 and NR^2R^3 and a maximum chain length of 4 atoms extending between E and NR^2R^3 , wherein one of

the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom α with respect to the NR^2R^3 group and
5 provided that the oxo group when present is located at a carbon atom α with respect to the NR^2R^3 group;

E is a monocyclic or bicyclic carbocyclic or heterocyclic group;

HET is a monocyclic heterocyclic group having 4 to 7 ring members of which up to 4 are heteroatoms selected from O, N and S;

10 R^1 is an aryl or heteroaryl group;

R^2 and R^3 are independently selected from hydrogen, C_{1-4} hydrocarbyl and C_{1-4} acyl wherein the hydrocarbyl and acyl moieties are optionally substituted by one or more substituents selected from fluorine, hydroxy, amino, methylamino, dimethylamino and methoxy;

15 or R^2 and R^3 together with the nitrogen atom to which they are attached form a cyclic group selected from an imidazole group and a saturated monocyclic heterocyclic group having 4-7 ring members and optionally containing a second heteroatom ring member selected from O and N;

20 or one of R^2 and R^3 together with the nitrogen atom to which they are attached and one or more atoms from the linker group A form a saturated monocyclic heterocyclic group having 4-7 ring members and optionally containing a second heteroatom ring member selected from O and N;

or NR^2R^3 and the carbon atom of linker group A to which it is attached together form a cyano group;

25 n is 0 to 4;

each R^4 is independently selected from oxo; halogen; C_{1-6} hydrocarbyl optionally substituted by halogen, hydroxy or C_{1-2} alkoxy; cyano; C_{1-6} hydrocarbyloxy optionally substituted by halogen, hydroxy or C_{1-2} alkoxy; CONH_2 ; CONHR^9 ; CF_3 ; NH_2 ; NHCOR^9 ; NHCONHR^9 ; and NHR^9 ;

30 R^9 is a group R^{9a} or $(\text{CH}_2)\text{R}^{9a}$, wherein R^{9a} is a monocyclic or bicyclic group which may be carbocyclic or heterocyclic;

the carbocyclic group or heterocyclic group R^{9a} being optionally substituted by one or more substituents selected from halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, mono- or di- C_{1-4} hydrocarbylamino; a group $\text{R}^a\text{-R}^b$ wherein R^a is a bond,

O, CO, $X^1C(X^2)$, $C(X^2)X^1$, $X^1C(X^2)X^1$, S, SO, SO₂, NR^c, SO₂NR^c or NR^cSO₂; and R^b is selected from hydrogen, heterocyclic groups having from 3 to 12 ring members, and a C₁₋₈ hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, carboxy, amino, mono- or di-C₁₋₄ hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C₁₋₈ hydrocarbyl group may optionally be replaced by O, S, SO, SO₂, NR^c, $X^1C(X^2)$, $C(X^2)X^1$ or $X^1C(X^2)X^1$;

R^c is selected from hydrogen and C₁₋₄ hydrocarbyl; and

X¹ is O, S or NR^c and X² is =O, =S or =NR^c;

provided that:

(a-1) HET is other than a substituted or unsubstituted pyrazole-4-yl group;

(b-1) when E is phenyl, A is a saturated hydrocarbyl group bearing a hydroxy substituent and NR²R³ forms an imidazolyl group, then HET is other than a pyridyl group;

(b-2) when HET is a thienyl group, E is an optionally substituted phenyl group and the moiety ANR²R³ forms an optionally substituted piperidine group, then R¹ is other than a phenyl group bearing a substituent at the *meta* position thereof and optionally a second substituent; and

(c-1) when E is phenyl and the moiety R¹ANR²R³ is an N-monosubstituted or N,N-disubstituted phenylacetamide group, then HET is other than a morpholine or N-methylpiperazine group.

The invention further provides:

- A compound *per se* of the formula (II), (III), (IV), (V), (VI), (VII) or any other sub-group or embodiment of the formula (I) as defined herein.
- A compound of the formula (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) or any sub-group thereof as defined herein for use in the prophylaxis or treatment of a disease state or condition mediated by protein kinase B.
- The use of a compound of formula (I), (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) or any sub-group thereof as defined herein for the manufacture of a medicament for the prophylaxis or treatment of a disease state or condition mediated by protein kinase B.

- A method for the prophylaxis or treatment of a disease state or condition mediated by protein kinase B, which method comprises administering to a subject in need thereof a compound of the formula (I), (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) or any sub-group thereof as defined herein.
- 5 • A compound of the formula (I), (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) or any sub-group thereof as defined herein for use in treating a disease or condition comprising or arising from abnormal cell growth or abnormally arrested cell death in a mammal.
- 10 • The use of a compound of (I), (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) or any sub-group thereof as defined herein for the manufacture of a medicament for treating a disease or condition comprising or arising from abnormal cell growth or abnormally arrested cell death in a mammal.
- 15 • A method for treating a disease or condition comprising or arising from abnormal cell growth or abnormally arrested cell death in a mammal, the method comprising administering to the mammal a compound of the formula (I), (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) or any sub-group thereof as defined herein in an amount effective to inhibit protein kinase B activity.
- 20 • A method of inhibiting protein kinase B, which method comprises contacting the kinase with a kinase-inhibiting compound of the formula (I), (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) or any sub-group thereof as defined herein.
- 25 • A method of modulating a cellular process (for example cell division) by inhibiting the activity of a protein kinase B using a compound of the formula (I), (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) or any sub-group thereof as defined herein.
- 30 • A compound of the formula (I), (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) or any sub-group or embodiment thereof as defined herein for use in the prophylaxis or treatment of a disease state or condition mediated by protein kinase A.
- The use of a compound of formula (I), (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) or any sub-group or embodiment thereof as defined herein for the manufacture of a medicament for the prophylaxis or treatment of a disease state or condition mediated by protein kinase A.

- A method for the prophylaxis or treatment of a disease state or condition mediated by protein kinase A, which method comprises administering to a subject in need thereof a compound of the formula (I), (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) or any sub-group or embodiment thereof as defined herein.
- 5 • A method for treating a disease or condition comprising or arising from abnormal cell growth or abnormally arrested cell death in a mammal, the method comprising administering to the mammal a compound of the formula (I), (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) or any sub-group or embodiment thereof as defined herein in an amount effective to inhibit protein kinase A activity.
- 10 • A method of inhibiting protein kinase A, which method comprises contacting the kinase with a kinase-inhibiting compound of the formula (I), (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) or any sub-group or embodiment thereof as defined herein.
- A method of modulating a cellular process (for example cell division) by inhibiting the activity of a protein kinase A using a compound of the formula (I), (Ia), (Ib),
15 (II), (III), (IV), (V), (VI), (VII) or any sub-group or embodiment thereof as defined herein.
- The use of a compound of the formula (I), (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) or any sub-group thereof as defined herein for the manufacture of a medicament for the prophylaxis or treatment of a disease state or condition arising from abnormal
20 cell growth or abnormally arrested cell death.
- A method for treating a disease or condition comprising or arising from abnormal cell growth in a mammal, which method comprises administering to the mammal a compound of the formula (I), (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) or any sub-group thereof as defined herein in an amount effective in inhibiting abnormal cell
25 growth or abnormally arrested cell death.
- A method for alleviating or reducing the incidence of a disease or condition comprising or arising from abnormal cell growth or abnormally arrested cell death in a mammal, which method comprises administering to the mammal a compound of the formula (I), (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) or any sub-group
30 thereof as defined herein in an amount effective in inhibiting abnormal cell growth.

- A pharmaceutical composition comprising a novel compound of the formula (I), (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) or any sub-group thereof as defined herein and a pharmaceutically acceptable carrier.
- 5 • A compound of the formula (I), (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) or any sub-group thereof as defined herein for use in medicine.
- The use of a compound of the formula (I), (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) or any sub-group thereof as defined herein for the manufacture of a medicament for the prophylaxis or treatment of any one of the disease states or conditions disclosed herein.
- 10 • A method for the treatment or prophylaxis of any one of the disease states or conditions disclosed herein, which method comprises administering to a patient (e.g. a patient in need thereof) a compound (e.g. a therapeutically effective amount) of the formula (I), (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) or any sub-group thereof as defined herein.
- 15 • A method for alleviating or reducing the incidence of a disease state or condition disclosed herein, which method comprises administering to a patient (e.g. a patient in need thereof) a compound (e.g. a therapeutically effective amount) of the formula (I), (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) or any sub-group thereof as defined herein.
- 20 • A method for the diagnosis and treatment of a disease state or condition mediated by protein kinase B, which method comprises (i) screening a patient to determine whether a disease or condition from which the patient is or may be suffering is one which would be susceptible to treatment with a compound having activity against protein kinase B; and (ii) where it is indicated that the disease or condition from
25 which the patient is thus susceptible, thereafter administering to the patient a compound of the formula (I), (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) or any sub-group thereof as defined herein.
- The use of a compound of the formula (I), (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) or any sub-group thereof as defined herein for the manufacture of a medicament for
30 the treatment or prophylaxis of a disease state or condition in a patient who has

been screened and has been determined as suffering from, or being at risk of suffering from, a disease or condition which would be susceptible to treatment with a compound having activity against protein kinase B.

- 5 • A method for the diagnosis and treatment of a disease state or condition mediated by protein kinase A, which method comprises (i) screening a patient to determine whether a disease or condition from which the patient is or may be suffering is one which would be susceptible to treatment with a compound having activity against protein kinase A; and (ii) where it is indicated that the disease or condition from which the patient is thus susceptible, thereafter administering to the patient a
10 compound of the formula (I), (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) or any sub-group or embodiment thereof as defined herein.
- 15 • The use of a compound of the formula (I), (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) or any sub-group or embodiment thereof as defined herein for the manufacture of a medicament for the treatment or prophylaxis of a disease state or condition in a patient who has been screened and has been determined as suffering from, or being at risk of suffering from, a disease or condition which would be susceptible to treatment with a compound having activity against protein kinase A.

Where they do not already apply, any one or more of the following provisos may apply in any combination to each of formulae (I), (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) and any
20 other sub-group of compounds within formula (I):

Proviso (a-1)

Proviso (b-1)

Proviso (b-2)

Proviso (c-1)

- 25 (d-1) when E is an optionally substituted phenyl group or pyridyl group and the moiety ANR^2R^3 forms an optionally substituted piperidine group or optionally substituted morpholine group, then R^1 may be other than phenyl group substituted at the *meta* position thereof with a hydroxy, alkoxy, methoxy, fluorine, ester, amide, sulphonamide or carbinol group and optionally bearing a second substituent.

(d-2) when E is an optionally substituted phenyl group or pyridyl group, the moiety ANR² forms a piperidine group or morpholine group, and R¹ is a phenyl group substituted at the *meta* position thereof and optionally bearing a second substituent, then R³ may be hydrogen.

- 5 (d-3) when E is phenyl, HET is pyridyl, piperidinyl or pyrrolidinyl, and A is a saturated hydrocarbon group bearing a hydroxy substituent, then the moiety NR²R³ may be other than an imidazole group.

(d-4) the moiety NR²R³ may be other than an imidazole group.

The provisos (a-1) to (d-4) are directed to the following prior art documents:

(a-1)	WO 2005/061463 (Astex)
(b-1)	WO 91/11445 (Dupont Merck)
(b-2)	WO 00/39091 (Pfizer)
(c-1)	Simig <i>et al.</i> , <i>Acta Chimica Hungarica</i> , 118 (4), pp 309-314 (1985) and Nagarajan <i>et al.</i> , <i>Tetrahedron Letters</i> , No. 22, pp 2717-2720 (1968)
(d-1)	WO 00/14066 (Pfizer) & WO 00/39091 (Pfizer)
(d-2)	WO 00/14066 (Pfizer) & WO 00/39091 (Pfizer)
(d-3)	WO 91/11445 (Dupont Merck)
(d-4)	WO 91/11445 (Dupont Merck)


10

General Preferences and Definitions

The following general preferences and definitions shall apply to each of the moieties A, E, R¹ to R⁴ and R⁹ and any sub-definition, sub-group or embodiment thereof, unless the context indicates otherwise.

Any references to Formula (I) herein shall be taken also to refer to formulae (Ia), (Ib), (II), (III), (IV), (V), (VI), (VII) and any other sub-group of compounds within formula (I) unless the context requires otherwise.

In this application, the moiety:



5

may be referred to for convenience as “the cyclic group HET” or just “HET”.

References to “carbocyclic” and “heterocyclic” groups as used herein shall, unless the context indicates otherwise, include both aromatic and non-aromatic ring systems. In general, such groups may be monocyclic or bicyclic and may contain, for example, 3 to 12 ring members, more usually 5 to 10 ring members. Examples of monocyclic groups are groups containing 3, 4, 5, 6, 7, and 8 ring members, more usually 3 to 7, and preferably 5 or 6 ring members. Examples of bicyclic groups are those containing 8, 9, 10, 11 and 12 ring members, and more usually 9 or 10 ring members.

The carbocyclic or heterocyclic groups can be aryl or heteroaryl groups having from 5 to 12 ring members, more usually from 5 to 10 ring members. The term “aryl” as used herein refers to a carbocyclic group having aromatic character and the term “heteroaryl” is used herein to denote a heterocyclic group having aromatic character. The terms “aryl” and “heteroaryl” embrace polycyclic (e.g. bicyclic) ring systems wherein one or more rings are non-aromatic, provided that at least one ring is aromatic. In such polycyclic systems, the group may be attached by the aromatic ring, or by a non-aromatic ring. The aryl or heteroaryl groups can be monocyclic or bicyclic groups and can be unsubstituted or substituted with one or more substituents, for example one or more groups R^{10} as defined herein.

The term non-aromatic group embraces unsaturated ring systems without aromatic character, partially saturated and fully saturated carbocyclic and heterocyclic ring systems. The terms “unsaturated” and “partially saturated” refer to rings wherein the ring structure(s) contains atoms sharing more than one valence bond i.e. the ring contains at least one multiple bond e.g. a $C=C$, $C\equiv C$ or $N=C$ bond. The term “fully saturated” refers to rings where there are no multiple bonds between ring atoms. Saturated carbocyclic groups

include cycloalkyl groups as defined below. Partially saturated carbocyclic groups include cycloalkenyl groups as defined below, for example cyclopentenyl, cycloheptenyl and cyclooctenyl.

- 5 Examples of heteroaryl groups are monocyclic and bicyclic groups containing from five to twelve ring members, and more usually from five to ten ring members. The heteroaryl group can be, for example, a five membered or six membered monocyclic ring or a bicyclic structure formed from fused five and six membered rings or two fused six membered rings. Each ring may contain up to about four heteroatoms typically selected from nitrogen, sulphur and oxygen. Typically the heteroaryl ring will contain up to 3 heteroatoms, more
10 usually up to 2, for example a single heteroatom. In one embodiment, the heteroaryl ring contains at least one ring nitrogen atom. The nitrogen atoms in the heteroaryl rings can be basic, as in the case of an imidazole or pyridine, or essentially non-basic as in the case of an indole or pyrrole nitrogen. In general the number of basic nitrogen atoms present in the heteroaryl group, including any amino group substituents of the ring, will be less than five.
- 15 Examples of five membered heteroaryl groups include but are not limited to pyrrole, furan, thiophene, imidazole, furazan, oxazole, oxadiazole, oxatriazole, isoxazole, thiazole, isothiazole, pyrazole, triazole and tetrazole groups.

Examples of six membered heteroaryl groups include but are not limited to pyridine, pyrazine, pyridazine, pyrimidine and triazine.

- 20 A bicyclic heteroaryl group may be, for example, a group selected from:
- a) a benzene ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms;
 - b) a pyridine ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms;
 - 25 c) a pyrimidine ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;
 - d) a pyrrole ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms;
 - 30 e) a pyrazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;

- f) a pyrazine ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;
 - g) an imidazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;
 - 5 h) an oxazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;
 - i) an isoxazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;
 - 10 j) a thiazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;
 - k) an isothiazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;
 - l) a thiophene ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms;
 - 15 m) a furan ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms;
 - n) a cyclohexyl ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; and
 - o) a cyclopentyl ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms.
- 20 Examples of bicyclic heteroaryl groups containing a six membered ring fused to a five membered ring include but are not limited to benzfuran, benzthiophene, benzimidazole, benzoxazole, benzisoxazole, benzthiazole, benzisothiazole, isobenzofuran, indole, isoindole, indolizine, indoline, isoindoline, purine (e.g., adenine, guanine), indazole, benzodioxole and pyrazolopyridine groups.
- 25 Examples of bicyclic heteroaryl groups containing two fused six membered rings include but are not limited to quinoline, isoquinoline, chroman, thiochroman, chromene, isochromene, isochroman, benzodioxan, quinolizine, benzoxazine, benzodiazine, pyridopyridine, quinoxaline, quinazoline, cinnoline, phthalazine, naphthyridine and pteridine groups.

Examples of polycyclic aryl and heteroaryl groups containing an aromatic ring and a non-aromatic ring include tetrahydronaphthalene, tetrahydroisoquinoline, tetrahydroquinoline, dihydrobenzthiene, dihydrobenzofuran, 2,3-dihydro-benzo[1,4]dioxine, benzo[1,3]dioxole, 4,5,6,7-tetrahydrobenzofuran, indoline and indane groups.

- 5 Examples of carbocyclic aryl groups include phenyl, naphthyl, indenyl, and tetrahydronaphthyl groups.

Examples of non-aromatic heterocyclic groups are groups having from 3 to 12 ring members, more usually 5 to 10 ring members. Such groups can be monocyclic or bicyclic, for example, and typically have from 1 to 5 heteroatom ring members (more usually 1, 2, 3
10 or 4 heteroatom ring members), usually selected from nitrogen, oxygen and sulphur.

The heterocyclic groups can contain, for example, cyclic ether moieties (e.g. as in tetrahydrofuran and dioxane), cyclic thioether moieties (e.g. as in tetrahydrothiophene and dithiane), cyclic amine moieties (e.g. as in pyrrolidine), cyclic sulphones (e.g. as in sulfolane and sulfolene), cyclic sulfoxides, cyclic sulphonamides and combinations
15 thereof (e.g. thiomorpholine). Other examples of non-aromatic heterocyclic groups include cyclic amide moieties (e.g. as in pyrrolidone) and cyclic ester moieties (e.g. as in butyrolactone).

Examples of monocyclic non-aromatic heterocyclic groups include 5-, 6- and 7-membered monocyclic heterocyclic groups. Particular examples include morpholine, thiomorpholine
20 and its S-oxide and S,S-dioxide (particularly thiomorpholine), piperidine (e.g. 1-piperidinyl, 2-piperidinyl 3-piperidinyl and 4-piperidinyl), N-alkyl piperidines such as N-methyl piperidine, piperidone, pyrrolidine (e.g. 1-pyrrolidinyl, 2-pyrrolidinyl and 3-pyrrolidinyl), pyrrolidone, azetidine, pyran (2H-pyran or 4H-pyran), dihydrothiophene, dihydropyran, dihydrofuran, dihydrothiazole, tetrahydrofuran, tetrahydrothiophene,
25 dioxane, tetrahydropyran (e.g. 4-tetrahydro pyranyl), imidazoline, imidazolidinone, oxazoline, thiazoline, 2-pyrazoline, pyrazolidine, piperazone, piperazine, and N-alkyl piperazines such as N-methyl piperazine, N-ethyl piperazine and N-isopropylpiperazine.

One sub-group of monocyclic non-aromatic heterocyclic groups includes morpholine, piperidine (e.g. 1-piperidinyl, 2-piperidinyl 3-piperidinyl and 4-piperidinyl), piperidone,
30 pyrrolidine (e.g. 1-pyrrolidinyl, 2-pyrrolidinyl and 3-pyrrolidinyl), pyrrolidone, pyran (2H-pyran or 4H-pyran), dihydrothiophene, dihydropyran, dihydrofuran, dihydrothiazole,

tetrahydrofuran, tetrahydrothiophene, dioxane, tetrahydropyran (e.g. 4-tetrahydro pyranyl), imidazoline, imidazolidinone, oxazoline, thiazoline, 2-pyrazoline, pyrazolidine, piperazone, piperazine, and N-alkyl piperazines such as N-methyl piperazine. In general, preferred non-aromatic heterocyclic groups include piperidine, pyrrolidine, azetidine, morpholine, piperazine and N-alkyl piperazines. A further particular example of a non-aromatic heterocyclic group, which also forms part of the above group of preferred non-aromatic heterocyclic groups, is azetidine.

Examples of non-aromatic carbocyclic groups include cycloalkane groups such as cyclohexyl and cyclopentyl, cycloalkenyl groups such as cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl, as well as cyclohexadienyl, cyclooctatetraene, tetrahydronaphthenyl and decalinyl.

Where reference is made herein to carbocyclic and heterocyclic groups, the carbocyclic or heterocyclic ring can, unless the context indicates otherwise, be unsubstituted or substituted by one or more substituent groups R^{10} selected from halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, mono- or di- C_{1-4} hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members; a group R^a-R^b wherein R^a is a bond, O, CO, $X^1C(X^2)$, $C(X^2)X^1$, $X^1C(X^2)X^1$, S, SO, SO_2 , NR^c , SO_2NR^c or NR^cSO_2 ; and R^b is selected from hydrogen, carbocyclic and heterocyclic groups having from 3 to 12 ring members, and a C_{1-8} hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, carboxy, amino, mono- or di- C_{1-4} hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C_{1-8} hydrocarbyl group may optionally be replaced by O, S, SO, SO_2 , NR^c , $X^1C(X^2)$, $C(X^2)X^1$ or $X^1C(X^2)X^1$;


R^c is selected from hydrogen and C_{1-4} hydrocarbyl; and
 X^1 is O, S or NR^c and X^2 is =O, =S or = NR^c .

Where the substituent group R^{10} comprises or includes a carbocyclic or heterocyclic group, the said carbocyclic or heterocyclic group may be unsubstituted or may itself be substituted with one or more further substituent groups R^{10} . In one sub-group of compounds of the formula (I), such further substituent groups R^{10} may include carbocyclic or heterocyclic groups, which are typically not themselves further substituted. In another sub-group of compounds of the formula (I), the said further substituents do not include carbocyclic or

heterocyclic groups but are otherwise selected from the groups listed above in the definition of R^{10} .

The substituents R^{10} may be selected such that they contain no more than 20 non-hydrogen atoms, for example, no more than 15 non-hydrogen atoms, e.g. no more than 12, or 10, or 9, or 8, or 7, or 6, or 5 non-hydrogen atoms.

Where the carbocyclic and heterocyclic groups have a pair of substituents on adjacent ring atoms, the two substituents may be linked so as to form a cyclic group. For example, an adjacent pair of substituents on adjacent carbon atoms of a ring may be linked via one or more heteroatoms and optionally substituted alkylene groups to form a fused oxa-, dioxo-, aza-, diaza- or oxa-aza-cycloalkyl group. Examples of such linked substituent groups include:



Examples of halogen substituents include fluorine, chlorine, bromine and iodine. Fluorine and chlorine are particularly preferred.

In the case of the cyclic group HET, as shown in formula (I) and other formulae herein, this is optionally substituted by one or more substituents R^4 but the group HET is not itself further substituted by a substituent R^{10} . However, where the substituents making up the group R^4 contain a carbocyclic or heterocyclic group, the carbocyclic or heterocyclic group in question can be further substituted by R^{10} and the above definition of R^{10} applies to such substituents.

In the definition of the compounds of the formula (I) above and as used hereinafter, the term “hydrocarbyl” is a generic term encompassing aliphatic, alicyclic and aromatic groups having an all-carbon backbone, except where otherwise stated. In certain cases, as defined herein, one or more of the carbon atoms making up the carbon backbone may be replaced by a specified atom or group of atoms. Examples of hydrocarbyl groups include alkyl,

cycloalkyl, cycloalkenyl, carbocyclic aryl, alkenyl, alkynyl, cycloalkylalkyl, cycloalkenylalkyl, and carbocyclic aralkyl, aralkenyl and aralkynyl groups. Such groups can be unsubstituted or, where stated, can be substituted by one or more substituents as defined herein. The examples and preferences expressed below apply to each of the

5 hydrocarbyl substituent groups or hydrocarbyl-containing substituent groups referred to in the various definitions of substituents for compounds of the formula (I) unless the context indicates otherwise.

Generally by way of example, the hydrocarbyl groups can have up to eight carbon atoms, unless the context requires otherwise. Within the sub-set of hydrocarbyl groups having 1 to

10 8 carbon atoms, particular examples are C₁₋₆ hydrocarbyl groups, such as C₁₋₄ hydrocarbyl groups (e.g. C₁₋₃ hydrocarbyl groups or C₁₋₂ hydrocarbyl groups), specific examples being any individual value or combination of values selected from C₁, C₂, C₃, C₄, C₅, C₆, C₇ and C₈ hydrocarbyl groups.

The term "alkyl" covers both straight chain and branched chain alkyl groups. Examples of

15 alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, 2-methyl butyl, 3-methyl butyl, and n-hexyl and its isomers. Within the sub-set of alkyl groups having 1 to 8 carbon atoms, particular examples are C₁₋₆ alkyl groups, such as C₁₋₄ alkyl groups (e.g. C₁₋₃ alkyl groups or C₁₋₂ alkyl groups).

Examples of cycloalkyl groups are those derived from cyclopropane, cyclobutane,

20 cyclopentane, cyclohexane and cycloheptane. Within the sub-set of cycloalkyl groups the cycloalkyl group will have from 3 to 8 carbon atoms, particular examples being C₃₋₆ cycloalkyl groups.

Examples of alkenyl groups include, but are not limited to, ethenyl (vinyl), 1-propenyl, 2-propenyl (allyl), isopropenyl, butenyl, buta-1,4-dienyl, pentenyl, and hexenyl. Within the

25 sub-set of alkenyl groups the alkenyl group will have 2 to 8 carbon atoms, particular examples being C₂₋₆ alkenyl groups, such as C₂₋₄ alkenyl groups.

Examples of cycloalkenyl groups include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl and cyclohexenyl. Within the sub-set of cycloalkenyl groups the cycloalkenyl groups have from 3 to 8 carbon atoms, and particular

30 examples are C₃₋₆ cycloalkenyl groups.

Examples of alkynyl groups include, but are not limited to, ethynyl and 2-propynyl (propargyl) groups. Within the sub-set of alkynyl groups having 2 to 8 carbon atoms, particular examples are C₂₋₆ alkynyl groups, such as C₂₋₄ alkynyl groups.

5 Examples of carbocyclic aryl groups include substituted and unsubstituted phenyl, naphthyl, indane and indene groups.

Examples of cycloalkylalkyl, cycloalkenylalkyl, carbocyclic aralkyl, aralkenyl and aralkynyl groups include phenethyl, benzyl, styryl, phenylethynyl, cyclohexylmethyl, cyclopentylmethyl, cyclobutylmethyl, cyclopropylmethyl and cyclopentenylmethyl groups.

10 The term C₁₋₈ hydrocarbyl as used herein encompasses alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, phenyl, benzyl and phenylethyl groups wherein the preferences for and examples of each of the aforesaid groups are as defined above. Within this definition, particular hydrocarbyl groups are alkyl, cycloalkyl, phenyl, benzyl and phenylethyl (e.g. 1-phenylethyl or 2-phenylethyl) groups, one subset of hydrocarbyl groups consisting of alkyl and cycloalkyl groups and in particular C₁₋₄ alkyl and cycloalkyl groups such as methyl, 15 ethyl, n-propyl, isopropyl, n-butyl, isobutyl, *tert*-butyl, cyclopropyl and cyclobutyl.

The term C₁₋₄ hydrocarbyl as used herein encompasses alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl groups wherein the preferences for and examples of the aforesaid groups are as defined above. Within this definition, particular C₁₋₄ hydrocarbyl groups are alkyl and cycloalkyl groups, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, *tert*- 20 butyl, cyclopropyl and cyclobutyl.

When present, and where stated, a hydrocarbyl group can be optionally substituted by one or more substituents selected from hydroxy, oxo, alkoxy, carboxy, halogen, cyano, nitro, amino, mono- or di-C₁₋₄ hydrocarbylamino, and monocyclic or bicyclic carbocyclic and heterocyclic groups having from 3 to 12 (typically 3 to 10 and more usually 5 to 10) ring 25 members. Preferred substituents include halogen such as fluorine. Thus, for example, the substituted hydrocarbyl group can be a partially fluorinated or perfluorinated group such as difluoromethyl or trifluoromethyl. In one embodiment preferred substituents include monocyclic carbocyclic and heterocyclic groups having 3-7 ring members.

Where stated, one or more carbon atoms of a hydrocarbyl group may optionally be replaced 30 by O, S, SO, SO₂, NR^c, X¹C(X²), C(X²)X¹ or X¹C(X²)X¹ (or a sub-group thereof) wherein X¹ and X² are as hereinbefore defined, provided that at least one carbon atom of the

hydrocarbyl group remains. For example, 1, 2, 3 or 4 carbon atoms of the hydrocarbyl group may be replaced by one of the atoms or groups listed, and the replacing atoms or groups may be the same or different. In general, the number of linear or backbone carbon atoms replaced will correspond to the number of linear or backbone atoms in the group replacing them. Examples of groups in which one or more carbon atom of the hydrocarbyl group have been replaced by a replacement atom or group as defined above include ethers and thioethers (C replaced by O or S), amides, esters, thioamides and thioesters (C-C replaced by $X^1C(X^2)$ or $C(X^2)X^1$), sulphones and sulfoxides (C replaced by SO or SO₂), amines (C replaced by NR^c). Further examples include ureas, carbonates and carbamates (C-C-C replaced by $X^1C(X^2)X^1$).

Where an amino group has two hydrocarbyl substituents, they may, together with the nitrogen atom to which they are attached, and optionally with another heteroatom such as nitrogen, sulphur, or oxygen, link to form a ring structure of 4 to 7 ring members.

The definition "R^a-R^b" as used herein, either with regard to substituents present on a carbocyclic or heterocyclic moiety, or with regard to other substituents present at other locations on the compounds of the formula (I), includes *inter alia* compounds wherein R^a is selected from a bond, O, CO, OC(O), SC(O), NR^cC(O), OC(S), SC(S), NR^cC(S), OC(NR^c), SC(NR^c), NR^cC(NR^c), C(O)O, C(O)S, C(O)NR^c, C(S)O, C(S)S, C(S)NR^c, C(NR^c)O, C(NR^c)S, C(NR^c)NR^c, OC(O)O, SC(O)O, NR^cC(O)O, OC(S)O, SC(S)O, NR^cC(S)O, OC(NR^c)O, SC(NR^c)O, NR^cC(NR^c)O, OC(O)S, SC(O)S, NR^cC(O)S, OC(S)S, SC(S)S, NR^cC(S)S, OC(NR^c)S, SC(NR^c)S, NR^cC(NR^c)S, OC(O)NR^c, SC(O)NR^c, NR^cC(O)NR^c, OC(S)NR^c, SC(S)NR^c, NR^cC(S)NR^c, OC(NR^c)NR^c, SC(NR^c)NR^c, NR^cC(NR^c)NR^c, S, SO, SO₂, NR^c, SO₂NR^c and NR^cSO₂ wherein R^c is as hereinbefore defined.

The moiety R^b can be hydrogen or it can be a group selected from carbocyclic and heterocyclic groups having from 3 to 12 ring members (typically 3 to 10 and more usually from 5 to 10), and a C₁₋₈ hydrocarbyl group optionally substituted as hereinbefore defined. Examples of hydrocarbyl, carbocyclic and heterocyclic groups are as set out above.

When R^a is O and R^b is a C₁₋₈ hydrocarbyl group, R^a and R^b together form a hydrocarbyloxy group. Preferred hydrocarbyloxy groups include saturated hydrocarbyloxy such as alkoxy (e.g. C₁₋₆ alkoxy, more usually C₁₋₄ alkoxy such as ethoxy and methoxy, particularly methoxy), cycloalkoxy (e.g. C₃₋₆ cycloalkoxy such as cyclopropyloxy,

cyclobutyloxy, cyclopentyloxy and cyclohexyloxy) and cycloalkyalkoxy (e.g. C₃₋₆ cycloalkyl-C₁₋₂ alkoxy such as cyclopropylmethoxy).

The hydrocarbyloxy groups can be substituted by various substituents as defined herein. For example, the alkoxy groups can be substituted by halogen (e.g. as in difluoromethoxy and trifluoromethoxy), hydroxy (e.g. as in hydroxyethoxy), C₁₋₂ alkoxy (e.g. as in methoxyethoxy), hydroxy-C₁₋₂ alkyl (as in hydroxyethoxyethoxy) or a cyclic group (e.g. a cycloalkyl group or non-aromatic heterocyclic group as hereinbefore defined). Examples of alkoxy groups bearing a non-aromatic heterocyclic group as a substituent are those in which the heterocyclic group is a saturated cyclic amine such as morpholine, piperidine, pyrrolidine, piperazine, C₁₋₄-alkyl-piperazines, C₃₋₇-cycloalkyl-piperazines, tetrahydropyran or tetrahydrofuran and the alkoxy group is a C₁₋₄ alkoxy group, more typically a C₁₋₃ alkoxy group such as methoxy, ethoxy or n-propoxy.

Alkoxy groups may be substituted by, for example, a monocyclic group such as pyrrolidine, piperidine, morpholine and piperazine and N-substituted derivatives thereof such as N-benzyl, N-C₁₋₄ acyl and N-C₁₋₄ alkoxycarbonyl. Particular examples include pyrrolidinoethoxy, piperidinoethoxy and piperazinoethoxy.

When R^a is a bond and R^b is a C₁₋₈ hydrocarbyl group, examples of hydrocarbyl groups R^a-R^b are as hereinbefore defined. The hydrocarbyl groups may be saturated groups such as cycloalkyl and alkyl and particular examples of such groups include methyl, ethyl and cyclopropyl. The hydrocarbyl (e.g. alkyl) groups can be substituted by various groups and atoms as defined herein. Examples of substituted alkyl groups include alkyl groups substituted by one or more halogen atoms such as fluorine and chlorine (particular examples including bromoethyl, chloroethyl, difluoromethyl, 2,2,2-trifluoroethyl and perfluoroalkyl groups such as trifluoromethyl), or hydroxy (e.g. hydroxymethyl and hydroxyethyl), C₁₋₈ acyloxy (e.g. acetoxymethyl and benzyloxymethyl), amino and mono- and dialkylamino (e.g. aminoethyl, methylaminoethyl, dimethylaminomethyl, dimethylaminoethyl and *tert*-butylaminomethyl), alkoxy (e.g. C₁₋₂ alkoxy such as methoxy – as in methoxyethyl), and cyclic groups such as cycloalkyl groups, aryl groups, heteroaryl groups and non-aromatic heterocyclic groups as hereinbefore defined).

Particular examples of alkyl groups substituted by a cyclic group are those wherein the cyclic group is a saturated cyclic amine such as morpholine, piperidine, pyrrolidine, piperazine, C₁₋₄-alkyl-piperazines, C₃₋₇-cycloalkyl-piperazines, tetrahydropyran or

5 tetrahydrofuran and the alkyl group is a C₁₋₄ alkyl group, more typically a C₁₋₃ alkyl group such as methyl, ethyl or n-propyl. Specific examples of alkyl groups substituted by a cyclic group include pyrrolidinomethyl, pyrrolidinopropyl, morpholinomethyl, morpholinoethyl, morpholinopropyl, piperidinylmethyl, piperazinomethyl and N-substituted forms thereof as defined herein.

Particular examples of alkyl groups substituted by aryl groups and heteroaryl groups include benzyl, phenethyl and pyridylmethyl groups.

10 When R^a is SO₂NR^c, R^b can be, for example, hydrogen or an optionally substituted C₁₋₈ hydrocarbyl group, or a carbocyclic or heterocyclic group. Examples of R^a-R^b where R^a is SO₂NR^c include aminosulphonyl, C₁₋₄ alkylaminosulphonyl and di-C₁₋₄ alkylaminosulphonyl groups, and sulphonamides formed from a cyclic amino group such as piperidine, morpholine, pyrrolidine, or an optionally N-substituted piperazine such as N-methyl piperazine.

15 Examples of groups R^a-R^b where R^a is SO₂ include alkylsulphonyl, heteroarylsulphonyl and arylsulphonyl groups, particularly monocyclic aryl and heteroaryl sulphonyl groups. Particular examples include methylsulphonyl, phenylsulphonyl and toluenesulphonyl.


20 When R^a is NR^c, R^b can be, for example, hydrogen or an optionally substituted C₁₋₈ hydrocarbyl group, or a carbocyclic or heterocyclic group. Examples of R^a-R^b where R^a is NR^c include amino, C₁₋₄ alkylamino (e.g. methylamino, ethylamino, propylamino, isopropylamino, *tert*-butylamino), di-C₁₋₄ alkylamino (e.g. dimethylamino and diethylamino) and cycloalkylamino (e.g. cyclopropylamino, cyclopentylamino and cyclohexylamino).

Specific Embodiments and Preferences

The Group "A"

25 In formula (I), A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R¹ and NR²R³ and a maximum chain length of 4 atoms extending between E and NR²R³. Within these constraints, the moieties E and R¹ can each be attached at any location on the group A.

The term "maximum chain length" as used herein refers to the number of atoms lying directly between the two moieties in question, and does not take into account any branching in the chain or any hydrogen atoms that may be present. For example, in the structure A shown below:



the chain length between R^1 and NR^2R^3 is 3 atoms whereas the chain length between E and NR^2R^3 is 2 atoms.

In general it is presently preferred that the linker group has a maximum chain length of 3 atoms (for example 1 or 2 atoms).

- 10 In one embodiment, the linker group has a chain length of 1 atom extending between R^1 and NR^2R^3 .

In another embodiment, the linker group has a chain length of 2 atoms extending between R^1 and NR^2R^3 .

- 15 In a further embodiment, the linker group has a chain length of 3 atoms extending between R^1 and NR^2R^3 .

It is preferred that the linker group has a maximum chain length of 3 atoms extending between E and NR^2R^3 .

- 20 In one particularly preferred group of compounds, the linker group has a chain length of 2 or 3 atoms extending between R^1 and NR^2R^3 and a chain length of 2 or 3 atoms extending between E and NR^2R^3 .

One of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom.

When present, the nitrogen atom may be linked directly to the group E.

- 25 In one embodiment, the carbon atom to which the group R^1 is attached is replaced by an oxygen atom.

In another embodiment, R^1 and E are attached to the same carbon atom of the linker group, and a carbon atom in the chain extending between E and NR^2R^3 is replaced by an oxygen atom.

5 When a nitrogen atom or oxygen atom are present, it is preferred that the nitrogen or oxygen atom and the NR^2R^3 group are spaced apart by at least two intervening carbon atoms.

In one particular group of compounds within formula (I), the linker atom linked directly to the group E is a carbon atom and the linker group A has an all-carbon skeleton.

10 The carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group is not located at a carbon atom α with respect to the NR^2R^3 group, and provided also that the oxo group is located at a carbon atom α with respect to the NR^2R^3 group. Typically, the hydroxy group, if present, is located at a position β with respect to the NR^2R^3 group. In general, no more than one hydroxy group will be present. Where fluorine is present, it may be present as a
15 single fluorine substituent or may be present in a difluoromethylene or trifluoromethyl group, for example. In one embodiment, a fluorine atom is located at a position β with respect to the NR^2R^3 group.

It will be appreciated that that when an oxo group is present at the carbon atom adjacent the NR^2R^3 group, the compound of the formula (I) will be an amide.

20 In one embodiment of the invention, no fluorine atoms are present in the linker group A.

In another embodiment of the invention, no hydroxy groups are present in the linker group A.

In a further embodiment, no oxo group is present in the linker group A.

25 In one group of compounds of the formula (I) neither hydroxy groups nor fluorine atoms are present in the linker group A, e.g. the linker group A is unsubstituted.

Preferably, when a carbon atom in the linker group A is replaced by a nitrogen atom, the group A bears no more than one hydroxy substituent and more preferably bears no hydroxy substituents.

When there is a chain length of four atoms between E and NR^2R^3 , it is preferred that the linker group A contains no nitrogen atoms and more preferably has an all carbon skeleton.

5 The linker group A can have a branched configuration at the carbon atom attached to the NR^2R^3 group. For example, the carbon atom attached to the NR^2R^3 group can be attached to a pair of *gem*-dimethyl groups.

In one particular group of compounds of the formula (I), the portion $\text{R}^1\text{-A-NR}^2\text{R}^3$ of the compound is represented by the formula $\text{R}^1\text{-(G)}_k\text{-(CH}_2\text{)}_m\text{-W-O}_b\text{-(CH}_2\text{)}_n\text{-(CR}^6\text{R}^7\text{)}_p\text{-NR}^2\text{R}^3$ wherein G is NH, NMe or O; W is attached to the group E and is selected from $(\text{CH}_2)_j\text{-CR}^{20}$, $(\text{CH}_2)_j\text{-N}$ and $(\text{NH})_j\text{-CH}$; b is 0 or 1, j is 0 or 1, k is 0 or 1, m is 0 or 1, n is 0, 1, 2, or 3 and p is 0 or 1; the sum of b and k is 0 or 1; the sum of j, k, m, n and p does not exceed 4; R^6 and R^7 are the same or different and are selected from methyl and ethyl, or CR^6R^7 forms a cyclopropyl group; and R^{20} is selected from hydrogen, methyl, hydroxy and fluorine;

15 In another sub-group of compounds of the formula (I), the portion $\text{R}^1\text{-A-NR}^2\text{R}^3$ of the compound is represented by the formula $\text{R}^1\text{-(G)}_k\text{-(CH}_2\text{)}_m\text{-X-(CH}_2\text{)}_n\text{-(CR}^6\text{R}^7\text{)}_p\text{-NR}^2\text{R}^3$ wherein G is NH, NMe or O; X is attached to the group E and is selected from $(\text{CH}_2)_j\text{-CH}$, $(\text{CH}_2)_j\text{-N}$ and $(\text{NH})_j\text{-CH}$; j is 0 or 1, k is 0 or 1, m is 0 or 1, n is 0, 1, 2, or 3 and p is 0 or 1, and the sum of j, k, m, n and p does not exceed 4; and R^6 and R^7 are the same or different and are selected from methyl and ethyl, or CR^6R^7 forms a cyclopropyl group.

20 A particular group CR^6R^7 is $\text{C(CH}_3\text{)}_2$.

Preferably X is $(\text{CH}_2)_j\text{-CH}$.

Particular configurations where the portion $\text{R}^1\text{-A-NR}^2\text{R}^3$ of the compound is represented by the formula $\text{R}^1\text{-(G)}_k\text{-(CH}_2\text{)}_m\text{-X-(CH}_2\text{)}_n\text{-(CR}^6\text{R}^7\text{)}_p\text{-NR}^2\text{R}^3$ are those wherein:

- k is 0, m is 0 or 1, n is 0, 1, 2 or 3 and p is 0.
- 25 • k is 0, m is 0 or 1, n is 0, 1 or 2 and p is 1.
- X is $(\text{CH}_2)_j\text{-CH}$, k is 1, m is 0, n is 0, 1, 2 or 3 and p is 0.
- X is $(\text{CH}_2)_j\text{-CH}$, k is 1, m is 0, n is 0, 1 or 2 and p is 1.
- X is $(\text{CH}_2)_j\text{-CH}$, G is O, k is 1, m is 0, n is 0, 1, 2 or 3 and p is 0.










Particular configurations wherein the portion $R^1-A-NR^2R^3$ of the compound is represented by the formula $R^1-(G)_k-(CH_2)_m-W-O_b-(CH_2)_n-(CR^6R^7)_p-NR^2R^3$ are those wherein:
















- k is 0, m is 0, W is $(CH_2)_j-CR^{20}$, j is 0, R^{20} is hydrogen, b is 1, n is 2 and p is 0.
- k is 0, m is 0, W is $(CH_2)_j-CR^{20}$, j is 0, R^{20} is hydroxy, b is 0, n is 1 and p is 0.
- 5 • k is 0, m is 0, W is $(CH_2)_j-CR^{20}$, j is 0, R^{20} is methyl, b is 0, n is 1 and p is 0.
- k is 0, m is 0, W is $(CH_2)_j-CR^{20}$, j is 0, R^{20} is fluorine, b is 0, n is 1 and p is 0.


In one preferred configuration, the portion $R^1-A-NR^2R^3$ of the compound is represented by the formula $R^1-X-(CH_2)_n-NR^2R^3$ wherein X is attached to the group E and is a group CH, and n is 2.

- 10 Particular examples of the linker group A, together with their points of attachment to the groups R^1 , E and NR^2R^3 , are shown in Table 1 below.

Table 1:

 <p style="text-align: right;">A1</p>	 <p style="text-align: right;">A2</p>	 <p style="text-align: right;">A3</p>
 <p style="text-align: right;">A4</p>	 <p style="text-align: right;">A5</p>	 <p style="text-align: right;">A6</p>
 <p style="text-align: right;">A7</p>	 <p style="text-align: right;">A8</p>	 <p style="text-align: right;">A9</p>

 <p>A10</p>	 <p>A11</p>	 <p>A12</p>
 <p>A13</p>	 <p>A14</p>	 <p>A15</p>
 <p>A16</p>	 <p>A17</p>	 <p>A18</p>
 <p>A19</p>	 <p>A20</p>	 <p>A21</p>
 <p>A22</p>	 <p>A23</p>	 <p>A24</p>



Currently preferred groups include A1, A2, A3, A6, A10, A11, A22 and A23.

One particular set of groups includes A1, A2, A3, A10 and A11.

A further particular set of groups includes A2 and A11.

Another particular set of groups includes A6, A22 and A23.

- 5 A further set of groups includes A1, A2 and A3.

In group A2, the asterisk designates a chiral centre and the compounds can have either the *R* or *S* configuration about the chiral centre.

In one embodiment, the compounds have the *R* configuration at this chiral centre.

In another embodiment, compounds have the *S* configuration at this chiral centre.

- 10 Compounds having the *R* configuration at this chiral centre represent one preferred sub-group of compounds of the invention.

R¹

The group R¹ is an aryl or heteroaryl group and may be selected from the list of such groups set out in the section headed General Preferences and Definitions.

- 15 R¹ can be monocyclic or bicyclic and, in one preferred embodiment, is monocyclic. Particular examples of monocyclic aryl and heteroaryl groups are six membered aryl and heteroaryl groups containing up to 2 nitrogen ring members, and five membered heteroaryl groups containing up to 3 heteroatom ring members selected from O, S and N.

- 20 Examples of such groups include phenyl, naphthyl, thienyl, furan, pyrimidine and pyridine, with phenyl being presently preferred.

The group R¹ can be unsubstituted or substituted by up to 5 substituents, and examples of substituents are those listed in group R¹⁰ above.

Particular substituents include hydroxy; C₁₋₄ acyloxy; fluorine; chlorine; bromine; trifluoromethyl; cyano; CONH₂; nitro; C₁₋₄ hydrocarbyloxy and C₁₋₄ hydrocarbyl each optionally substituted by C₁₋₂ alkoxy, carboxy or hydroxy; C₁₋₄ acylamino; benzoylamino; pyrrolidinocarbonyl; piperidinocarbonyl; morpholinocarbonyl; piperazinocarbonyl; five and six membered heteroaryl and heteroaryloxy groups containing one or two heteroatoms selected from N, O and S; phenyl; phenyl-C₁₋₄ alkyl; phenyl-C₁₋₄ alkoxy; heteroaryl-C₁₋₄ alkyl; heteroaryl-C₁₋₄ alkoxy and phenoxy, wherein the heteroaryl, heteroaryloxy, phenyl, phenyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkoxy, heteroaryl-C₁₋₄ alkyl, heteroaryl-C₁₋₄ alkoxy and phenoxy groups are each optionally substituted with 1, 2 or 3 substituents selected from C₁₋₂ acyloxy, fluorine, chlorine, bromine, trifluoromethyl, cyano, CONH₂, C₁₋₂ hydrocarbyloxy and C₁₋₂ hydrocarbyl each optionally substituted by methoxy or hydroxy.

Preferred substituents include hydroxy; C₁₋₄ acyloxy; fluorine; chlorine; bromine; trifluoromethyl; cyano; C₁₋₄ hydrocarbyloxy and C₁₋₄ hydrocarbyl each optionally substituted by C₁₋₂ alkoxy or hydroxy; C₁₋₄ acylamino; benzoylamino; pyrrolidinocarbonyl; piperidinocarbonyl; morpholinocarbonyl; piperazinocarbonyl; five and six membered heteroaryl groups containing one or two heteroatoms selected from N, O and S, the heteroaryl groups being optionally substituted by one or more C₁₋₄ alkyl substituents; phenyl; pyridyl; and phenoxy wherein the phenyl, pyridyl and phenoxy groups are each optionally substituted with 1, 2 or 3 substituents selected from C₁₋₂ acyloxy, fluorine, chlorine, bromine, trifluoromethyl, cyano, C₁₋₂ hydrocarbyloxy and C₁₋₂ hydrocarbyl each optionally substituted by methoxy or hydroxy.

In one sub-group of compounds, the substituents for R¹ are chosen from hydroxy; C₁₋₄ acyloxy; fluorine; chlorine; bromine; trifluoromethyl; cyano; C₁₋₄ hydrocarbyloxy and C₁₋₄ hydrocarbyl each optionally substituted by C₁₋₂ alkoxy or hydroxy.

Although up to 5 substituents may be present, more typically there are 0, 1, 2, 3 or 4 substituents, preferably 0, 1, 2 or 3, and more preferably 0, 1 or 2.

In one embodiment, the group R¹ is unsubstituted or substituted by up to 5 substituents selected from hydroxy; C₁₋₄ acyloxy; fluorine; chlorine; bromine; trifluoromethyl; cyano;

C₁₋₄ hydrocarbyloxy and C₁₋₄ hydrocarbyl each optionally substituted by C₁₋₂ alkoxy or hydroxy.

In another embodiment, the group R¹ is unsubstituted or substituted by up to 5 substituents selected from hydroxy; C₁₋₄ acyloxy; fluorine; chlorine; bromine; trifluoromethyl; cyano;
5 pyridyl; C₁₋₄ hydrocarbyloxy and C₁₋₄ hydrocarbyl each optionally substituted by C₁₋₂ alkoxy or hydroxy.

In a further embodiment, the group R¹ can have one or two substituents selected from hydroxy, fluorine, chlorine, cyano, phenoxy, pyrazinyloxy, benzyloxy, methyl and methoxy.

10 In another embodiment, the group R¹ can have one or two substituents selected from fluorine, chlorine, trifluoromethyl, methyl and methoxy.

When R¹ is a phenyl group, particular examples of substituent combinations include mono-chlorophenyl and dichlorophenyl.

Further examples of substituent combinations include those wherein R¹ is hydroxyphenyl,
15 fluoro-chlorophenyl, cyanophenyl, methoxyphenyl, methoxy-chlorophenyl, fluorophenyl, difluorophenyl, phenoxyphenyl, pyrazinyloxyphenyl or benzyloxyphenyl.

Another group of substituent combinations consists of mono-chlorophenyl, dichlorophenyl, hydroxyphenyl, fluoro-chlorophenyl, cyanophenyl, methoxyphenyl, methoxy-chlorophenyl, fluorophenyl, difluorophenyl, phenoxyphenyl, pyrazinyloxyphenyl, benzyloxyphenyl and
20 pyridyl-methoxyphenyl.

When R¹ is a six membered aryl or heteroaryl group, a substituent may advantageously be present at the *para* position on the six-membered ring. Where a substituent is present at the *para* position, it is preferably larger in size than a fluorine atom.

When two substituents are present on a six-membered aryl (e.g. phenyl) or heteroaryl
25 group, they may be located at the *para* and *meta* positions.

R² and R³

In one group of compounds of the formula (I), R² and R³ are independently selected from hydrogen, C₁₋₄ hydrocarbyl and C₁₋₄ acyl wherein the hydrocarbyl and acyl moieties are

optionally substituted by one or more substituents selected from fluorine, hydroxy, amino, methylamino, dimethylamino and methoxy.

When the hydrocarbyl moiety is substituted by a hydroxy, amino, methylamino, dimethylamino or methoxy group, typically there are at least two carbon atoms between the substituent and the nitrogen atom of the group NR^2R^3 . Particular examples of substituted hydrocarbyl groups are hydroxyethyl and hydroxypropyl.

In another group of compounds of the invention, R^2 and R^3 are independently selected from hydrogen, C_{1-4} hydrocarbyl and C_{1-4} acyl.

Typically the hydrocarbyl group, whether substituted or unsubstituted, is an alkyl group, more usually a C_1 , C_2 or C_3 alkyl group, and preferably a methyl group. In one particular sub-group of compounds, R^2 and R^3 are independently selected from hydrogen and methyl and hence NR^2R^3 can be an amino, methylamino or dimethylamino group. In one particular embodiment, NR^2R^3 can be an amino group. In another particular embodiment, NR^2R^3 can be a methylamino group.

In an alternative embodiment, the C_{1-4} hydrocarbyl group can be a cyclopropyl, cyclopropylmethyl or cyclobutyl group.

In another group of compounds, R^2 and R^3 together with the nitrogen atom to which they are attached form a cyclic group selected from an imidazole group and a saturated monocyclic heterocyclic group having 4-7 ring members and optionally containing a second heteroatom ring member selected from O and N.

In a further group of compounds, R^2 and R^3 together with the nitrogen atom to which they are attached form a saturated monocyclic heterocyclic group having 4-7 ring members and optionally containing a second heteroatom ring member selected from O and N.


The saturated monocyclic heterocyclic group can be unsubstituted or substituted by one or more substituents R^{10} as defined above in the General Preferences and Definitions section of this application. Typically, however, any substituents on the heterocyclic group will be relatively small substituents such as C_{1-4} hydrocarbyl (e.g. methyl, ethyl, *n*-propyl, *i*-propyl, cyclopropyl, *n*-butyl, *sec*-butyl and *tert*-butyl), fluorine, chlorine, hydroxy, amino, methylamino, ethylamino and dimethylamino. Particular substituents are methyl groups.

The saturated monocyclic ring can be an azacycloalkyl group such as an azetidine, pyrrolidine, piperidine or azepane ring, and such rings are typically unsubstituted. Alternatively, the saturated monocyclic ring can contain an additional heteroatom selected from O and N, and examples of such groups include morpholine and piperazine. Where an additional N atom is present in the ring, this can form part of an NH group or an N-C₁₋₄ alkyl group such as an N-methyl, N-ethyl, N-propyl or N-isopropyl group.

Where NR²R³ forms an imidazole group, the imidazole group can be unsubstituted or substituted, for example by one or more relatively small substituents such as C₁₋₄ hydrocarbyl (e.g. methyl, ethyl, propyl, cyclopropyl and butyl), fluorine, chlorine, hydroxy, amino, methylamino, ethylamino and dimethylamino. Particular substituents are methyl groups.


In a further group of compounds, one of R² and R³ together with the nitrogen atom to which they are attached and one or more atoms from the linker group A form a saturated monocyclic heterocyclic group having 4-7 ring members and optionally containing a second heteroatom ring member selected from O and N.

Examples of such compounds include compounds wherein NR²R³ and A form a unit of the formula:




where t and u are each 0, 1, 2 or 3 provided that the sum of t and u falls within the range of 2 to 4.

Further examples of such compounds include compounds wherein NR²R³ and A form a cyclic group of the formula:



where v and w are each 0, 1, 2 or 3 provided that the sum of v and w falls within the range of 2 to 5. Particular examples of cyclic compounds are those in which v and w are both 2.

Further examples of such compounds include compounds wherein NR^2R^3 and A form a cyclic group of the formula:



where x and w are each 0, 1, 2 or 3 provided that the sum of x and w falls within the range of 2 to 4. Particular examples of cyclic compounds are those in which x is 2 and w is 1.

In each of the foregoing embodiments and examples where NR^2R^3 and A together form a cyclic group, one of the R-groups (usually R^2) forms part of a ring system and the other (usually R^3) typically does not. The R-group (e.g. R^3) which does not form part of a ring system may be hydrogen or optionally substituted C_{1-4} hydrocarbyl and C_{1-4} acyl as defined herein. In one preferred embodiment however, R^3 is hydrogen.

In each of the above examples, R^1 and E are shown to illustrate the location of A and NR^2R^3 with respect to the remainder of the molecule. However, it is not intended to imply that R^1 and E form part of A.

The Group "E"

In formula (I), E is a monocyclic or bicyclic carbocyclic or heterocyclic group and can be selected from the groups set out above in the section headed General Preferences and Definitions.

Preferred groups E are monocyclic and bicyclic aryl and heteroaryl groups and, in particular, groups containing a five or six membered aromatic or heteroaromatic ring such as a phenyl, pyridine, pyrazole, pyrazine, pyridazine or pyrimidine ring, more particularly a phenyl, pyridine, pyrazole, pyrazine or pyrimidine ring, and more preferably a pyridine, pyrazole or phenyl ring.

Examples of bicyclic groups include benzo-fused and pyrido-fused groups wherein the group A and the cyclic group HET are both attached to the benzo- or pyrido- moiety.

In one embodiment, E is a monocyclic group.

Particular examples of monocyclic groups include monocyclic aryl and heteroaryl groups such as phenyl, thiophene, furan, pyrazole, pyrimidine, pyrazine and pyridine, phenyl being presently preferred.

One subset of monocyclic aryl and heteroaryl groups comprises phenyl, pyrazole,
5 thiophene, furan, pyrimidine and pyridine.

Examples of non-aromatic monocyclic groups include cycloalkanes such as cyclohexane and cyclopentane, and nitrogen-containing rings such as piperazine and piperazone.

It is preferred that the group A and the cyclic group HET are not attached to adjacent ring members of the group E. For example, the cyclic group HET can be attached to the group
10 E in a *meta* or *para* relative orientation. Examples of such groups E include 1,4-phenylene, 1,3-phenylene, 2,5-pyridylene and 2,4-pyridylene, 1,4-piperaziny, and 1,4-piperazonyl. Further examples include 1,3-disubstituted five membered rings .


The groups E can be unsubstituted or can have up to 4 substituents R^8 which may be selected from the group R^{10} as hereinbefore defined. More typically however, the
15 substituents R^8 are selected from hydroxy; oxo (when E is non-aromatic); halogen (e.g. chlorine and bromine); trifluoromethyl; cyano; C_{1-4} hydrocarbyloxy optionally substituted by C_{1-2} alkoxy or hydroxy; C_{1-4} hydrocarbyl optionally substituted by C_{1-2} alkoxy or hydroxy; and phenyl optionally substituted by halogen (e.g. chlorine and bromine), trifluoromethyl, cyano, methyl or methoxy.

20 Preferably there are 0-3 substituents, more preferably 0-2 substituents, for example 0 or 1 substituent. In one embodiment, the group E is unsubstituted.

E may be other than:


- a substituted pyridone group;
- a substituted thiazole group;
- 25 - a substituted or unsubstituted pyrazole or pyrazolone group;
- a substituted or unsubstituted bicyclic fused pyrazole group;
- a phenyl ring fused to a thiophene ring or a six membered nitrogen-containing heteroaryl ring fused to a thiophene ring;
- a substituted or unsubstituted piperazine group;

The group E can be an aryl or heteroaryl group having five or six members and containing up to three heteroatoms selected from O, N and S, the group E being represented by the formula:




- 5 where * denotes the point of attachment to the cyclic group HET, and "a" denotes the attachment of the group A;
 r is 0, 1 or 2;
 U is selected from N and CR^{12a}; and
 V is selected from N and CR^{12b}; where R^{12a} and R^{12b} are the same or different and each is
 10 hydrogen or a substituent containing up to ten atoms selected from C, N, O, F, Cl and S provided that the total number of non-hydrogen atoms present in R^{12a} and R^{12b} together does not exceed ten;
 or R^{12a} and R^{12b} together with the carbon atoms to which they are attached form an unsubstituted five or six membered saturated or unsaturated ring containing up to two
 15 heteroatoms selected from O and N; and
 R¹⁰ is as hereinbefore defined.

In one preferred group of compounds, E is a group:



- 20 where * denotes the point of attachment to the cyclic group HET, and "a" denotes the attachment of the group A;
 P, Q and T are the same or different and are selected from N, CH and NCR¹⁰, provided that the group A is attached to a carbon atom; and U, V and R¹⁰ are as hereinbefore defined.

In another preferred group of compounds, E is a group:



wherein R^{16} is hydrogen or a group R^{10} , R^{12a} or R^{12b} as defined herein.












Examples of R^{12a} and R^{12b} include hydrogen and substituent groups R^{10} as hereinbefore defined having no more than ten non-hydrogen atoms. Particular examples of R^{12a} and R^{12b} include methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, phenyl, fluorine, chlorine, methoxy, trifluoromethyl, hydroxymethyl, hydroxyethyl, methoxymethyl, difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethyl, cyano, amino, methylamino, dimethylamino, CONH_2 , CO_2Et , CO_2H , acetamido, azetidiny, pyrrolidino, piperidine, piperazino, morpholino, methylsulphonyl, aminosulphonyl, mesylamino and trifluoroacetamido.

Preferably, when U is CR^{12a} and/or V is CR^{12b} the atoms or groups in R^{12a} and R^{12b} that are directly attached to the carbon atom ring members C are selected from H, O (e.g. as in methoxy), NH (e.g. as in amino and methylamino) and CH_2 (e.g. as in methyl and ethyl).

Particular examples of the linker group E, together with their points of attachment to the group A (a) and the ring HET (*) are shown in Table 2 below.

Table 2:

<p>B1</p>	<p>B2</p>	<p>B3</p>	<p>B4</p>
-----------	-----------	-----------	-----------

 B5	 B6	 B7	 B8
 B9	 B10	 B11	 B12
 B13	 B14	 B15	


In the table, the substituent group R¹³ is selected from methyl, chlorine, fluorine and trifluoromethyl.

One preferred group E is group B1 in Table 2.

- 5 The following optional exclusions may apply to the definition of E in any of formulae (I), (Ia), (Ib), (II), (III), (IV), (V), (VI) and (VII) and any sub-groups or sub-definitions thereof as defined herein:

- E may be other than a phenyl group having a sulphur atom attached to the position *para* with respect to the group HET.

- 10
- E may be other than a substituted or unsubstituted benzimidazole, benzoxazole or benzthiazole group.

The Group HET

The cyclic group HET is a monocyclic heterocyclic group having 4 to 7 ring members of which up to 4 are heteroatoms selected from O, N and S.


- 5 Examples of monocyclic heterocyclic groups are as set out above in the General Preferences and Definitions section.

Typically, the cyclic group HET has 4 to 6 ring members for example 5 or 6 ring members.

In one embodiment, the cyclic group HET is an optionally substituted monocyclic heteroaryl group.

- 10 Particular examples of monocyclic heteroaryl groups include pyridine, pyrimidine, pyrazine, thiophene, furan, oxazole, triazole, imidazole, with pyridine and pyrimidine being particularly preferred.

In one embodiment, the cyclic group HET may take the form:




- 15 where Q^x is a hydrogen bond acceptor atom or group.

The term “hydrogen bond acceptor” is a well established term and refers to a group capable of forming a hydrogen bond with a hydrogen atom in the same or an adjacent molecule; see for example “*Advanced Organic Chemistry*” by Jerry March, 4th edition, pages 75-79 and references therein. In the present context, hydrogen bond acceptors include nitrogen,
20 oxygen and sulphur atoms; and groups containing nitrogen, oxygen and sulphur atoms.

Particular examples of hydrogen bond acceptors are the groups set out in Table 3 below. The asterisk marks the point of attachment to the group E.


Table 3



A cyclic group X may contain one hydrogen bond acceptor, or more than one (e.g. two or three) hydrogen bond acceptor moieties.

The cyclic group HET may contain a hydrogen bond donor group adjacent the group G and hence the cyclic group HET may take the form:

5



where Q^x is a hydrogen bond acceptor atom or group and D is a hydrogen bond donor group.

The hydrogen bond donor group can be, for example, NH, C-NH₂, C-NH, C-OH, C-SH, or C-H.

10 n & R⁴

Excluding from consideration any atoms or groups that may form part of the hydrogen bond acceptor Q^x where present, the cyclic group HET may be an unsubstituted ring system ($n = 0$) or a substituted ring system ($n = 1, 2, 3$ or 4).

15 In formula (I), R^4 is independently selected from oxo; halogen; C₁₋₆ hydrocarbonyl optionally substituted by halogen, hydroxy or C₁₋₂ alkoxy; cyano; C₁₋₆ hydrocarbyloxy optionally substituted by halogen, hydroxy or C₁₋₂ alkoxy; CONH₂; CONHR⁹; CF₃; NH₂; NHCOR⁹; NHCONHR⁹; and NHR⁹.

More typically, R^4 is selected from oxo, amino, $NHCO R^9$; NHR^9 ; halogen, C_{1-5} saturated hydrocarbyl, cyano and CF_3 . Preferred values for R^4 include oxo and methyl.

Preferably n is 0, 1 or 2.

In one embodiment, n is 0.

- 5 In another embodiment, n is 1 or 2.

Where R^4 is $CONHR^9$, $NHCO R^9$; $NHCONHR^9$; or NHR^9 ; R^9 is a group R^{9a} or $(CH_2)R^{9a}$, wherein R^{9a} is a monocyclic or bicyclic group which may be carbocyclic or heterocyclic.

Examples of carbocyclic and heterocyclic groups are set out above in the General Preferences and Definitions section.

- 10 Typically the carbocyclic and heterocyclic groups are monocyclic.


Preferably the carbocyclic and heterocyclic groups are aromatic.

The group R^9 is typically unsubstituted phenyl or benzyl, or phenyl or benzyl substituted by 1,2 or 3 substituents selected from halogen; hydroxy; trifluoromethyl; cyano; carboxy; C_{1-4} alkoxycarbonyl; C_{1-4} acyloxy; amino; mono- or di- C_{1-4} alkylamino; C_{1-4} alkyl optionally substituted by halogen, hydroxy or C_{1-2} alkoxy; C_{1-4} alkoxy optionally substituted by halogen, hydroxy or C_{1-2} alkoxy; phenyl, five and six membered heteroaryl groups containing up to 3 heteroatoms selected from O, N and S; and saturated carbocyclic and heterocyclic groups containing up to 2 heteroatoms selected from O, S and N.

15

























Examples of the moiety:

























20















are set out in Table 4. The asterisk marks the point of attachment to the group E.

Table 4

 D1	 D2	 D3	 D4
 D5	 D6	 D7	 D8
 D9	 D10	 D11	 D12
 D13	 D14	 D15	 D16
 D17	 D18	 D19	 D20
 D21	 D22	 D23	 D24

 D25	 D26	 D27	 D28
 D29	 D30	 D31	 D32
 D33	 D34	 D35	 D36
 D37	 D38	 D39	 D40
 D41	 D42	 D43	 D44
 D45	 D46	 D47	 D48


 D49	 D50	 D51	 D52
 D53	 D54	 D55	 D56
 D57	 D58	 D59	 D60

Preferred groups include D1, D4, D7, D9 and D11.

A particularly preferred group is D1.

Particular and Preferred Sub-groups of the formula (I)

One sub-group of compounds of the formula (I) has the general formula (II):




5

wherein the group A is attached to the *meta* or *para* position of the benzene ring, *q* is 0-4; R^1 , R^2 , R^3 , R^4 and R^5 are as defined herein in respect of formula (I) and sub-groups, examples and preferences thereof; and R^8 is a substituent group as hereinbefore defined. In

formula (II), q is preferably 0, 1 or 2, more preferably 0 or 1 and most preferably 0.


Preferably the group A is attached to the *para* position of the benzene ring.

Within formula (II), one particular sub-group of compounds of the invention is represented by the formula (III):




where A' is the residue of the group A and R¹ to R⁴ are as defined herein.

Within formula (III), one preferred group of compounds is represented by the formula (IV):



wherein z is 0, 1 or 2, R²⁰ is selected from hydrogen, methyl, hydroxy and fluorine and R¹ to R⁴ are as defined herein, provided that when z is 0, R²⁰ is other than hydroxy.


Another group of compounds within formula (III) is represented by formula (V):



wherein R^1 and R^3 to R^4 are as defined herein.

In formula (V), R^3 is preferably selected from hydrogen and C_{1-4} hydrocarbyl, for example C_{1-4} alkyl such as methyl, ethyl and isopropyl. More preferably R^3 is hydrogen.

- 5 Another group of preferred compounds of the invention can be represented by the formula (VI):




wherein T is N or CH, n is 0, 1 or 2 (preferably 0 or 1, and more preferably 0), R^{16} is selected from hydrogen and amino; and A, E and R^1 to R^4 are as defined herein.

- 10 In formula (VI), E is preferably a phenyl group.

In formula (VI), R^4 is preferably absent (i.e. n is 0).

Within formula (VI), one preferred sub-group of compounds can be represented by the formula (VII);



In one sub-group of compounds within formula (VII), T is CH and R¹⁶ is hydrogen.

In another sub-group of compounds within formula (VII), T is N. Within this sub-group, R¹⁶ is preferably amino.

- 5 In each of formulae (II) to (V), R¹ is preferably an optionally substituted phenyl group as defined herein.

- For the avoidance of doubt, it is to be understood that each general and specific preference, embodiment and example of the groups R¹ may be combined with each general and specific preference, embodiment and example of the groups R² and/or R³ and/or R⁴ and/or R⁵ and/or R⁹ and that all such combinations are embraced by this application.
- 10

- The various functional groups and substituents making up the compounds of the formula (I) are typically chosen such that the molecular weight of the compound of the formula (I) does not exceed 1000. More usually, the molecular weight of the compound will be less than 750, for example less than 700, or less than 650, or less than 600, or less than 550.
- 15 More preferably, the molecular weight is less than 525 and, for example, is 500 or less.

Particular compounds of the invention are as illustrated in the examples below.

Salts, Solvates, Tautomers, Isomers, N-Oxides, Esters, Prodrugs and Isotopes

- In this section, as in all other sections of this application, unless the context indicates otherwise, references to formula (I) included references to formulae (II), (III), (IV), (V), (VI) and (VII) and all other sub-groups, preferences and examples thereof as defined herein.
- 20

Unless otherwise specified, a reference to a particular compound also includes ionic, salt, solvate, and protected forms thereof, for example, as discussed below.

Many compounds of the formula (I) can exist in the form of salts, for example acid addition salts or, in certain cases salts of organic and inorganic bases such as carboxylate,

- 5 sulphonate and phosphate salts. All such salts are within the scope of this invention, and references to compounds of the formula (I) include the salt forms of the compounds. As in the preceding sections of this application, all references to formula (I) should be taken to refer also to formula (II) and sub-groups thereof unless the context indicates otherwise.

Salt forms may be selected and prepared according to methods described in

- 10 *Pharmaceutical Salts: Properties, Selection, and Use*, P. Heinrich Stahl (Editor), Camille G. Wermuth (Editor), ISBN: 3-90639-026-8, Hardcover, 388 pages, August 2002. For example, acid addition salts may be prepared by dissolving the free base in an organic solvent in which a given salt form is insoluble or poorly soluble and then adding the required acid in an appropriate solvent so that the salt precipitates out of solution.

- 15 Acid addition salts may be formed with a wide variety of acids, both inorganic and organic. Examples of acid addition salts include salts formed with an acid selected from the group consisting of acetic, 2,2-dichloroacetic, adipic, alginic, ascorbic (e.g. L-ascorbic), L-aspartic, benzenesulphonic, benzoic, 4-acetamidobenzoic, butanoic, (+) camphoric, camphor-sulphonic, (+)-(1*S*)-camphor-10-sulphonic, capric, caproic, caprylic, cinnamic, 20 citric, cyclamic, dodecylsulphuric, ethane-1,2-disulphonic, ethanesulphonic, 2-hydroxyethanesulphonic, formic, fumaric, galactaric, gentisic, glucoheptonic, D-gluconic, glucuronic (e.g. D-glucuronic), glutamic (e.g. L-glutamic), α -oxoglutaric, glycolic, hippuric, hydrobromic, hydrochloric, hydriodic, isethionic, lactic (e.g. (+)-L-lactic and (\pm)-DL-lactic), lactobionic, maleic, malic, (-)-L-malic, malonic, (\pm)-DL-mandelic, 25 methanesulphonic, naphthalenesulphonic (e.g. naphthalene-2-sulphonic), naphthalene-1,5-disulphonic, 1-hydroxy-2-naphthoic, nicotinic, nitric, oleic, orotic, oxalic, palmitic, pamoic, phosphoric, propionic, L-pyroglutamic, salicylic, 4-amino-salicylic, sebacic, stearic, succinic, sulphuric, tannic, (+)-L-tartaric, thiocyanic, toluenesulphonic (e.g. *p*-toluenesulphonic), undecylenic and valeric acids, as well as acylated amino acids and 30 cation exchange resins.

One particular group of acid addition salts includes salts formed with hydrochloric, hydriodic, phosphoric, nitric, sulphuric, citric, lactic, succinic, maleic, malic, isethionic,

fumaric, benzenesulphonic, toluenesulphonic, methanesulphonic, ethanesulphonic, naphthalenesulphonic, valeric, acetic, propanoic, butanoic, malonic, glucuronic and lactobionic acids.

Another group of acid addition salts includes salts formed from acetic, adipic, ascorbic, aspartic, citric, DL-Lactic, fumaric, gluconic, glucuronic, hippuric, hydrochloric, glutamic, DL-malic, methanesulphonic, sebacic, stearic, succinic and tartaric acids.

A further group of acid addition salts includes salts formed with formic, hydrochloric, acetic and trifluoroacetic acids.

Particular salts are those formed with hydrochloric, formic and acetic acids, and more particularly hydrochloric and acetic acids

The compounds of the invention may exist as mono- or di-salts depending upon the pKa of the acid from which the salt is formed.

If the compound is anionic, or has a functional group which may be anionic (e.g., -COOH may be -COO^-), then a salt may be formed with a suitable cation. Examples of suitable inorganic cations include, but are not limited to, alkali metal ions such as Na^+ and K^+ , alkaline earth cations such as Ca^{2+} and Mg^{2+} , and other cations such as Al^{3+} . Examples of suitable organic cations include, but are not limited to, ammonium ion (i.e., NH_4^+) and substituted ammonium ions (e.g., NH_3R^+ , NH_2R_2^+ , NHR_3^+ , NR_4^+). Examples of some suitable substituted ammonium ions are those derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids, such as lysine and arginine. An example of a common quaternary ammonium ion is $\text{N}(\text{CH}_3)_4^+$.

Where the compounds of the formula (I) contain an amine function, these may form quaternary ammonium salts, for example by reaction with an alkylating agent according to methods well known to the skilled person. Such quaternary ammonium compounds are within the scope of formula (I).

Compounds of the formula (I) containing an amine function may also form N-oxides. A reference herein to a compound of the formula (I) that contains an amine function also includes the N-oxide.

Where a compound contains several amine functions, one or more than one nitrogen atom may be oxidised to form an N-oxide. Particular examples of N-oxides are the N-oxides of a tertiary amine or a nitrogen atom of a nitrogen-containing heterocycle.

- 5 N-Oxides can be formed by treatment of the corresponding amine with an oxidizing agent such as hydrogen peroxide or a per-acid (e.g. a peroxycarboxylic acid), see for example *Advanced Organic Chemistry*, by Jerry March, 4th Edition, Wiley Interscience, pages. More particularly, N-oxides can be made by the procedure of L. W. Deady (*Syn. Comm.* 1977, 7, 509-514) in which the amine compound is reacted with *m*-chloroperoxybenzoic acid (MCPBA), for example, in an inert solvent such as dichloromethane.
- 10 Compounds of the formula (I) may exist in a number of different geometric isomeric, and tautomeric forms and references to compounds of the formula (I) include all such forms. For the avoidance of doubt, where a compound can exist in one of several geometric isomeric or tautomeric forms and only one is specifically described or shown, all others are nevertheless embraced by formula (I).
- 15 Where compounds of the formula (I) contain one or more chiral centres, and can exist in the form of two or more optical isomers, references to compounds of the formula (I) include all optical isomeric forms thereof (e.g. enantiomers and diastereoisomers), either as individual optical isomers, or mixtures or two or more optical isomers, unless the context requires otherwise.
- 20 For example, the group A can include one or more chiral centres. Thus, when E and R¹ are both attached to the same carbon atom on the linker group A, the said carbon atom is typically chiral and hence the compound of the formula (I) will exist as a pair of enantiomers (or more than one pair of enantiomers where more than one chiral centre is present in the compound).
- 25 The optical isomers may be characterised and identified by their optical activity (i.e. as + and – isomers) or they may be characterised in terms of their absolute stereochemistry using the “R and S” nomenclature developed by Cahn, Ingold and Prelog, see *Advanced Organic Chemistry* by Jerry March, 4th Edition, John Wiley & Sons, New York, 1992, pages 109-114, and see also Cahn, Ingold & Prelog, *Angew. Chem. Int. Ed. Engl.*, 1966, 5, 30 385-415.

Optical isomers can be separated by a number of techniques including chiral chromatography (chromatography on a chiral support) and such techniques are well known to the person skilled in the art.

5 As an alternative to chiral chromatography, optical isomers can be separated by forming diastereoisomeric salts with chiral acids such as (+)-tartaric acid, (-)-pyroglutamic acid, (-)-di-toluloyl-L-tartaric acid, (+)-mandelic acid, (-)-malic acid, and (-)-camphorsulphonic, separating the diastereoisomers by preferential crystallisation, and then dissociating the salts to give the individual enantiomer of the free base.

10 Where compounds of the formula (I) exist as two or more optical isomeric forms, one enantiomer in a pair of enantiomers may exhibit advantages over the other enantiomer, for example, in terms of biological activity. Thus, in certain circumstances, it may be desirable to use as a therapeutic agent only one of a pair of enantiomers, or only one of a plurality of diastereoisomers. Accordingly, the invention provides compositions containing a compound of the formula (I) having one or more chiral centres, wherein at least 55% (e.g.
15 at least 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95%) of the compound of the formula (I) is present as a single optical isomer (e.g. enantiomer or diastereoisomer). In one general embodiment, 99% or more (e.g. substantially all) of the total amount of the compound of the formula (I) may be present as a single optical isomer (e.g. enantiomer or diastereoisomer).

20 Esters such as carboxylic acid esters and acyloxy esters of the compounds of formula (I) bearing a carboxylic acid group or a hydroxyl group are also embraced by Formula (I). In one embodiment of the invention, formula (I) includes within its scope esters of compounds of the formula (I) bearing a carboxylic acid group or a hydroxyl group. In another embodiment of the invention, formula (I) does not include within its scope esters of
25 compounds of the formula (I) bearing a carboxylic acid group or a hydroxyl group. Examples of esters are compounds containing the group $-C(=O)OR$, wherein R is an ester substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Particular examples of ester groups include, but are not limited to, $-C(=O)OCH_3$, $-C(=O)OCH_2CH_3$, $-C(=O)OC(CH_3)_3$, and $-C(=O)OPh$. Examples
30 of acyloxy (reverse ester) groups are represented by $-OC(=O)R$, wherein R is an acyloxy substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Particular examples of acyloxy groups include, but are not

limited to, $-\text{OC}(=\text{O})\text{CH}_3$ (acetoxy), $-\text{OC}(=\text{O})\text{CH}_2\text{CH}_3$, $-\text{OC}(=\text{O})\text{C}(\text{CH}_3)_3$, $-\text{OC}(=\text{O})\text{Ph}$, and $-\text{OC}(=\text{O})\text{CH}_2\text{Ph}$.

Also encompassed by formula (I) are any polymorphic forms of the compounds, solvates (e.g. hydrates), complexes (e.g. inclusion complexes or clathrates with compounds such as cyclodextrins, or complexes with metals) of the compounds, and pro-drugs of the compounds. By “prodrugs” is meant for example any compound that is converted *in vivo* into a biologically active compound of the formula (I).

For example, some prodrugs are esters of the active compound (e.g., a physiologically acceptable metabolically labile ester). During metabolism, the ester group ($-\text{C}(=\text{O})\text{OR}$) is cleaved to yield the active drug. Such esters may be formed by esterification, for example, of any of the carboxylic acid groups ($-\text{C}(=\text{O})\text{OH}$) in the parent compound, with, where appropriate, prior protection of any other reactive groups present in the parent compound, followed by deprotection if required.

Examples of such metabolically labile esters include those of the formula $-\text{C}(=\text{O})\text{OR}$ wherein R is:

C_{1-7} alkyl (e.g., -Me, -Et, -nPr, -iPr, -nBu, -sBu, -iBu, -tBu);
 C_{1-7} aminoalkyl (e.g., aminoethyl; 2-(N,N-diethylamino)ethyl; 2-(4-morpholino)ethyl); and
acyloxy- C_{1-7} alkyl (e.g., acyloxymethyl; acyloxyethyl; pivaloyloxymethyl; acetoxymethyl;
1-acetoxyethyl; 1-(1-methoxy-1-methyl)ethyl-carbonyloxyethyl; 1-(benzoyloxy)ethyl;
isopropoxy-carbonyloxymethyl; 1-isopropoxy-carbonyloxyethyl; cyclohexyl-
carbonyloxymethyl; 1-cyclohexyl-carbonyloxyethyl; cyclohexyloxy-carbonyloxymethyl; 1-
cyclohexyloxy-carbonyloxyethyl; (4-tetrahydropyranyloxy) carbonyloxymethyl; 1-(4-
tetrahydropyranyloxy)-carbonyloxyethyl; (4-tetrahydropyranyl)carbonyloxymethyl; and
1-(4-tetrahydropyranyl)-carbonyloxyethyl).

Also, some prodrugs are activated enzymatically to yield the active compound, or a compound which, upon further chemical reaction, yields the active compound (for example, as in antigen-directed enzyme pro-drug therapy (ADEPT), gene-directed enzyme pro-drug therapy (GDEPT) and ligand-directed enzyme pro-drug therapy (LIDEPT). For example, the prodrug may be a sugar derivative or other glycoside conjugate, or may be an amino acid ester derivative.

Methods for the preparation of compounds of the formula (I)

In this section, as in all other sections of this application, unless the context indicates otherwise, references to formula (I) included references to formulae (Ia), (Ib), (II), (III), (IV), (V), (VI) and (VII) and all other sub-groups, preferences and examples thereof as defined herein.

- 5 Compounds of the formula (I) can be prepared by reaction of a compound of the formula (X) with a compound of the formula (XI) or an N-protected derivative thereof:



- wherein A, E, G, n and R¹ to R⁴ are as hereinbefore defined, one of the groups X and Y is chlorine, bromine or iodine or a trifluoromethanesulphonate (triflate) group, and the other one of the groups X and Y is a boronate residue, for example a boronate ester or boronic acid residue.
- 10

- The reaction can be carried out under typical Suzuki Coupling conditions in the presence of a palladium catalyst such as bis(tri-*t*-butylphosphine)palladium and a base (e.g. a carbonate such as potassium carbonate). The reaction may be carried out in an aqueous solvent system, for example aqueous ethanol, and the reaction mixture is typically subjected to heating, for example to a temperature in excess of 100°C.
- 15


- An illustrative synthetic route involving a Suzuki coupling step is shown in Scheme 1. The starting material for the synthetic route shown in scheme 1 is the halo-substituted aryl- or heteroarylmethyl nitrile (XII) in which X is a chlorine, bromine or iodine atom or a triflate group. The nitrile (XII) is condensed with the aldehyde R¹CHO in the presence of an alkali such as sodium or potassium hydroxide in an aqueous solvent system such as aqueous ethanol. The reaction can be carried out at room temperature.
- 20

- The resulting substituted acrylonitrile derivative (XIII) is then treated with a reducing agent that will selectively reduce the alkene double bond without reducing the nitrile group. A borohydride such as sodium borohydride may be used for this purpose to give the substituted acetonitrile derivative (XIV). The reduction reaction is typically carried out in a
- 25

solvent such as ethanol and usually with heating, for example to a temperature up to about 65°C.

The reduced nitrile (XIV) is then coupled with the boronate ester (XV) under the Suzuki coupling conditions described above to give a compound of the formula (I) in which A-

5 NR^2R^3 is a substituted acetonitrile group.





Scheme 1

The substituted acetonitrile compound (XVI) may then be reduced to the corresponding amine (XVII) by treatment with a suitable reducing agent such as Raney nickel and ammonia in ethanol.

5 The synthetic route shown in Scheme 1 gives rise to amino compounds of the formula (I) in which the aryl or heteroaryl group E is attached to the β -position of the group A relative to the amino group. In order to give amino compounds of the formula (I) in which R¹ is attached to the β -position relative to the amino group, the functional groups on the two starting materials in the condensation step can be reversed so that a compound of the formula X-E-CHO wherein X is bromine, chlorine, iodine or a triflate group is condensed
10 with a compound of the formula R¹-CH₂-CN to give a substituted acrylonitrile derivative which is then reduced to the corresponding acetonitrile derivative before coupling with the boronate (XV) and reducing the cyano group to an amino group.


Compounds of the formula (I) in which R¹ is attached to the α -position relative to the amino group can be prepared by the sequence of reactions shown in Scheme 2.

15 In Scheme 2, the starting material is a halo-substituted aryl- or heteroarylmethyl Grignard reagent (XVIII, X = bromine or chlorine) which is reacted with the nitrile R¹-CN in a dry ether such as diethyl ether to give an intermediate imine (not shown) which is reduced to give the amine (XIX) using a reducing agent such as lithium aluminium hydride. The amine (XIX) can be reacted with the boronate ester (XV) under the Suzuki coupling
20 conditions described above to yield the amine (XX).




Scheme 2

Compounds of the formula (I) can also be prepared from the substituted nitrile compound (XXI).




The nitrile (XXI) can be condensed with an aldehyde of the formula $R^1-(CH_2)_r-CHO$, wherein r is 0 or 1, and the resulting substituted acrylonitrile subsequently reduced to the corresponding substituted nitrile under conditions analogous to those set out in Scheme 1 above. The protecting group PG can then be removed by an appropriate method. The nitrile compound may subsequently be reduced to the corresponding amine by the use of a suitable reducing agent as described above.

The nitrile compound (XXI) may also be reacted with a Grignard reagent of the formula $R^1-(CH_2)_r-MgBr$ under standard Grignard reaction conditions followed by deprotection to give an amino compound of the invention which has the structure shown in formula (XXII).



In the preparative procedures outlined above, the group E and the cyclic group HET are coupled together by the reaction of a halo-aryl or heteroaryl compound with a boronate ester or boronic acid in the presence of a palladium catalyst and base. Many boronates suitable for use in preparing compounds of the invention are commercially available, for example from Boron Molecular Limited of Noble Park, Australia, or from Combi-Blocks Inc, of San Diego, USA. Where the boronates are not commercially available, they can be prepared by methods known in the art, for example as described in the review article by N. Miyaura and A. Suzuki, *Chem. Rev.* 1995, 95, 2457. Thus, boronates can be prepared by reacting the corresponding bromo-compound with an alkyl lithium such as butyl lithium and then reacting with a borate ester. The resulting boronate ester derivative can, if desired, be hydrolysed to give the corresponding boronic acid.

Compounds of the formula (I) in which the group A contains a nitrogen atom attached to the group E can be prepared by well known synthetic procedures from compounds of the formula (XXIII) or a protected form thereof. Compounds of the formula (XXIII) can be obtained by a Suzuki coupling reaction of a compound of the formula (XV) (see Scheme 1) with a compound of the formula $Br-E-NH_2$ such as 4-bromoaniline.




Compounds of the formula (I) in which R^1 and E are connected to the same carbon atom can be prepared as shown in Scheme 3.

In Scheme 3, an aldehyde compound (XXIV) where X is bromine, chlorine, iodine or a triflate group is condensed with ethyl cyanoacetate in the presence of a base to give a cyanoacrylate ester intermediate (XXV). The condensation is typically carried out in the presence of a base, preferably a non-hydroxide such as piperidine, by heating under Dean Stark conditions.

The cyanoacrylate intermediate (XXV) is then reacted with a Grignard reagent R^1MgBr suitable for introducing the group R^1 by Michael addition to the carbon-carbon double bond of the acrylate moiety. The Grignard reaction may be carried out in a polar non-protic solvent such as tetrahydrofuran at a low temperature, for example at around 0 °C. The product of the Grignard reaction is the cyano propionic acid ester (XXVI) and this is subjected to hydrolysis and decarboxylation to give the propionic acid derivative (XXVII). The hydrolysis and decarboxylation steps can be effected by heating in an acidic medium, for example a mixture of sulphuric acid and acetic acid.

The propionic acid derivative (XXVII) is converted to the amide (XXVIII) by reaction with an amine HNR^2R^3 under conditions suitable for forming an amide bond. The coupling reaction between the propionic acid derivative (XXVII) and the amine HNR^2R^3 is preferably carried out in the presence of a reagent of the type commonly used in the formation of peptide linkages. Examples of such reagents include 1,3-dicyclohexylcarbodiimide (DCC) (Sheehan *et al*, *J. Amer. Chem Soc.* 1955, 77, 1067), 1-ethyl-3-(3'-dimethylaminopropyl)-carbodiimide (referred to herein either as EDC or EDAC) (Sheehan *et al*, *J. Org. Chem.*, 1961, 26, 2525), uronium-based coupling agents such as *O*-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (HATU) and phosphonium-based coupling agents such as 1-benzo-triazolyloxytris-(pyrrolidino)phosphonium hexafluorophosphate (PyBOP) (Castro *et al*, *Tetrahedron Letters*, 1990, 31, 205).



Scheme 3

Carbodiimide-based coupling agents are advantageously used in combination with 1-hydroxy-7-azabenzotriazole (HOAt) (L. A. Carpino, *J. Amer. Chem. Soc.*, 1993, 115, 4397) or 1-hydroxybenzotriazole (HOBt) (Konig *et al*, *Chem. Ber.*, 103, 708, 2024-2034).

Preferred coupling reagents include EDC (EDAC) and DCC in combination with HOAt or
5 HOBt.

The coupling reaction is typically carried out in a non-aqueous, non-protic solvent such as acetonitrile, dioxan, dimethylsulphoxide, dichloromethane, dimethylformamide or N-methylpyrrolidine, or in an aqueous solvent optionally together with one or more miscible co-solvents. The reaction can be carried out at room temperature or, where the reactants
10 are less reactive (for example in the case of electron-poor anilines bearing electron withdrawing groups such as sulphonamide groups) at an appropriately elevated temperature. The reaction may be carried out in the presence of a non-interfering base, for example a tertiary amine such as triethylamine or *N,N*-diisopropylethylamine.

Where the amine HNR^2R^3 is ammonia, the amide coupling reaction can be carried out
15 using 1,1'-carbonyldiimidazole (CDI) to activate the carboxylic acid before addition of the ammonia.

As an alternative, a reactive derivative of the carboxylic acid, e.g. an anhydride or acid chloride, may be used. Reaction with a reactive derivative such as an anhydride is typically accomplished by stirring the amine and anhydride at room temperature in the presence of a
20 base such as pyridine.

The amide (XXVIII) can be converted to a compound of the formula (XXX) (which corresponds to a compound of the formula (I) wherein A has an oxo substituent next to the NR^2R^3 group) by reaction with a boronate (XV) under Suzuki coupling conditions as described above. The amide (XXX) can subsequently be reduced using a hydride reducing
25 agent such as lithium aluminium hydride in the presence of aluminium chloride to give an amine of the formula (XXXI) (which corresponds to a compound of the formula (I) wherein A is $\text{CH-CH}_2\text{-CH}_2\text{-}$). The reduction reaction is typically carried out in an ether solvent, for example diethyl ether, with heating to the reflux temperature of the solvent.

Rather than reacting the amide (XXVIII) with the boronate (XV), the amide may instead be
30 reduced with lithium aluminium hydride/aluminium chloride, for example in an ether solvent at ambient temperature, to give the amine (XXIX) which is then reacted with the

boronate (XV) under the Suzuki coupling conditions described above to give the amine (XXX).

In order to obtain the homologue of the amine (XXIX) containing one fewer methylene group, the carboxylic acid (XXVII) can be converted to the azide by standard methods and
5 subjected to a Curtius rearrangement in the presence of an alcohol such as benzyl alcohol to give a carbamate (see *Advanced Organic Chemistry*, 4th edition, by Jerry March, John Wiley & sons, 1992, pages 1091-1092). The benzylcarbamate can function as a protecting group for the amine during the subsequent Suzuki coupling step, and the
10 benzyloxycarbonyl moiety in the carbamate group can then be removed by standard methods after the coupling step. Alternatively, the benzylcarbamate group can be treated with a hydride reducing agent such as lithium aluminium hydride to give a compound in which NR^2R^3 is a methylamino group instead of an amino group.


In a variation on the reaction sequence shown in Scheme 3, the aldehyde starting material (XXIX) can be one in which the moiety X is a cyclic group corresponding to the cyclic
15 group HET, rather than being bromine, chlorine, iodine or a triflate group. In this case, the need for the Suzuki coupling step later in the reaction sequence is avoided.

Intermediate compounds of the formula (X) where the moiety X is a chlorine, bromine or iodine atom and A is a group $\text{CH-CH}_2\text{-}$ can be prepared by the reductive amination of an aldehyde compound of the formula (XXXII):




with an amine of the formula HNR^2R^3 under standard reductive amination conditions, for example in the presence of sodium cyanoborohydride in an alcohol solvent such as methanol or ethanol.


The aldehyde compound (XXXII) can be obtained by oxidation of the corresponding
25 alcohol (XXXIII) using, for example, the Dess-Martin periodinane (see Dess, D.B.; Martin, J.C. *J. Org. Soc.*, 1983, 48, 4155 and *Organic Syntheses*, Vol. 77, 141).



Compounds of the formula (I) where A, N and R² together form a cyclic group can be formed by the Suzuki coupling of a boronate compound of the formula (XV) with a cyclic intermediate of the formula (XXXIV) or an N-protected derivative thereof.



Cyclic intermediates of the formula (XXXIV), where R¹ is an aryl group such as an optionally substituted phenyl group, can be formed by Friedel Crafts alkylation of an aryl compound R¹-H with a compound of the formula (XXXV):





- 10 The alkylation is typically carried out in the presence of a Lewis acid such as aluminium chloride at a reduced temperature, for example less than 5 °C.

The Friedel Crafts reaction has been found to be of general applicability to the preparation of a range of intermediates of the formula (X). Accordingly, in a general method of making compounds of the formula (X), a compound of the formula (LXX):




is reacted with a compound of the formula R¹-H under Friedel Crafts alkylation conditions, for example in the presence of an aluminium halide (e.g. AlCl₃).

- In a further method for the preparation of a compound of the formula (I) wherein the moiety NR^2R^3 is attached to a CH_2 group of the moiety A, an aldehyde of the formula (XXXVI) can be coupled with an amine of the formula HNR^2R^3 under reductive amination conditions as described above. In the formulae (XXXVI) and (XXXVII), A' is the residue of the group A – i.e. the moieties A' and CH_2 together form the group A. The aldehyde (XXXVI) can be formed by oxidation of the corresponding alcohol using, for example, Dess-Martin periodinane.



- A Friedel Crafts alkylation procedure of the type described above for the synthesis of intermediates of the formula (XXXIV) can also be used to prepare intermediates of the formula (X) wherein X is bromine. An example of such a procedure is shown in Scheme 4.



Scheme 4


- The starting material for the synthetic route shown in Scheme 4 is the epoxide (XXXVIII) which can either be obtained commercially or can be made by methods well known to the skilled person, for example by reaction of the aldehyde Br-E-CHO with trimethylsulphonium iodide. The epoxide (XXXVIII) is reacted with an amine HNR^2R^3

under conditions suitable for a ring-opening reaction with the epoxide to give a compound of the formula (XXXIX). The ring opening reaction can be carried out in a polar solvent such as ethanol at room temperature or optionally with mild heating, and typically with a large excess of the amine.


- 5 The amine (XXXIX) is then reacted with an aryl compound R^1H , typically a phenyl compound, capable of taking part in a Friedel Crafts alkylation (see for example *Advanced Organic Chemistry*, by Jerry March, pages 534-542). Thus, the amine of formula (XXXIX) is typically reacted with the aryl compound R^1H in the presence of an aluminium chloride catalyst at or around room temperature. Where the aryl compound R^1H is a liquid,
- 10 e.g. as in the case of a methoxybenzene (e.g. anisole) or a halobenzene such as chlorobenzene, the aryl compound may serve as the solvent. Otherwise, a less reactive solvent such as nitrobenzene may be used. The Friedel Crafts alkylation of the compound R^1H with the amine (XXXIX) gives a compound of the formula (XL) which corresponds to a compound of the formula (X) wherein X is bromine and A is $CHCH_2$.
- 15 The hydroxy intermediate (XXXIX) in Scheme 4 can also be used to prepare compounds of the formula (X) in which the carbon atom of the hydrocarbon linker group A adjacent the group R^1 is replaced by an oxygen atom. Thus the compound of formula (XXXIX), or an N-protected derivative thereof (where R^2 or R^3 are hydrogen) can be reacted with a phenolic compound of the formula R^1-OH under Mitsunobu alkylation conditions, e.g. in
- 20 the presence of diethyl azodicarboxylate and triphenylphosphine. The reaction is typically carried out in a polar non-protic solvent such as tetrahydrofuran at a moderate temperature such as ambient temperature.

- A further use of the hydroxy-intermediate (XXXIX) is for the preparation of the corresponding fluoro-compound. Thus, the hydroxy group can be replaced by fluorine by
- 25 reaction with pyridine:hydrogen fluoride complex (Olah's reagent). The fluorinated intermediate can then be subjected to a Suzuki coupling reaction to give a compound of the formula (I) with a fluorinated hydrocarbon group A. A fluorinated compound of the formula (I) could alternatively be prepared by first coupling the hydroxy intermediate (XXXIX), or a protected form thereof, with a heteroaryl boronic acid or boronate under
- 30 Suzuki conditions and then replacing the hydroxy group in the resulting compound of formula (I) with fluorine using pyridine: hydrogen fluoride complex.


Compounds of the formula (I) in which the moiety:



is a group:



where A'' is the hydrocarbon residue of the group A, can be prepared by the sequence of
5 reactions shown in Scheme 5.



Scheme 5


As shown in Scheme 5, the aldehyde (XXIV) is reacted with a Grignard reagent R^1MgBr under standard Grignard conditions to give the secondary alcohol (XLI). The secondary alcohol can then be reacted with a compound of the formula (XLII) in which $R^{2'}$ and $R^{3'}$ represent the groups R^2 and R^3 or an amine-protecting group, A'' is the residue of the group A, and X' represents a hydroxy group or a leaving group.

The amine protecting group can be, for example, a phthalolyl group in which case $NR^{2'}R^{3'}$ is a phthalimido group.


When X' is a hydroxy group, the reaction between compounds (XLI) and (XLII) can take the form of an toluene sulphonic acid catalysed condensation reaction. Alternatively, when X' is a leaving group such as halogen, the alcohol (XLI) can first be treated with a strong base such as sodium hydride to form the alcoholate which then reacts with the compound (XLII).

The resulting compound of the formula (XLIII) is then subjected to a Suzuki coupling reaction with the boronate reagent (XV) under typical Suzuki coupling conditions of the type described above to give a compound of the formula (XLIV). The protecting group can then be removed from the protected amine group $NR^{2'}R^{3'}$ to give a compound of the formula (I).


Compounds of the formula (I) in which the moiety:



is a group:



where A'' is the hydrocarbon residue of the group A, can be prepared by the sequence of reactions shown in Scheme 6.



Scheme 6

- The starting material in Scheme 6 is the chloroacyl compound (XLV) which can be prepared by literature methods (e.g. the method described in *J. Med. Chem.*, 2004, 47, 3924-3926) or methods analogous thereto. Compound (XLV) is converted into the secondary alcohol (XLVI) by reduction with a hydride reducing agent such as sodium borohydride in a polar solvent such as water/tetrahydrofuran. The secondary alcohol (XLVI) can then be reacted with a phenolic compound of the formula R¹-OH under Mitsunobu alkylation conditions, e.g. in the presence of diethyl azodicarboxylate and triphenylphosphine, as described above, to give the aryl ether compound (XLVII). The chlorine atom in the aryl ether compound (XLVII) is then displaced by reaction with an amine HNR²R³ to give a compound of the formula (XLVIII). The nucleophilic displacement reaction may be carried out by heating the amine with the aryl ether in a polar

solvent such as an alcohol at an elevated temperature, for example approximately 100 °C. The heating may advantageously be achieved using a microwave heater. The resulting amine (XLVIII) can then be subjected to a Suzuki coupling procedure with a boronate of the formula (XV) as described above to give the compound (XLIX).

- 5 In a variation on the reaction sequence shown in Scheme 6, the secondary alcohol (XLVI) can be subjected to a nucleophilic displacement reaction with an amine HNR^2R^3 before introducing the group R^1 by means of the Mitsunobu ether-forming reaction.


Another route to compounds of the formula (I) in which E and R^1 are attached to the same carbon atom in the group A is illustrated in Scheme 7.

- 10 In Scheme 7, boronic acid compound (L) is reacted under Suzuki coupling conditions with the cyano compound X-E-CN in which X is typically a halogen such as bromine or chlorine. The boronic acid (L) can be prepared using the method described in EP 1382603 or methods analogous thereto.

- The resulting nitrile (LI) may then be reacted with a Grignard reagent $\text{R}^1\text{-MgBr}$ to
15 introduce the group R^1 and form the ketone (LII). The ketone (LII) is converted to the enamine (LIV) by reaction with the diphenylphosphinoylmethylamine (LIII) in the presence of a strong base such as an alkyl lithium, particularly butyl lithium.


- The enamine (LIV) is then subjected to hydrogenation over a palladium on charcoal catalyst to reduce the double bond of the enamine and remove the 1-phenethyl group,
20 thereby yielding a compound of the formula (LV).

Alternatively, the enamine (LIV) can be reduced with a hydride reducing agent under the conditions described in *Tetrahedron: Asymmetry* 14 (2003) 1309-1316 and subjected to a chiral separation. Removal of the protecting 2-phenethyl group then gives an optically active form of the compound of formula (LV).



Scheme 7

Intermediates of the formula (X) wherein A and R^2 link to form a ring containing an oxygen atom can be prepared by the general method illustrated in Scheme 8.




Scheme 8

In Scheme 8, a ketone (LVI) is reacted with trimethylsulphonium iodide to form the epoxide (LVII). The reaction is typically carried out in the presence of a hydride base such as sodium hydride in a polar solvent such as dimethylsulphoxide.


- 5 The epoxide (LVII) is subjected to a ring opening reaction with ethanolamine in the presence of a non-interfering base such as triethylamine in a polar solvent such as an alcohol (e.g. isopropanol), usually with mild heating (e.g. up to approximately 50 °C). The resulting secondary alcohol is then cyclised to form the morpholine ring by treatment with concentrated sulphuric acid in a solvent such as ethanolic dichloromethane.
- 10 The morpholine intermediate (LIX) can then reacted with the boronate (XV) under Suzuki coupling conditions to give the compound of formula (LX), which corresponds to a compound of the formula (I) in which A-NR²R³ forms a morpholine group.

Instead of reacting the epoxide (LVII) with ethanolamine, it may instead be reacted with mono- or dialkylamines thereby providing a route to compounds containing the moiety:



- Compounds wherein R² and R³ are both hydrogen can be prepared by reacting the epoxide (LVII) with potassium phthalimide in a polar solvent such as DMSO. During the Suzuki coupling step, the phthalimide group may undergo partial hydrolysis to give the corresponding phthalamic acid which can be cleaved using hydrazine to give the amino group NH₂. Alternatively, the phthalamic acid can be recycled to the phthalimide using a standard amide-forming reagent and the phthaloyl group then removed using hydrazine to give the amine.

A further synthetic route to compounds of the formula (I) wherein A and NR²R³ combine to form a cyclic group is illustrated in Scheme 9.




Scheme 9

- In Scheme 9, the starting material (LXI) is typically a di-aryl/heteroaryl methane in which one or both of the aryl/heteroaryl groups is capable of stabilising or facilitating formation of an anion formed on the methylene group between E and R¹. For example, R¹ may advantageously be a pyridine group. The starting material (LXI) is reacted with the N-


protected bis-2-chloroethylamine (LXII) in the presence of a non-interfering strong base such as sodium hexamethyldisilazide in a polar solvent such as tetrahydrofuran at a reduced temperature (e.g. around 0 °C) to give the N-protected cyclic intermediate (LXIII). The protecting group can be any standard amine-protecting group such as a Boc group.

- 5 Following cyclisation, the intermediate (LXIII) is coupled to a boronate of the formula (XV) under Suzuki coupling conditions and then deprotected to give the compound of the formula (I).


Compounds of the formula (I) in which the moiety:



- 10 is a group:




wherein "Alk" is a small alkyl group such as methyl or ethyl can be formed by the synthetic route illustrated in Scheme 10.



Scheme 10

In Scheme 10, a carboxylic acid of the formula (LXIV) is esterified by treatment with methanol in the presence of an acid catalyst such as hydrochloric acid. The ester (LXV) is then reacted with a strong base such as lithium diisopropylamide (LDA) and an alkyl iodide such as methyl iodide at reduced temperature (e.g. between 0 °C and -78 °C). The branched ester (LXVI) is then hydrolysed to the acid (LXVII) and coupled with an amine HNR^2R^3 under standard amide forming conditions of the type described above. The amide (LXVIII) can then be reduced to the amine (LXIX) using lithium aluminium hydride, and the amine (LXIX) is then reacted with a heteroaryl boronate or boronic acid under Suzuki coupling conditions to give a compound of the formula (I).


When the group E is a heterocyclic group in which a nitrogen atom of the group E is linked directly to the group A, the group R^1 -A- NR^2R^3 can be introduced by means of an alkylation procedure such as a Mitsunobu alkylation as shown in Scheme 11.



Scheme 11


- 5 In Scheme 11, the oxirane (LXXVIII) starting material can be formed by epoxidisation of an aldehyde R^1 -CHO using trimethylsulphonium iodide under conditions analogous to those set out above in Scheme 4 above. The oxirane is reacted with an amine HNR^2R^3 , suitably protected as necessary, to give the substituted ethanolamine (LXXIX).

- 10 The ethanolamine is then used in a Mitsunobu reaction to alkylate the nitrogen atom of the group E in compound (LXXX) to give, after deprotection where necessary, the product (LXXXI). The Mitsunobu reaction is typically carried out in a polar aprotic solvent such as tetrahydrofuran in the presence of diethyl azodicarboxylate (DEAD) and triphenyl phosphine, usually at a temperature of around room temperature. In formula (LXXXI), the moiety:



represents a group E containing a nitrogen atom. Examples of such a group are imidazole and pyrazole groups.

- Another method of preparing compounds of the formula (I) involves the replacement of the
 5 bromine atom in the intermediate of formula (LXX) with a range of heterocyclic ring-precursor groups, and then the conversion of a ring precursor group into a heterocyclic ring.



- In particular, when the group E is an aryl or heteroaryl group such as a phenyl group, the
 bromine atom in the compound of formula (LXX) can be converted by well known
 10 synthetic methods into, for example, CONH₂, NH₂, COOH, CHO or C(O)CH₃ group, each of which groups may be used for the construction of various heterocyclic ring systems.

- By way of example, the bromo-compound of formula (LXX) may be converted to the
 aldehyde (LXXI) by reacting the bromo-compound with an alkyl lithium such as butyl
 lithium and then formylating the resulting lithiated intermediate using dimethylformamide.
 15 The lithiation step is typically carried out in a dry polar aprotic solvent such as THF at a low temperature (e.g. less than -50 °C).

- The aldehyde group in the compound (LXXI) can then be converted into a range of
 heterocyclic groups using chemistry well known to the skilled person. For example, by
 reacting the aldehyde with tosylmethylisocyanide (tosmic), the aldehyde can be converted
 20 into an oxazole ring.

- Compounds of the formula (I) wherein the cyclic group HET is a 1,2,3-triazol-4-yl group
 (Table 4, D39) can be prepared from an aldehyde of the formula (LXXI) by reaction with
 nitromethane in the presence of a base to form a nitrovinyl group followed by reaction with
 sodium azide and cyclisation to the triazole: see for example Zefirov *et al.*, *J. Chem. Soc.*
 25 *Chem. Commun.*, 1971, 1001.


Compounds of the formula (I) wherein the cyclic group HET is a pyrrolidine-2,5-dione-3-yl group (Table 4, D74) can be prepared from an aldehyde of the formula (LXXI) by the method of Saeed *et al.*, *Pharmaceutical Sciences*, (1997), 3(5/6), 265-277. The Saeed *et al.* method involves condensation of the aldehyde with (i) ethylcyanoacetate in the presence of acetic acid and ammonium acetate followed by (ii) reaction of the resulting product with potassium cyanide in ethanol, (iii) treatment with acid and (iv) cyclisation with ammonium hydroxide.

Compounds of the formula (I) wherein the cyclic group HET is a 4-isothiazolidine 1,1-dioxide group (Table 4, D75) can be prepared from an aldehyde of the formula (LXXI) by the method of Fild *et al.*, *Chem. Ber.*, 1980, 113, 142 followed by the method of Avlessi *et al.*, *Zh. Org. Khim.*, 1994, 30 (4), 517-520.

Compounds of the formula (I) wherein the cyclic group HET is a 3-[1,2,5]thiadiazolidine 1,1-dioxide group (Table 4, D76) can be prepared from an aldehyde of the formula (LXXI) using the conditions described in Stout *et al.*, *J. Org. Chem.*, 1983, 48 (26), 5369 or the conditions described in Harada *et al.*, *Naturwissenschaften*, 1964, 51, 106.

In an alternative approach, the bromine atom in compound (LXXI) can be displaced by the nitrogen atom of a heterocyclic group in a coupling reaction mediated by copper (II) acetate. Thus, for example, the compound of formula (LXXI) can be reacted with a heteroaryl compound such as pyrazole, imidazole, 1,2,4-triazole, 1,2,3-triazole or 1H-tetrazole in the presence of copper (II) acetate under conditions of the type described in *Tetrahedron Letters*, 1998, 39, 2941, *J. Org. Chem.*, 2002, 67, 1699 or *J. Org. Chem.*, 2001, 66, 7892, to give a compound of the formula (I) wherein the cyclic group HET is an imidazole, 1,2,4-triazole, 1,2,3-triazole, 1H-tetrazole or pyrazol-1-yl group (Table 4, D14, D10, D32, D37 & D28).

The bromo-compound (LXX) can be converted to the corresponding amine (LXXIII) by a palladium catalysed amination; see for example Hartwig *et al.*, *Org. Lett.*, 2001, 3, 17, 2729-2732.



The amino group of amine (LXXIII) may serve as the starting point for the construction of a number of heterocyclic rings.


Thus for example, a triazolinone ring (Table 4, D34 above) can be formed by reaction with phenyl chloroformate, hydrazine and formamidine according to the method described in
 5 Bolos *et al.*, *J. Heterocyclic Chem.*, 1997, 34 (6), 1709-1713.

Compounds wherein the cyclic group HET is a maleimide group (Table 4, D72) can be prepared by diazotisation of amine (LXXIII) and reaction with maleimide in the presence of copper (II) chloride; see Rondestvedt *et al.*, *J. Amer. Chem. Soc.*, (1956), 78, 6115-20.

Compounds wherein the cyclic group HET is a 1-imidazolidine-2,4-dione group (Table 4,
 10 D73) can be prepared from the amine (LXXIII) by reaction with chloroacetic acid and urea according to the method of Kochkanyan *et al.*, *Khimiya Geterotsiklicheskikh Soedinenii*, KGSSAQ (1978), (1), 87-9; ISSN: 0453-8234.

Compounds wherein the cyclic group HET is a morpholine group (Table 4, D27) can be prepared from the amine (LXXIII) by reaction with *bis*-(2-bromoethyl)ether according to
 15 the method described in Wu *et al.*, *Bioorg. Med. Chem. Lett.*, 2003, 13 (10), 1725-1728.

The bromo-compound (LXX) can be converted to the corresponding acetyl derivative (LXXIV) using conditions analogous to those described in Wommack, *et al.*; *J. Heterocycl. Chem.*, 1969, 6, 243; Worden *et al.*; *J. Chem. Soc. (C)* 1970, 227; Xu *et al.*, *Org. Lett.*, 2001, 3 (2), 295-297 and Vallin *et al.*; *J. Org. Chem.*, 2001, 66 (12), 4340-4343.





The ketone (LXXV) can in turn be converted into the thioketone (LXXV) using methods well known to the skilled person, see for example Steliou *et al.*, *J. Amer. Chem. Soc.*, 1982, 104, 3104.

Ketones of the formula (LXXV) can be reacted with dimethylformamide-dimethylacetal under standard cyclisation conditions to give compounds in which the cyclic group HET is a pyrazol-3-yl group.

5 The ketone (LXXV) can also be converted into compounds wherein the cyclic group HET is a 4-pyrrolidone group (Table 4, D46) or a 1H-pyrimidine-2,4-dione – 6-yl group (Table 4, D77; see for example Thakur *et al.*, *Tetrahedron, Asymmetry*, (2003), 14(5), 581-586 and Shahak *et al.*, *Synthetic Communications*, (2002), 32(6), 851-855 respectively.

10 The thioketone (LXXV) can be converted into a thiazole-5-yl group (Table 4, D78) by reaction with dimethylformamide dimethyl acetal followed by hydroxylamine-O-sulphonic acid according to the method of Lin *et al.*, *J. HeterocyclicChem.*, 2002, 39(1), 237-239.

Carboxylic acids of the formula (LXXVI) can be prepared by oxidation of aldehydes of the formula (LXXI) by standard methods, for example as described in the article by Looker *et al.*, *J. Amer. Chem. Soc.*, 1957,79, 745.



15 The carboxylic acid (LXXVI) can be turned into the acylhydrazide by a standard amide coupling with hydrazine using EDCI and HOBt in a solvent such as dimethylformamide with subsequent cyclisation to form an oxadiazole ring (Table 4, D60) by condensation reaction with triethylorthoformate.

20 The carboxylic acid (LXXVI) can be converted into the amide (LXXVII) by standard methods of amide formation, see for example *Advanced Organic Chemistry*, by Jerry March (reference below), or the article by Kamal *et al.*, *Bioorg. Med. Chem. Lett.*, 2002, 12 (13), 1735-1738.

Once formed, many compounds of the formula (I) can be converted into other compounds of the formula (I) using standard functional group interconversions. For example,
25 compounds of the formula (I) in which the NR^2R^3 forms part of a nitrile group can be reduced to the corresponding amine. Compounds in which NR^2R^3 is an NH_2 group can be

converted to the corresponding alkylamine by reductive alkylation, or to a cyclic group. Compounds wherein R^1 contains a halogen atom such as chlorine or bromine can be used to introduce an aryl or heteroaryl group substituent into the R^1 group by means of a Suzuki coupling reaction. Further examples of interconversions of one compound of the formula (I) to another compound of the formula (I) can be found in the examples below. Additional examples of functional group interconversions and reagents and conditions for carrying out such conversions can be found in, for example, *Advanced Organic Chemistry*, by Jerry March, 4th edition, 119, Wiley Interscience, New York, *Fiesers' Reagents for Organic Synthesis*, Volumes 1-17, John Wiley, edited by Mary Fieser (ISBN: 0-471-58283-2), and *Organic Syntheses*, Volumes 1-8, John Wiley, edited by Jeremiah P. Freeman (ISBN: 0-471-31192-8).

In many of the reactions described above, it may be necessary to protect one or more groups to prevent reaction from taking place at an undesirable location on the molecule. Examples of protecting groups, and methods of protecting and deprotecting functional groups, can be found in *Protective Groups in Organic Synthesis* (T. Green and P. Wuts; 3rd Edition; John Wiley and Sons, 1999).

A hydroxy group may be protected, for example, as an ether (-OR) or an ester (-OC(=O)R), for example, as: a t-butyl ether; a benzyl, benzhydryl (diphenylmethyl), or trityl (triphenylmethyl) ether; a trimethylsilyl or t-butyldimethylsilyl ether; or an acetyl ester (-OC(=O)CH₃, -OAc). An aldehyde or ketone group may be protected, for example, as an acetal (R-CH(OR)₂) or ketal (R₂C(OR)₂), respectively, in which the carbonyl group (>C=O) is converted to a diether (>C(OR)₂), by reaction with, for example, a primary alcohol. The aldehyde or ketone group is readily regenerated by hydrolysis using a large excess of water in the presence of acid. An amine group may be protected, for example, as an amide (-NRCO-R) or a urethane (-NRCO-OR), for example, as: a methyl amide (-NHCO-CH₃); a benzyloxy amide (-NHCO-OCH₂C₆H₅, -NH-Cbz); as a t-butoxy amide (-NHCO-OC(CH₃)₃, -NH-Boc); a 2-biphenyl-2-propoxy amide (-NHCO-OC(CH₃)₂C₆H₄C₆H₅, -NH-Bpoc), as a 9-fluorenylmethoxy amide (-NH-Fmoc), as a 6-nitroveratryloxy amide (-NH-Nvoc), as a 2-trimethylsilylethyloxy amide (-NH-Teoc), as a 2,2,2-trichloroethyloxy amide (-NH-Troc), as an allyloxy amide (-NH-Alloc), or as a 2-(phenylsulphonyl)ethyloxy amide (-NH-Psec). Other protecting groups for amines, such as cyclic amines and heterocyclic N-H groups, include toluenesulphonyl (tosyl) and methanesulphonyl (mesyl) groups and benzyl groups such as a *para*-methoxybenzyl (PMB) group. A carboxylic acid group may be protected as

an ester for example, as: an C₁₋₇ alkyl ester (e.g., a methyl ester; a t-butyl ester); a C₁₋₇ haloalkyl ester (e.g., a C₁₋₇ trihaloalkyl ester); a triC₁₋₇ alkylsilyl-C₁₋₇alkyl ester; or a C₅₋₂₀ aryl-C₁₋₇ alkyl ester (e.g., a benzyl ester; a nitrobenzyl ester); or as an amide, for example, as a methyl amide. A thiol group may be protected, for example, as a thioether (-SR), for example, as: a benzyl thioether; an acetamidomethyl ether (-S-CH₂NHC(=O)CH₃).

Many of the chemical intermediates described above are novel and such novel intermediates form a further aspect of the invention.

Pharmaceutical Formulations

While it is possible for the active compound to be administered alone, it is preferable to present it as a pharmaceutical composition (e.g. formulation) comprising at least one active compound of the invention together with one or more pharmaceutically acceptable carriers, adjuvants, excipients, diluents, fillers, buffers, stabilisers, preservatives, lubricants, or other materials well known to those skilled in the art and optionally other therapeutic or prophylactic agents

Thus, the present invention further provides pharmaceutical compositions, as defined above, and methods of making a pharmaceutical composition comprising admixing at least one active compound, as defined above, together with one or more pharmaceutically acceptable carriers, excipients, buffers, adjuvants, stabilizers, or other materials, as described herein.

The term "pharmaceutically acceptable" as used herein pertains to compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of a subject (e.g. human) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. Each carrier, excipient, etc. must also be "acceptable" in the sense of being compatible with the other ingredients of the formulation.

Pharmaceutical compositions containing compounds of the formula (I) can be formulated in accordance with known techniques, see for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, USA.

Accordingly, in a further aspect, the invention provides compounds of the formula (I) and sub-groups thereof as defined herein in the form of pharmaceutical compositions.

The pharmaceutical compositions can be in any form suitable for oral, parenteral, topical, intranasal, ophthalmic, otic, rectal, intra-vaginal, or transdermal administration. Where the compositions are intended for parenteral administration, they can be formulated for intravenous, intramuscular, intraperitoneal, subcutaneous administration or for direct
5 delivery into a target organ or tissue by injection, infusion or other means of delivery. The delivery can be by bolus injection, short term infusion or longer term infusion and can be via passive delivery or through the utilisation of a suitable infusion pump.

Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers,
10 bacteriostats, co-solvents, organic solvent mixtures, cyclodextrin complexation agents, emulsifying agents (for forming and stabilizing emulsion formulations), liposome components for forming liposomes, gellable polymers for forming polymeric gels, lyophilisation protectants and combinations of agents for, *inter alia*, stabilising the active ingredient in a soluble form and rendering the formulation isotonic with the blood of the intended
15 recipient. Pharmaceutical formulations for parenteral administration may also take the form of aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents (R. G. Strickly, Solubilizing Excipients in oral and injectable formulations, Pharmaceutical Research, Vol 21(2) 2004, p 201-230).

Liposomes are closed spherical vesicles composed of outer lipid bilayer membranes and an
20 inner aqueous core and with an overall diameter of <100 μm . Depending on the level of hydrophobicity, moderately hydrophobic drugs can be solubilized by liposomes if the drug becomes encapsulated or intercalated within the liposome. Hydrophobic drugs can also be solubilized by liposomes if the drug molecule becomes an integral part of the lipid bilayer membrane, and in this case, the hydrophobic drug is dissolved in the lipid portion of the
25 lipid bilayer.

The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.

30 The pharmaceutical formulation can be prepared by lyophilising a compound of formula (I), or sub-groups thereof. Lyophilisation refers to the procedure of freeze-drying a composition. Freeze-drying and lyophilisation are therefore used herein as synonyms.

Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.

Pharmaceutical compositions of the present invention for parenteral injection can also comprise pharmaceutically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

The compositions of the present invention may also contain adjuvants such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

In one preferred embodiment of the invention, the pharmaceutical composition is in a form suitable for i.v. administration, for example by injection or infusion. For intravenous administration, the solution can be dosed as is, or can be injected into an infusion bag (containing a pharmaceutically acceptable excipient, such as 0.9% saline or 5% dextrose), before administration.

In another preferred embodiment, the pharmaceutical composition is in a form suitable for sub-cutaneous (s.c.) administration.

Pharmaceutical dosage forms suitable for oral administration include tablets, capsules, caplets, pills, lozenges, syrups, solutions, powders, granules, elixirs and suspensions, sublingual tablets, wafers or patches and buccal patches.

Thus, tablet compositions can contain a unit dosage of active compound together with an inert diluent or carrier such as a sugar or sugar alcohol, eg; lactose, sucrose, sorbitol or

- mannitol; and/or a non-sugar derived diluent such as sodium carbonate, calcium phosphate, calcium carbonate, or a cellulose or derivative thereof such as methyl cellulose, ethyl cellulose, hydroxypropyl methyl cellulose, and starches such as corn starch. Tablets may also contain such standard ingredients as binding and granulating agents such as
- 5 polyvinylpyrrolidone, disintegrants (e.g. swellable crosslinked polymers such as crosslinked carboxymethylcellulose), lubricating agents (e.g. stearates), preservatives (e.g. parabens), antioxidants (e.g. BHT), buffering agents (for example phosphate or citrate buffers), and effervescent agents such as citrate/bicarbonate mixtures. Such excipients are well known and do not need to be discussed in detail here.
- 10 Capsule formulations may be of the hard gelatin or soft gelatin variety and can contain the active component in solid, semi-solid, or liquid form. Gelatin capsules can be formed from animal gelatin or synthetic or plant derived equivalents thereof.
- The solid dosage forms (eg; tablets, capsules etc.) can be coated or un-coated, but typically have a coating, for example a protective film coating (e.g. a wax or varnish) or a release
- 15 controlling coating. The coating (e.g. a Eudragit TM type polymer) can be designed to release the active component at a desired location within the gastro-intestinal tract. Thus, the coating can be selected so as to degrade under certain pH conditions within the gastrointestinal tract, thereby selectively release the compound in the stomach or in the ileum or duodenum.
- 20 Instead of, or in addition to, a coating, the drug can be presented in a solid matrix comprising a release controlling agent, for example a release delaying agent which may be adapted to selectively release the compound under conditions of varying acidity or alkalinity in the gastrointestinal tract. Alternatively, the matrix material or release retarding
- 25 coating can take the form of an erodible polymer (e.g. a maleic anhydride polymer) which is substantially continuously eroded as the dosage form passes through the gastrointestinal tract. As a further alternative, the active compound can be formulated in a delivery system that provides osmotic control of the release of the compound. Osmotic release and other delayed release or sustained release formulations may be prepared in accordance with methods well known to those skilled in the art.
- 30 The pharmaceutical compositions comprise from approximately 1% to approximately 95%, preferably from approximately 20% to approximately 90%, active ingredient.

Pharmaceutical compositions according to the invention may be, for example, in unit dose form, such as in the form of ampoules, vials, suppositories, dragées, tablets or capsules.

Pharmaceutical compositions for oral administration can be obtained by combining the active ingredient with solid carriers, if desired granulating a resulting mixture, and
5 processing the mixture, if desired or necessary, after the addition of appropriate excipients, into tablets, dragee cores or capsules. It is also possible for them to be incorporated into plastics carriers that allow the active ingredients to diffuse or be released in measured amounts.

The compounds of the invention can also be formulated as solid dispersions. Solid
10 dispersions are homogeneous extremely fine disperse phases of two or more solids. Solid solutions (molecularly disperse systems), one type of solid dispersion, are well known for use in pharmaceutical technology (see (Chiou and Riegelman, J. Pharm. Sci., 60, 1281-1300 (1971)) and are useful in increasing dissolution rates and increasing the bioavailability of poorly water-soluble drugs.

15 This invention also provides solid dosage forms comprising the solid solution described above. Solid dosage forms include tablets, capsules and chewable tablets. Known excipients can be blended with the solid solution to provide the desired dosage form. For example, a capsule can contain the solid solution blended with (a) a disintegrant and a lubricant, or (b) a disintegrant, a lubricant and a surfactant. A tablet can contain the solid
20 solution blended with at least one disintegrant, a lubricant, a surfactant, and a glidant. The chewable tablet can contain the solid solution blended with a bulking agent, a lubricant, and if desired an additional sweetening agent (such as an artificial sweetener), and suitable flavours.

The pharmaceutical formulations may be presented to a patient in "patient packs"
25 containing an entire course of treatment in a single package, usually a blister pack. Patient packs have an advantage over traditional prescriptions, where a pharmacist divides a patient's supply of a pharmaceutical from a bulk supply, in that the patient always has access to the package insert contained in the patient pack, normally missing in patient prescriptions. The inclusion of a package insert has been shown to improve patient
30 compliance with the physician's instructions.

Compositions for topical use include ointments, creams, sprays, patches, gels, liquid drops and inserts (for example intraocular inserts). Such compositions can be formulated in accordance with known methods.

5 Examples of formulations for rectal or intra-vaginal administration include pessaries and suppositories which may be, for example, formed from a shaped moldable or waxy material containing the active compound.

Compositions for administration by inhalation may take the form of inhalable powder compositions or liquid or powder sprays, and can be administered in standard form using powder inhaler devices or aerosol dispensing devices. Such devices are well known. For
10 administration by inhalation, the powdered formulations typically comprise the active compound together with an inert solid powdered diluent such as lactose.

The compounds of the formula (I) will generally be presented in unit dosage form and, as such, will typically contain sufficient compound to provide a desired level of biological activity. For example, a formulation may contain from 1 nanogram to 2 grams of active
15 ingredient, e.g. from 1 nanogram to 2 milligrams of active ingredient. Within this range, particular sub-ranges of compound are 0.1 milligrams to 2 grams of active ingredient (more usually from 10 milligrams to 1 gram, e.g. 50 milligrams to 500 milligrams), or 1 microgram to 20 milligrams (for example 1 microgram to 10 milligrams, e.g. 0.1 milligrams to 2 milligrams of active ingredient).

20 For oral compositions, a unit dosage form may contain from 1 milligram to 2 grams, more typically 10 milligrams to 1 gram, for example 50 milligrams to 1 gram, e.g. 100 milligrams to 1 gram, of active compound.

The active compound will be administered to a patient in need thereof (for example a human or animal patient) in an amount sufficient to achieve the desired therapeutic effect.

25 **Protein Kinase Inhibitory Activity**

The activity of the compounds of the invention as inhibitors of protein kinase A and protein kinase B can be measured using the assays set forth in the examples below and the level of activity exhibited by a given compound can be defined in terms of the IC₅₀ value. Preferred compounds of the present invention are compounds having an IC₅₀ value of less than 1 μ M,
30 more preferably less than 0.1 μ M, against protein kinase B.

Therapeutic Uses

Prevention or Treatment of Proliferative Disorders

The compounds of the formula (I) are inhibitors of protein kinase A and protein kinase B. As such, they are expected to be useful in providing a means of preventing the growth of or inducing apoptosis of neoplasias. It is therefore anticipated that the compounds will prove useful in treating or preventing proliferative disorders such as cancers. In particular tumours with deletions or inactivating mutations in PTEN or loss of PTEN expression or rearrangements in the (T-cell lymphocyte) TCL-1 gene may be particularly sensitive to PKB inhibitors. Tumours which have other abnormalities leading to an upregulated PKB pathway signal may also be particularly sensitive to inhibitors of PKB. Examples of such abnormalities include but are not limited to overexpression of one or more PI3K subunits, over-expression of one or more PKB isoforms, or mutations in PI3K, PDK1, or PKB which lead to an increase in the basal activity of the enzyme in question, or upregulation or overexpression or mutational activation of a growth factor receptor such as a growth factor selected from the epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), platelet derived growth factor receptor (PDGFR), insulin-like growth factor 1 receptor (IGF-1R) and vascular endothelial growth factor receptor (VEGFR) families.

It is also envisaged that the compounds of the invention will be useful in treating other conditions which result from disorders in proliferation or survival such as viral infections, and neurodegenerative diseases for example. PKB plays an important role in maintaining the survival of immune cells during an immune response and therefore PKB inhibitors could be particularly beneficial in immune disorders including autoimmune conditions.

Therefore, PKB inhibitors could be useful in the treatment of diseases in which there is a disorder of proliferation, apoptosis or differentiation.

PKB inhibitors may also be useful in diseases resulting from insulin resistance and insensitivity, and the disruption of glucose, energy and fat storage such as metabolic disease and obesity.

Examples of cancers which may be inhibited include, but are not limited to, a carcinoma, for example a carcinoma of the bladder, breast, colon (e.g. colorectal carcinomas such as colon adenocarcinoma and colon adenoma), kidney, epidermal, liver, lung, for example

adenocarcinoma, small cell lung cancer and non-small cell lung carcinomas, oesophagus, gall bladder, ovary, pancreas e.g. exocrine pancreatic carcinoma, stomach, cervix, endometrium, thyroid, prostate, or skin, for example squamous cell carcinoma; a hematopoietic tumour of lymphoid lineage, for example leukaemia, acute lymphocytic leukaemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma, or Burkett's lymphoma; a hematopoietic tumour of myeloid lineage, for example acute and chronic myelogenous leukaemias, myelodysplastic syndrome, or promyelocytic leukaemia; thyroid follicular cancer; a tumour of mesenchymal origin, for example fibrosarcoma or habdomyosarcoma; a tumour of the central or peripheral nervous system, for example astrocytoma, neuroblastoma, glioma or schwannoma; melanoma; seminoma; teratocarcinoma; osteosarcoma; xenoderoma pigmentosum; keratocanthoma; thyroid follicular cancer; or Kaposi's sarcoma.

Thus, in the pharmaceutical compositions, uses or methods of this invention for treating a disease or condition comprising abnormal cell growth, the disease or condition comprising abnormal cell growth in one embodiment is a cancer.

Particular subsets of cancers include breast cancer, ovarian cancer, colon cancer, prostate cancer, oesophageal cancer, squamous cancer and non-small cell lung carcinomas.

A further subset of cancers includes breast cancer, ovarian cancer, prostate cancer, endometrial cancer and glioma.

It is also possible that some protein kinase B inhibitors can be used in combination with other anticancer agents. For example, it may be beneficial to combine of an inhibitor that induces apoptosis with another agent which acts via a different mechanism to regulate cell growth thus treating two of the characteristic features of cancer development. Examples of such combinations are set out below.

Immune Disorders

Immune disorders for which PKA and PKB inhibitors may be beneficial include but are not limited to autoimmune conditions and chronic inflammatory diseases, for example systemic lupus erythematosus, autoimmune mediated glomerulonephritis, rheumatoid arthritis, psoriasis, inflammatory bowel disease, and autoimmune diabetes mellitus, Eczema hypersensitivity reactions, asthma, COPD, rhinitis, and upper respiratory tract disease.

Other Therapeutic Uses

- PKB plays a role in apoptosis, proliferation, differentiation and therefore PKB inhibitors could also be useful in the treatment of the following diseases other than cancer and those associated with immune dysfunction; viral infections, for example herpes virus, pox virus,
- 5 Epstein-Barr virus, Sindbis virus, adenovirus, HIV, HPV, HCV and HCMV; prevention of AIDS development in HIV-infected individuals; cardiovascular diseases for example cardiac hypertrophy, restenosis, atherosclerosis; neurodegenerative disorders, for example Alzheimer's disease, AIDS-related dementia, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, spinal muscular atrophy and cerebellar degeneration;
- 10 glomerulonephritis; myelodysplastic syndromes, ischemic injury associated myocardial infarctions, stroke and reperfusion injury, degenerative diseases of the musculoskeletal system, for example, osteoporosis and arthritis, aspirin-sensitive rhinosinusitis, cystic fibrosis, multiple sclerosis, kidney diseases.

Advantages of Compounds of the Invention

- 15 It is envisaged that compounds of the formula (I) and sub-groups thereof as defined herein have advantages over prior art compounds.

Potentially the compounds of the invention have physiochemical properties suitable for oral exposure.

- Compounds of the formula (I) should exhibit improved oral bioavailability relative to prior art compounds. Oral bioavailability can be defined as the ratio (F) of the plasma exposure
- 20 of a compound when dosed by the oral route to the plasma exposure of the compound when dosed by the intravenous (i.v.) route, expressed as a percentage.

- Compounds having an oral bioavailability (F value) of greater than 30%, more preferably greater than 40%, are particularly advantageous in that they may be administered orally
- 25 rather than, or as well as, by parenteral administration.

Furthermore, it is envisaged that compounds of the invention are both more potent and more selective in their activities against different kinases, and demonstrate enhanced selectivity for and potency against PKB and PKB kinases in particular.

It is also envisaged that compounds of the invention are advantageous over prior art compounds in that they have different susceptibilities to P450 enzymes and in that they exhibit improvements with regard to drug metabolism and pharmacokinetic properties.

5 Furthermore, it is considered that compounds of the invention should exhibit reduced dosage requirements.

Compounds of the invention are advantageous in that they have improved thermodynamic solubilities, thereby leading potentially to an improved dose: solubility ratio and reduced development risk.

10 It is further envisaged that compounds of the invention also demonstrate improved cell activity in proliferation and clonogenic assays thereby indicating improved anti-cancer activity.

Compounds of the invention are potentially less toxic than prior art compounds.

For example, it is envisaged that compounds of formula (I) will have reduced, negligible or no HERG ion channel blocking activity.

15 **Methods of Treatment**

It is envisaged that the compounds of the formula (I) and sub-groups thereof as defined herein will be useful in the prophylaxis or treatment of a range of disease states or conditions mediated by protein kinase A and/or protein kinase B. Examples of such disease states and conditions are set out above.

20 The compounds are generally administered to a subject in need of such administration, for example a human or animal patient, preferably a human.

The compounds will typically be administered in amounts that are therapeutically or prophylactically useful and which generally are non-toxic. However, in certain situations (for example in the case of life threatening diseases), the benefits of administering a
25 compound of the formula (I) may outweigh the disadvantages of any toxic effects or side effects, in which case it may be considered desirable to administer compounds in amounts that are associated with a degree of toxicity.

The compounds may be administered over a prolonged term to maintain beneficial therapeutic effects or may be administered for a short period only. Alternatively they may be administered in a pulsatile or continuous manner.

5 A typical daily dose of the compound of formula (I) can be in the range from 100 picograms to 100 milligrams per kilogram of body weight, more typically 5 nanograms to 25 milligrams per kilogram of bodyweight, and more usually 10 nanograms to 15 milligrams per kilogram (e.g. 10 nanograms to 10 milligrams, and more typically 1 microgram per kilogram to 20 milligrams per kilogram, for example 1 microgram to 10 milligrams per kilogram) per kilogram of bodyweight although higher or lower doses may
10 be administered where required. The compound of the formula (I) can be administered on a daily basis or on a repeat basis every 2, or 3, or 4, or 5, or 6, or 7, or 10 or 14, or 21, or 28 days for example.

The compounds of the invention may be administered orally in a range of doses, for example 1 to 1500 mg, 2 to 800 mg, or 5 to 500 mg, e.g. 2 to 200 mg or 10 to 1000 mg,
15 particular examples of doses including 10, 20, 50 and 80 mg. The compound may be administered once or more than once each day. The compound can be administered continuously (i.e. taken every day without a break for the duration of the treatment regimen). Alternatively, the compound can be administered intermittently, i.e. taken continuously for a given period such as a week, then discontinued for a period such as a
20 week and then taken continuously for another period such as a week and so on throughout the duration of the treatment regimen. Examples of treatment regimens involving intermittent administration include regimens wherein administration is in cycles of one week on, one week off; or two weeks on, one week off; or three weeks on, one week off; or two weeks on, two weeks off; or four weeks on two weeks off; or one week on three weeks
25 off - for one or more cycles, e.g. 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more cycles.

In one particular dosing schedule, a patient will be given an infusion of a compound of the formula (I) for periods of one hour daily for up to ten days in particular up to five days for one week, and the treatment repeated at a desired interval such as two to four weeks, in particular every three weeks.

30 More particularly, a patient may be given an infusion of a compound of the formula (I) for periods of one hour daily for 5 days and the treatment repeated every three weeks.

In another particular dosing schedule, a patient is given an infusion over 30 minutes to 1 hour followed by maintenance infusions of variable duration, for example 1 to 5 hours, e.g. 3 hours.

5 In a further particular dosing schedule, a patient is given a continuous infusion for a period of 12 hours to 5 days, an in particular a continuous infusion of 24 hours to 72 hours.

Ultimately, however, the quantity of compound administered and the type of composition used will be commensurate with the nature of the disease or physiological condition being treated and will be at the discretion of the physician.

10 The compounds as defined herein can be administered as the sole therapeutic agent or they can be administered in combination therapy with one of more other compounds for treatment of a particular disease state, for example a neoplastic disease such as a cancer as hereinbefore defined. Examples of other therapeutic agents or treatments that may be administered together (whether concurrently or at different time intervals) with the compounds of the formula (I) include but are not limited to:

- 15
 - Topoisomerase I inhibitors
 - Antimetabolites
 - Tubulin targeting agents
 - DNA binder and topoisomerase II inhibitors
 - Alkylating Agents
- 20
 - Monoclonal Antibodies.
 - Anti-Hormones
 - Signal Transduction Inhibitors
 - Proteasome Inhibitors
 - DNA methyl transferases
- 25
 - Cytokines and retinoids
 - Chromatin targeted therapies
 - Radiotherapy, and,
- 30
 - Other therapeutic or prophylactic agents; for example agents that reduce or alleviate some of the side effects associated with chemotherapy. Particular examples of such agents include anti-emetic agents and agents that prevent or decrease the duration of chemotherapy-associated neutropenia and prevent

complications that arise from reduced levels of red blood cells or white blood cells, for example erythropoietin (EPO), granulocyte macrophage-colony stimulating factor (GM-CSF), and granulocyte-colony stimulating factor (G-CSF). Also included are agents that inhibit bone resorption such as bisphosphonate agents e.g. zoledronate, pamidronate and ibandronate, agents that suppress inflammatory responses (such as dexamethazone, prednisone, and prednisolone) and agents used to reduce blood levels of growth hormone and IGF-I in acromegaly patients such as synthetic forms of the brain hormone somatostatin, which includes octreotide acetate which is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Further included are agents such as leucovorin, which is used as an antidote to drugs that decrease levels of folic acid, or folinic acid it self and agents such as megestrol acetate which can be used for the treatment of side-effects including oedema and thromboembolic episodes.

Each of the compounds present in the combinations of the invention may be given in individually varying dose schedules and via different routes.

Where the compound of the formula (I) is administered in combination therapy with one, two, three, four or more other therapeutic agents (preferably one or two, more preferably one), the compounds can be administered simultaneously or sequentially. When administered sequentially, they can be administered at closely spaced intervals (for example over a period of 5-10 minutes) or at longer intervals (for example 1, 2, 3, 4 or more hours apart, or even longer periods apart where required), the precise dosage regimen being commensurate with the properties of the therapeutic agent(s).

The compounds of the invention may also be administered in conjunction with non-chemotherapeutic treatments such as radiotherapy, photodynamic therapy, gene therapy; surgery and controlled diets.

For use in combination therapy with another chemotherapeutic agent, the compound of the formula (I) and one, two, three, four or more other therapeutic agents can be, for example, formulated together in a dosage form containing two, three, four or more therapeutic agents. In an alternative, the individual therapeutic agents may be formulated separately and presented together in the form of a kit, optionally with instructions for their use.

A person skilled in the art would know through his or her common general knowledge the dosing regimes and combination therapies to use.

Methods of Diagnosis

5 Prior to administration of a compound of the formula (I), a patient may be screened to determine whether a disease or condition from which the patient is or may be suffering is one which would be susceptible to treatment with a compound having activity against protein kinase A and/or protein kinase B.

10 For example, a biological sample taken from a patient may be analysed to determine whether a condition or disease, such as cancer, that the patient is or may be suffering from is one which is characterised by a genetic abnormality or abnormal protein expression which leads to up-regulation of PKA and/or PKB or to sensitisation of a pathway to normal PKA and/or PKB activity, or to upregulation of a signal transduction component upstream of PKA and/or PKB such as, in the case of PKB, P13K, GF receptor and PDK 1 & 2.

15 Alternatively, a biological sample taken from a patient may be analysed for loss of a negative regulator or suppressor of the PKB pathway such as PTEN. In the present context, the term "loss" embraces the deletion of a gene encoding the regulator or suppressor, the truncation of the gene (for example by mutation), the truncation of the transcribed product of the gene, or the inactivation of the transcribed product (e.g. by point mutation) or sequestration by another gene product.

20 The term up-regulation includes elevated expression or over-expression, including gene amplification (i.e. multiple gene copies) and increased expression by a transcriptional effect, and hyperactivity and activation, including activation by mutations. Thus, the patient may be subjected to a diagnostic test to detect a marker characteristic of up-regulation of PKA and/or PKB. The term diagnosis includes screening. By marker we
25 include genetic markers including, for example, the measurement of DNA composition to identify mutations of PKA and/or PKB. The term marker also includes markers which are characteristic of up regulation of PKA and/or PKB, including enzyme activity, enzyme levels, enzyme state (e.g. phosphorylated or not) and mRNA levels of the aforementioned proteins.

30 The above diagnostic tests and screens are typically conducted on a biological sample selected from tumour biopsy samples, blood samples (isolation and enrichment of shed

tumour cells), stool biopsies, sputum, chromosome analysis, pleural fluid, peritoneal fluid, or urine.

Identification of an individual carrying a mutation in PKA and/or PKB or a rearrangement of TCL-1 or loss of PTEN expression may mean that the patient would be particularly
5 suitable for treatment with a PKA and/or PKB inhibitor. Tumours may preferentially be screened for presence of a PKA and/or PKB variant prior to treatment. The screening process will typically involve direct sequencing, oligonucleotide microarray analysis, or a mutant specific antibody.

Methods of identification and analysis of mutations and up-regulation of proteins are
10 known to a person skilled in the art. Screening methods could include, but are not limited to, standard methods such as reverse-transcriptase polymerase chain reaction (RT-PCR) or in-situ hybridisation.

In screening by RT-PCR, the level of mRNA in the tumour is assessed by creating a cDNA
15 copy of the mRNA followed by amplification of the cDNA by PCR. Methods of PCR amplification, the selection of primers, and conditions for amplification, are known to a person skilled in the art. Nucleic acid manipulations and PCR are carried out by standard methods, as described for example in Ausubel, F.M. et al., eds. Current Protocols in Molecular Biology, 2004, John Wiley & Sons Inc., or Innis, M.A. et-al., eds. PCR
20 Protocols: a guide to methods and applications, 1990, Academic Press, San Diego. Reactions and manipulations involving nucleic acid techniques are also described in Sambrook et al., 2001, 3rd Ed, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press. Alternatively a commercially available kit for RT-PCR (for example Roche Molecular Biochemicals) may be used, or methodology as set forth in United States patents 4,666,828; 4,683,202; 4,801,531; 5,192,659, 5,272,057, 5,882,864,
25 and 6,218,529 and incorporated herein by reference.

An example of an in-situ hybridisation technique for assessing mRNA expression would be fluorescence in-situ hybridisation (FISH) (see Angerer, 1987 Meth. Enzymol., 152: 649).

Generally, in situ hybridization comprises the following major steps: (1) fixation of tissue to be analyzed; (2) prehybridization treatment of the sample to increase accessibility of
30 target nucleic acid, and to reduce nonspecific binding; (3) hybridization of the mixture of nucleic acids to the nucleic acid in the biological structure or tissue; (4) post-hybridization

washes to remove nucleic acid fragments not bound in the hybridization, and (5) detection of the hybridized nucleic acid fragments. The probes used in such applications are typically labeled, for example, with radioisotopes or fluorescent reporters. Preferred probes are sufficiently long, for example, from about 50, 100, or 200 nucleotides to about 1000 or more nucleotides, to enable specific hybridization with the target nucleic acid(s) under stringent conditions. Standard methods for carrying out FISH are described in Ausubel, F.M. et al., eds. *Current Protocols in Molecular Biology*, 2004, John Wiley & Sons Inc and *Fluorescence In Situ Hybridization: Technical Overview* by John M. S. Bartlett in *Molecular Diagnosis of Cancer, Methods and Protocols*, 2nd ed.; ISBN: 1-59259-760-2; March 2004, pps. 077-088; Series: *Methods in Molecular Medicine*.

Alternatively, the protein products expressed from the mRNAs may be assayed by immunohistochemistry of tumour samples, solid phase immunoassay with microtitre plates, Western blotting, 2-dimensional SDS-polyacrylamide gel electrophoresis, ELISA, flow cytometry and other methods known in the art for detection of specific proteins. Detection methods would include the use of site specific antibodies. The skilled person will recognize that all such well-known techniques for detection of upregulation of PKB, or detection of PKB variants could be applicable in the present case.

Therefore all of these techniques could also be used to identify tumours particularly suitable for treatment with PKA and/or PKB inhibitors.

For example, as stated above, PKB beta has been found to be upregulated in 10 – 40% of ovarian and pancreatic cancers (Bellacosa et al 1995, *Int. J. Cancer* 64, 280 – 285; Cheng et al 1996, *PNAS* 93, 3636-3641; Yuan et al 2000, *Oncogene* 19, 2324 – 2330). Therefore it is envisaged that PKB inhibitors, and in particular inhibitors of PKB beta, may be used to treat ovarian and pancreatic cancers.

PKB alpha is amplified in human gastric, prostate and breast cancer (Staal 1987, *PNAS* 84, 5034 – 5037; Sun et al 2001, *Am. J. Pathol.* 159, 431 – 437). Therefore it is envisaged that PKB inhibitors, and in particular inhibitors of PKB alpha, may be used to treat human gastric, prostate and breast cancer.

Increased PKB gamma activity has been observed in steroid independent breast and prostate cell lines (Nakatani et al 1999, *J. Biol. Chem.* 274, 21528 – 21532). Therefore it is

envisaged that PKB inhibitors, and in particular inhibitors of PKB gamma, may be used to treat steroid independent breast and prostate cancers.

EXPERIMENTAL

5 The invention will now be illustrated, but not limited, by reference to the specific embodiments described in the following procedures and examples.

The starting materials for each of the procedures described below are commercially available unless otherwise specified.

10 In the examples, the compounds prepared were characterised by liquid chromatography, mass spectroscopy and ^1H nuclear magnetic resonance spectroscopy using the systems and operating conditions set out below.

Proton magnetic resonance (^1H NMR) spectra were recorded on a Bruker AV400 instrument operating at 400.13MHz, in $\text{Me-d}_3\text{-OD}$ at 27C, unless otherwise stated and are reported as follows: chemical shift δ/ppm (number of protons, multiplicity where s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, br=broad). The residual protic solvent MeOH ($\delta_{\text{H}} = 3.31 \text{ ppm}$) was used as the internal reference.

For the mass spectra, where chlorine is present, the mass quoted for the compound is for ^{35}Cl .

20 In each of the examples, where the compounds are isolated or formed as the free base, they can be converted into a salt form such as an acetic acid or hydrochloric acid salt. Conversely, where the compounds are isolated or formed as a salt, the salt can be converted into the corresponding free base by methods well known to the skilled person, and then optionally converted to another salt.

Mass spectra were recorded using the Platform system detailed below.

Platform System


25 HPLC System: Waters 2795
Mass Spec Detector: Micromass Platform LC
PDA Detector: Waters 2996 PDA

MS conditions:

- Capillary voltage: 3.5 kV or 3.6 kV
Cone voltage: 30 V
Source Temperature: 120 °C
Scan Range: 165-700 amu
5 Ionisation Mode: ElectroSpray Negative, Positive or Positive & Negative


GENERAL PROCEDURES

Method 1




- 10 To 4-bromobenzaldehyde (3g, 16.21 mmol) and ethyl cyanoacetate (1.9 ml, 17.84 mmol, 1.1 equiv.) in toluene was added piperidine (27 μ l) and the reaction mixture was refluxed for 1 hour with a Dean-Stark separator. The solvent was removed under reduced pressure, and the residue was triturated with warm ethyl acetate and filtered to yield the desired product as a yellow solid


15 Method 2



- A solution of 3-(4-bromo-phenyl)-2-cyano-acrylic acid ethyl ester (1.5 g, 5.36 mmol) in dry toluene (12 ml) was added dropwise to 4-chlorophenylmagnesium bromide (0.5 M solution in tetrahydrofuran, 14.0 ml, 6.96 mmol, 1.3 equiv.) at 0 °C. The reaction mixture was heated to 85 °C for 3 hours, poured onto ice, acidified with 1N HCl and extracted with ethyl acetate. The organic layer was separated, dried (MgSO_4), filtered and concentrated, and the crude product was purified over flash silica chromatography eluting with petroleum ether to ethyl acetate/petroleum ether (5:95) to afford the desired product.
- 20

Method 3


A mixture of 3-(4-bromo-phenyl)-3-(4-chloro-phenyl)-2-cyano-propionic acid ethyl ester (1.91, 4.87 mmol), acetic acid (10 ml), concentrated sulphuric acid (5 ml) and water (5 ml) were refluxed for 2 hours. Reaction mixture was poured into iced water and extracted with ethyl acetate. The organic layer was separated, dried (MgSO_4), filtered and concentrated, the crude product was purified over flash silica chromatography eluting with ethyl acetate/petroleum ether (1:1) to afford the desired product.

Method 4

10


A mixture of 3-(4-bromo-phenyl)-3-(4-chloro-phenyl)-propionic acid (0.25g, 0.74 mmol) and 1-hydroxybenzotriazole (0.12g, 0.88 mmol) in dichloromethane (3ml) was stirred for 15 minutes before addition of ammonia (2N solution in methanol, 0.74 ml, 1.47 mmol, 2.0 equiv.) and 1-(3-dimethylaminopropyl)-ethylcarbodiimide hydrochloride (0.17g, 0.88 mmol, 1.2 equiv). The reaction mixture was stirred for 16 hours, then the solvent removed under reduced pressure and the residue partitioned between ethyl acetate and 1N HCl. The organic layer was separated, washed with saturated sodium hydrogen carbonate, brine, dried (MgSO_4), filtered and concentrated to yield the title compound which was used in the next step without further purification.

20 Method 5




Under a nitrogen atmosphere, the crude 3-(4-bromo-phenyl)-3-(4-chloro-phenyl)-propionamide was cooled to 0 °C, and lithium aluminum hydride (0.075g, 1.97 mmol) and diethyl ether (3 ml) were added. With cooling, aluminum chloride (0.23 g, 1.69 mmol) was dissolved in diethyl ether (2 ml) and added. The reaction mixture was stirred for 16 hours, quenched with addition of water, basified (2N NaOH) and extracted with ethyl acetate. The organic layer was separated, dried (MgSO₄), filtered and concentrated, the crude product was purified over Phenomenex_Strata_SCX column chromatography eluting with methanol followed by 2N ammonia in methanol to afford the desired product.

10 Method 6




To a suspension of 3-(4-bromo-phenyl)-3-(4-chloro-phenyl)-propylamine (162 mg, 0.5 mmol, 1.0 equiv.) in toluene (0.8 ml) was added bis(tri-*t*-butylphosphine)palladium (0) (3 mg, 1 mol%) followed by a suspension of thiophene-3-boronic acid (70 mg, 0.55 mmol, 1.1 equiv.) in ethanol (0.8 ml) and potassium carbonate (415 mg, 3.0 mmol, 6 equiv.) in water (2.5 ml). The reaction mixture was heated in a CEM ExplorerTM microwave to 135 °C for 30 minutes using 50 watts power. The solvents were removed and the residue was partitioned between ethyl acetate and water. The aqueous layer was extracted with ethyl acetate and the combined organic layers were washed with brine, dried (MgSO₄) and concentrated under reduced pressure. The crude reaction mixture was purified by preparative HPLC to give the desired product.

Method 7




- A suspension of 4-(4-bromo-phenyl)-piperidin-4-ol (4.02 g, 15.7 mmol) in chlorobenzene (30 ml) was added dropwise to a suspension of aluminium chloride (7.32 g, 54.9 mmol) in chlorobenzene (10 ml) at 0 °C. The reaction mixture was stirred at 0 °C for 2 hours,
- 5 quenched by addition of ice and then methyl t-butyl ether was added. After stirring for 1 hour, the precipitate was collected by filtration and washed with water, methyl t-butyl ether and water to afford the desired compound.

Method 8



- 10 To a suspension of 4-(4-bromo-phenyl)-4-(4-chloro-phenyl)-piperidine hydrochloride (10 g, 25.8 mmol) in dichloromethane (150 ml) was added triethylamine (4.3 ml, 31.0 mmol) and di-tert-butyl dicarbonate (6.2 g, 28.4 mmol). After stirring for 72 hours, water was added and the organic layer was removed. The organic layer was washed with water then saturated sodium chloride solution before drying (MgSO₄) and concentrating *in vacuo* to
- 15 furnish the desired compound as a white solid.


Method 9



A mixture of 4-(4-bromo-phenyl)-4-(4-chloro-phenyl)-piperidine-1-carboxylic acid tert-butyl ester (5.0 g, 11.1 mmol), bis(pinacolato)diboron (2.8 g, 11.1 mmol), potassium acetate (3.3 g, 33.3 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloro

5 palladium(II) (406 mg, 0.55 mmol) was heated to 80 °C under nitrogen for 2.5 hours. The reaction was then allowed to cool, diluted with ethyl acetate then filtered under suction. The solid was triturated with ethyl acetate to furnish the desired compound as a beige solid.

Method 10




10

A mixture of 4-(4-chloro-phenyl)-4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-piperidine-1-carboxylic acid tert-butyl ester (200 mg, 0.4 mmol), bis(tri-
 butylphosphine)palladium (0) (6 mg, 3 mol%), 5-bromo-1-methylimidazole (84 mg, 0.5
 mmol), potassium carbonate (299 mg, 1.4 mmol), ethanol (1.1 ml), toluene (1.1 ml)
 15 methanol (1.6 ml) and water (1.5 ml) was heated in a CEM Explorer™ microwave to 80 °C
 for 30 minutes using ≤ 50 watts power. The solvents were removed and the residue was
 partitioned between ethyl acetate and water. The aqueous layer was extracted with ethyl
 acetate and the combined organic layers were washed with brine, dried (MgSO₄) and
 concentrated under reduced pressure. The crude reaction mixture was purified by SCX ion
 20 exchange column chromatography eluting with an ammonia-dichloromethane-methanol

- mixture to furnish the protected amine. The protecting group was removed by stirring at room temperature in dichloromethane (1 ml) and trifluoroacetic acid (1 ml) for 30 minutes before concentrating and re-concentrating from methanol (x3). The residue was purified by silica column chromatography eluting with a gradient from DMAW90 to DMAW60
- 5 furnishing the desired compound in ~90% purity.


Method 11



- A solution of 4-(4-chlorophenyl)-4-[4-(2-methylsulphanylpyrimidin-4-yl)phenyl]piperidine-1-carboxylic acid tert-butyl ester (121 mg, 0.2 mmol) and 3-chloroperoxybenzoic acid (120 mg, 0.537 mmol) in dichloromethane (2 ml) were stirred at room temperature for 18 hours. Dilute aqueous sodium sulphate was added then the organic layer was separated. The liquors were washed with water and concentrated *in vacuo* to furnish the desired compound as an oil.
- 10


Method 12

15




To a solution of 4-(4-chloro-phenyl)-4-[4-(2-methanesulphonyl-pyrimidin-4-yl)-phenyl]-piperidine-1-carboxylic acid tert-butyl ester (100 mg, 0.2 mmol) in dichloromethane (1 ml) and ethanol (1 ml) was added sodium borohydride (36mg, 0.9 mmol, portionwise). After stirring at room temperature for 4 hours, the reaction was quenched with water followed by 1N aqueous hydrochloric acid and was extracted with dichloromethane. The crude product was purified using silica column chromatography eluting with 50% ethyl acetate/ petrol to furnish the desired compound.

Method 13




A solution of 4-(4-chloro-phenyl)-4-[4-(2-methanesulphonyl-pyrimidin-4-yl)-phenyl]-piperidine-1-carboxylic acid tert-butyl ester (400 mg, 0.76 mmol) and 4-methoxybenzylamine (300 μ l, 2.3 mmol) in acetonitrile (5 ml) was irradiated in a sealed tube to 120 deg C, \leq 200W in a CEM ExplorerTM microwave. After 90 minutes, additional amine (100 μ l) was added and the mixture irradiated for a further 30 minutes. Aqueous ammonium chloride solution was added and the mixture extracted with ethyl acetate (x2). The combined liquors were washed with aqueous ammonium chloride and then saturated brine before drying (MgSO_4) and concentrating *in vacuo*. The residue was mixed with dichloromethane and filtered onto a silica chromatography column. The column was eluted using a gradient of 10-30% ethyl acetate/ petrol furnishing the desired compound as an oil.

Method 14



- A solution of 4-(4-chloro-phenyl)-4-{4-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-phenyl}-piperidine-1-carboxylic acid tert-butyl ester (60 mg, 0.1 mmol), benzoyl chloride (16mg, 0.1 mmol), triethylamine (19 μ l, 0.1 mmol) and dichloromethane (3 ml) were stirred at room temperature for 18 hours. The reaction was quenched with aqueous saturated sodium bicarbonate solution and the dichloromethane layer was separated. Purification by silica column chromatography using a stepped gradient (25, 50 and 75 % ethyl acetate/ petrol) furnished the desired compound as a colourless oil.


Method 15



- A solution of 4-(4-{2-[benzoyl-(4-methoxy-benzyl)-amino]-pyrimidin-4-yl}-phenyl)-4-(4-chloro-phenyl)-piperidine-1-carboxylic acid tert-butyl ester (83 mg, 0.1mmol), trifluoroacetic acid (1 ml) and anisole (0.5 mol) was heated to 50 $^{\circ}$ C. After 6.5 hours the reaction was allowed to cool. After concentrating *in vacuo* and re-concentrating from methanol (x2), the residue was partitioned between ethyl acetate and aqueous hydrochloric


acid (2N). The organic layer was separated extracted with 2N hydrochloric acid. The combined aqueous fractions were basified with solid potassium hydroxide then extracted into ethyl acetate (x2). The combined liquors were washed with saturated brine then dried (MgSO_4) and concentrated *in vacuo* to furnish the desired compound as a white solid.

5 Method 16




Aluminium chloride (278 mg, 2.087 mmol) was added portionwise to a stirred solution of 1-(4-bromo-phenyl)-2-methylamino-ethanol (160 mg, 0.696 mmol) in chlorobenzene (3 ml) and the reaction mixture was stirred at room temperature for 17 hours. Water (2ml) was added dropwise and the reaction mixture was then partitioned between dichloromethane (100 ml) and saturated NaHCO_3 (30 ml). The organic layer was dried (MgSO_4), filtered and concentrated under reduced pressure. The crude product was then purified by Phenomenex Strata SCX column chromatography eluting with methanol followed by 2N ammonia in methanol to afford the desired product.


15 Method 17




To a solution of [2-(4-bromo-phenyl)-2-(4-chlorophenyl)-ethyl]-methyl-amine (4.3 g, 13.3 mmol) in dichloromethane at room temperature (150 ml) was added triethylamine (2.22 ml, 16 mmol) and di-tert-butyl dicarbonate (3.2g, 15 mmol). The mixture was stirred for 3 hours whereupon water was added. The organic liquors were separated then concentrated *in vacuo*. The residue was purified by silica column chromatography using a gradient from 2-15% ethyl acetate/ petrol furnishing the desired compound as a colourless oil.

Method 18


5 A mixture of 4-(4-chloro-phenyl)-4-{4-[2-(4-methoxy-benzylamino)-pyrimidin-4-yl]-phenyl}-piperidine-1-carboxylic acid tert-butyl ester (10 mg), trifluoroacetic acid (1 ml) and dichloromethane (1 ml) were allowed to stand for 15 minutes. The reaction was then concentrated under a stream of nitrogen. After re-concentrating from methanol under nitrogen, the compound was purified by preparative HPLC to furnish the required compound as the formate salt.

Method 19

10 A solution of 2-(4-chloro-phenyl)-oxirane (2.47 g, 16.0 mmol, 1.0 equiv.) in methylamine (20 ml, of a 33% solution in ethanol, 160.0 mmol, 10.0 equiv) was stirred at room temperature for 15 hours. The solvents were removed under reduced pressure and the resultant crude material was dissolved in dichloromethane (80 ml). To the solution was added triethylamine (4.5 ml, 32.0 mmol, 2.0 equiv) and di-*tert*-butyl dicarbonate (5.2 g, 24.0 mmol, 1.5 equiv) portion-wise. The mixture was stirred at room temperature overnight. The solvents were removed under reduced pressure and the resultant crude material was partitioned between ethyl acetate and water. The layers were separated and the organic layer was washed with brine, dried (MgSO₄) and concentrated under reduced pressure. The resultant crude material was purified by column chromatography gradient eluted with 0→20% ethyl acetate-petrol to afford the desired product.

Method 20


To a solution of 4-(5-phenyl-1H-pyrazol-4-yl)-pyridine (332 mg, 1.5 mmol, 1.5 equiv), [2-(4-chloro-phenyl)-2-hydroxy-ethyl]-methyl-carbamic acid tert-butyl ester (286 mg, 1.0 mmol, 1.0 equiv) and triphenylphosphine (393 mg, 1.5 equiv, 1.5 equiv) in tetrahydrofuran (10 ml) was added diethyl azodicarboxylate (354 μ L, 1.5 mmol, 1.5 equiv) dropwise over 30 minutes. The solution was stirred for 15 hours, the solvents were then removed under reduced pressure and the resultant crude material was partitioned between ethyl acetate and water. The layers were separated and the organic layer was washed with brine, dried (MgSO₄) and concentrated under reduced pressure. The regio-isomers were separated by column chromatography eluted with ethyl acetate-petrol (0 \rightarrow 100% gradient) to afford the two products. The resulting pure [2-(4-chloro-phenyl)-2-(5-phenyl-4-pyridin-4-yl-pyrazol-1-yl)-ethyl]-methyl-carbamic acid tert-butyl ester was dissolved in dichloromethane (20 ml), trifluoroacetic acid (5 ml) was added drop-wise, and the solution was stirred for 4 hours. The solvents were removed under reduced pressure and the resultant crude material was purified by column chromatography eluted with DMAW90 to afford the desired product.

Method 21

To a solution of 4-(4-bromo-phenyl)-4-(4-chloro-phenyl)-piperidine-1-carboxylic acid tert-butyl ester (1.0g, 2.22mmol) in tetrahydrofuran (7ml) at $<-50^{\circ}\text{C}$ under nitrogen was added

dropwise a solution of n-butyllithium in hexanes (2.7M, 0.9 ml, 2.33 mmol). After stirring for 10 minutes, dimethylformamide (0.5 ml) was added and the reaction mixture was allowed to warm to room temperature. After 30 minutes the reaction mixture was cooled to 0 °C then quenched with hydrochloric acid solution (1N, 10 ml). Ethyl acetate was added and the mixture was shaken vigorously. The aqueous layer was separated and extracted again with ethyl acetate; and the combined organic liquors were washed with water and saturated brine before drying (MgSO₄) and concentrating *in vacuo*. The crude product was purified by silica column chromatography using a 10-35% ethyl acetate/ petrol gradient to furnish the desired compound as a colourless oil.




10 Method 22






A mixture of 4-(4-chloro-phenyl)-4-(4-formyl-phenyl)-piperidine-1-carboxylic acid tert-butyl ester (117 mg, 0.3 mmol), tosylmethylisocyanide (63 mg, 0.3 mmol), potassium carbonate (49 mg, 0.4 mmol), dichloromethane (0.5 ml) and methanol (2 ml) was heated to reflux for 1 hour. The reaction mixture was then allowed to cool before addition of water. The solution was extracted twice with ethyl acetate and the combined organic liquors were washed with water and saturated brine, dried (MgSO₄) and concentrated *in vacuo*. The crude product was purified using silica column chromatography using a gradient 15-25% ethyl acetate/ petrol to give the protected compound as a colourless oil. The protected compound was deprotected by stirring with trifluoroacetic acid (1ml) in dichloromethane (3ml) at room temperature for 15 minutes. The reaction mixture was then concentrated and re-concentrated from methanol (x3) before SCX ion exchange purification to furnish the desired compound as a yellow solid.

25 EXAMPLES 1 TO 28




By following the methods described above, the compounds of Examples 1 to 28 were prepared.




Example No.	Chemical structure	Chemical name	Method of preparation	NMR characterisation data	MS
1		3-(3,4-Dichloro-phenyl)-3-(4-pyridin-4-yl-phenyl)-propylamine diacetate	Methods 1-6 using 3,4-dichlorophenyl-magnesium bromide (0.5M in tetrahydrofuran) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyridine	¹ H NMR (Me-d ₃ -OD) 8.58 (2H, d), 7.78 (2H, d), 7.71 (2H, d), 7.54-7.47 (4H, m), 7.30 (1H, dd), 4.39 (1H, t), 2.88 (2H, t), 2.51-2.42 (2H, m), 1.95 (6H, s)	MS: [M+H] ⁺ 357
2		4-[3-Methyl-amino-1-(4-pyridin-4-yl-phenyl)-propyl]-phenol diacetate	Methods 1-6 using 4-methoxyphenyl-magnesium bromide (0.5M in tetrahydrofuran), methylamine (40% solution in water) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyridine	¹ H NMR (Me-d ₃ -OD) 8.57 (2H, d), 7.73 (2H, d), 7.70 (2H, d), 7.46 (2H, d), 7.17 (2H, d), 6.77 (2H, d), 4.04 (1H, t), 2.91 (2H, dd), 2.65 (3H, s), 2.47-2.40 (2H, m), 1.94 (6H)	MS: [M+H] ⁺ 319
3		4-[4-(1-Phenyl-2-pyrrolidin-1-yl-ethyl)-phenyl]-pyridine	Methods 4-6 using bis(4-chlorophenyl)-acetic acid, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyridine and pyrrolidine	¹ H NMR (Me-d ₃ -OD) 8.54 (2H, d), 7.73-7.65 (4H, m), 7.48 (2H, d), 7.35-7.27 (4H, m), 7.18 (1H, t), 4.28 (1H, t), 3.30-3.17 (2H, m), 2.58 (4H, s), 1.74 (4H, s)	MS: [M+H] ⁺ 329




Example No.	Chemical structure	Chemical name	Method of preparation	NMR characterisation data	MS
4		[2,2-Bis-(4-pyridin-4-yl-phenyl)-ethyl]-methyl-amine diacetate	Methods 4-6 using bis(4-chloro-phenyl)acetic acid, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyridine and methylamine	¹ H NMR (Me-d ₃ -OD) 8.60 (4H, d), 7.81 (4H, d), 7.72 (4H, d), 7.58 (4H, d), 4.59 (1H, t), 3.58 (2H, d), 2.70 (3H, s), 1.96 (6H, s)	MS: [M+H] ⁺ 366
5		4-[3-Amino-1-(4-pyridin-4-yl-phenyl)-propyl]-phenol diacetate	Methods 1-6 using 4-methoxyphenyl-magnesium bromide (0.5M in tetrahydrofuran) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyridine	¹ H NMR (Me-d ₃ -OD) 8.58 (2H, d), 7.73 (4H, t), 7.46 (2H, d), 7.17 (2H, d), 6.77 (2H, d), 4.06 (1H, t), 2.89-2.82 (2H, m), 2.45-2.38 (2H, m), 1.96 (6H, s)	MS: [M+H] ⁺ 305
6		[2-(4-Chloro-phenyl)-2-(4-pyridin-4-yl-phenyl)-ethyl]-methyl-amine diformate	Methods 4-6 using bis(4-chloro-phenyl)acetic acid, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyridine and methylamine	¹ H NMR (Me-d ₃ -OD) 8.60 (2H, d), 8.88 (2H, br s), 7.82 (2H, d), 7.73 (2H, d), 7.54 (2H, d), 7.42 (4H, s), 4.49 (1H, t), 3.71 (2H, d), 2.77 (3H, s)	MS: [M+H] ⁺ 323




Example No.	Chemical structure	Chemical name	Method of preparation	NMR characterisation data	MS
7		2-[2-(4-Chloro-phenyl)-2-(4-pyridin-4-yl-phenyl)-ethyl-amino]-ethanol formate	Methods 4-6 using bis(4-chloro-phenyl)acetic acid, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyridine and ethanolamine	¹ H NMR (Me-d ₃ -OD) 8.48-8.44 (3H, m), 7.65 (2H, d), 7.59 (2H, d), 7.37 (2H, d), 7.23 (4H, s), 4.23 (1H, t), 3.55 (2H, t), 3.32 (2H, dd), 2.77 (2H, t)	MS: [M+H] ⁺ 353
8		3-[2-(4-Chloro-phenyl)-2-(4-pyridin-4-yl-phenyl)-ethylamino]-propan-1-ol formate	Methods 4-6 using bis(4-chloro-phenyl)acetic acid, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyridine and 3-amino-1-propanol	¹ H NMR (Me-d ₃ -OD) 8.59-8.54 (3H, m), 7.56 (2H, d), 7.70 (2H, d), 7.50, (2H, d), 7.37 (4H, s), 4.42 (1H, t), 3.68-3.60 (4H, m), 3.08 (2H, t), 1.87-1.80 (2H, m)	MS: [M+H] ⁺ 367
9		N-(4-{4-[4-(4-Chloro-phenyl)-piperidin-4-yl]-phenyl}-pyrimidin-2-yl)-benzamide	Methods 7-11 and 13-15 – using 4-chloro-2-methylthio-pyrimidine	¹ H NMR (Me-d ₃ -OD) 8.70 (1H, d), 8.19 (2H, d), 8.02 (2H, d), 7.70 (1H, d), 7.64 (1H, t), 7.58 (2H, d), 7.52 (2H, d), 7.38 (2H, d), 7.32 (2H, d), 3.02 (4H, m), 2.58 (4H, m)	MS: [M+H] ⁺ 469




Example No.	Chemical structure	Chemical name	Method of preparation	NMR characterisation data	MS
10		(4-{4-[4-(4-Chloro-phenyl)-piperidin-4-yl]-phenyl}-pyrimidin-2-yl)-(4-methoxy-benzyl)-amine formate	Methods 7-11, 13 and 18 – using 4-chloro-2-methylthio-pyrimidine	¹ H NMR (Me-d ₃ -OD) 8.52 (1H, s), 8.30 (1H, d), 8.08 (2H, d), 7.50 (2H, d), 7.38 (4H, m), 7.32 (2H, d), 7.08 (1H, d), 7.38 (2H, d), 4.60 (2H, s), 3.79 (3H, s), 3.25 (4H, m), 2.80 (4H, m)	MS: [M+H] ⁺ 485
11		4-{4-[4-(4-Chloro-phenyl)-piperidin-4-yl]-phenyl}-pyrimidin-2-ylamine dihydrochloride	Methods 7-10 – using 4-chloro-2-aminopyrimidine	¹ H NMR (Me-d ₃ -OD) 8.34 (1H, d), 8.28 (2H, d), 7.62 (2H, d), 7.57 (1H, d), 7.52 (2H, d), 7.49 (2H, d), 3.28 (4H, m), 2.80 (4H, m)	MS: [M+H] ⁺ 365
12		4-{4-[4-(4-Chloro-phenyl)-piperidin-4-yl]-phenyl}-pyrimidine bis-trifluoroacetate	Methods 7-12 – using 4-chloro-2-methylthio-pyrimidine	¹ H NMR (Me-d ₃ -OD) 9.20 (1H, s), 8.80 (1H, d), 8.20 (2H, d), 8.00 (1H, d), 7.58 (2H, d), 7.40 (4H, m), 3.28 (4H, m), 2.76 (4H, m)	MS: [M+H] ⁺ 350




Example No.	Chemical structure	Chemical name	Method of preparation	NMR characterisation data	MS
13		4-[4-(4-Phenyl-piperidin-4-yl)-phenyl]-pyridine acetate	Method 6 using 4-(4-chloro-phenyl)-4-phenyl-piperidine and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyridine.	¹ H NMR (Me-d ₃ -OD) 8.58 (2H, d), 7.76 (2H, d), 7.70 (2H, d), 7.53 (2H, d), 7.43 (2H, d), 7.37 (2H, d), 7.24 (1H, t), 3.25-3.19 (4H, m), 2.77-2.69 (4H, m), 1.96 (3H, s)	MS: [M+H] ⁺ 315
14		4-{4-[4-(4-Chloro-phenyl)-piperidin-4-yl]-phenyl}-pyridine dihydrochloride	Method 6 using 4-(4-Bromo-phenyl)-4-(4-chloro-phenyl)-piperidine and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyridine.	¹ H NMR (Me-d ₃ -OD) 8.85 (2H, d), 8.39 (2H, d), 8.00 (2H, d), 7.65 (2H, d), 7.41-7.45 (2H, m), 7.37-7.40 (2H, m), 3.20-3.31 (4H, m), 2.70-2.82 (4H, m)	MS: [M+H] ⁺ 349
15		1-[Phenyl-(4-pyridin-4-yl-phenyl)-methyl]-piperazine dihydrochloride	Method 6 – using 1-(4,4'-dichloro-benzhydryl)-piperazine and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyridine	¹ H NMR (Me-d ₃ -OD) 8.88 (2H, d), 8.40 (2H, d), 8.06 (2H, d), 7.98 (2H, m), 7.71 (2H, m), 7.42 (2H, m), 7.35 (1H, m), 3.55 (4H, m), 3.10 (4H, m)	MS: [M+H] ⁺ 330




Example No.	Chemical structure	Chemical name	Method of preparation	NMR characterisation data	MS
16		[2-(4-Chloro-phenyl)-2-(5-phenyl-4-pyridin-4-yl-pyrazol-1-yl)-ethyl]-methylamine	Methods 19-20	¹ H NMR (Me-d ₃ -OD) 8.49 (2H, d), 8.45 (1H, s), 7.61 (1H, t), 7.57-7.52 (4H, m), 7.36 (2H, d), 7.18 (2H, d), 7.03 (2H, d), 5.64 (1H, dd), 4.24 (1H, dd), 3.68 (1H, dd), 2.70 (3H, s)	MS: [M+H] ⁺ 389
17		4-{4-[1-(4-pyridin-4-yl-phenyl)-2-pyrrolidin-1-yl-ethyl]-phenyl}-pyridine	Methods 4-6 were followed Starting materials: bis(4-chloro-phenyl)-acetic acid, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyridine. and pyrrolidine	¹ H NMR (Me-d ₃ -OD) 8.55 (4H, d), 7.73-7.68 (8H, m), 7.53 (4H, d), 4.40 (1H, t), 2.67 (4H, s), 1.78 (4H, s)	MS: [M+H] ⁺ 406
18		3-(4-Chloro-phenyl)-3-(4-thiophen-3-yl-phenyl)-propylamine formate	Methods 1 to 6 were followed	¹ H NMR (Me-d ₃ -OD) 8.59 (1H, s), 7.64 (2H, d), 7.60 (1H, s), 7.49-7.42 (2H, m), 7.37-7.28 (6H, m), 4.10 (1H, t), 2.83 (2H, t), 2.45-2.34 (2H, m)	MS: [M+H] ⁺ 328

Example No.	Chemical structure	Chemical name	Method of preparation	NMR characterisation data	MS
19		3-(4-Chlorophenyl)-3-(4-furan-3-ylphenyl)-propylamine	Methods 1 to 6 were followed. Starting material used 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-furan	¹ H NMR (Me- <i>d</i> ₃ -OD) 8.59 (1H, s), 7.86 (1H, s), 7.57-7.48 (3H, m), 7.38-7.27 (5H, m), 6.78 (1H, s), 4.10-4.05 (1H, m), 2.73 (2H, dd), 2.45-2.37 (2H, m)	MS: [M+H] ⁺ 312
20		4-(4-Chlorophenyl)-4-(4-furan-3-ylphenyl)-piperidine	Method 6 Starting materials used 4-(4-Bromophenyl)-4-(4-chlorophenyl)-piperidine and 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-furan	¹ H NMR (Me- <i>d</i> ₃ -OD) 8.57 (1H, s), 7.87 (1H, s), 7.56-7.52 (3H, m), 7.38-7.31 (5H, m), 6.79 (1H, s), 3.25-3.17 (4H, m), 2.76-2.58 (4H, m)	MS: [M+H] ⁺ 338
21		4-(4-Chlorophenyl)-4-(4-oxazol-5-ylphenyl)-piperidine hydrochloride	Methods 7, 8, 21 and 22	¹ H NMR (Me- <i>d</i> ₃ -OD) 8.32 (1H, s), 7.78 (2H, d), 7.56 (1H, s), 7.45 (2H, d), 7.40 (4H, m), 3.25 (4H, m), 2.70 (4H, m)	MS: [M+H] ⁺ 339

Example No.	Chemical structure	Chemical name	Method of preparation	NMR characterisation data	MS
22		3-(4-Chlorophenyl)-3-(4-[1,2,4]triazol-1-ylphenyl)-propionamide	Methods 1 to 4 were followed Starting material 4-[1,2,4]triazol-1-ylbenzaldehyde	¹ H NMR (Me-d ₃ -OD) 9.04 (1H, s), 8.17 (1H, s), 7.77, (2H, d), 7.48 (2H, d), 7.31 (4H, s), 4.62 (1H, t), 3.01 (2H, d)	MS: [M+H] ⁺ 327
23		3-(4-Chlorophenyl)-3-(4-[1,2,4]triazol-1-ylphenyl)-propylamine formate	Method 5 Starting material 3-(4-chloro-phenyl)-3-(4-[1,2,4]triazol-1-yl-phenyl)-propionamide	¹ H NMR (Me-d ₃ -OD) 9.05 (1H, s), 8.55 (1H, 8.17), (1H, s), 7.70 (2H, d), 7.51 (2H, d) 7.39-7.32 (4H, m), 4.18 (1H, t), 2.88 (2H, dd), 2.48-2.40 (2H, m)	MS: [M+H] ⁺ 313
24		4-(4-Chlorophenyl)-4-[4-(3-methyl-3H-imidazol-4-yl)-phenyl]-piperidine acetate	Methods 7,8,9 and 10	¹ H NMR (Me-d ₃ -OD) 8.98 (1H, s), 7.60 (1H, s), 7.56 (4H, s), 7.41 (2H, d), 7.39 (2H, d), 3.87 (3H, s), 3.25 (4H, m), 2.81 (4H, m), 1.99 (3H, s)	MS: [M+H] ⁺ 352

Example No.	Chemical structure	Chemical name	Method of preparation	NMR characterisation data	MS
25		C-(4-Chloro-phenyl)-C-(4-pyridin-4-yl-phenyl)-methylamine	Method 6 using C, C-bis-(4-chloro-phenyl)-methylamine and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyridine	¹ H NMR (Me- <i>d</i> ₃ -OD) 8.45 (2H, d), 7.65-7.55 (4H, m), 7.38 (2H, d), 7.25 (2H, d), 7.18 (2H, d), 5.10 (1H, s)	MS: [M+H] ⁺ 295
26		2-(3,4-Dichloro-phenyl)-2-(4-pyridin-4-yl-phenyl)-ethylamine	Method 16 using 1-(4-bromo-phenyl)-2-amino-ethanol and 1,2-dichlorobenzene. Then method 6 using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyridine	¹ H NMR (Me- <i>d</i> ₃ -OD) 8.56 (2H, d), 7.80-7.67 (4H, m), 7.55-7.45 (3H, m), 7.40-7.25 (2H, m), 4.20 (1H, q), 3.45-3.38 (2H, m)	MS: [M+H] ⁺ 343
27		[2-(3,4-Dichloro-phenyl)-2-(4-pyridin-4-yl-phenyl)-ethyl]-methylamine	Method 16 using 1,2-dichlorobenzene. Then method 6 using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyridine	¹ H NMR (Me- <i>d</i> ₃ -OD) 8.55 (2H, d), 7.75 (2H, d), 7.60 (2H, d), 7.52-7.42 (4H, m), 7.35-7.25 (1H, m), 4.25 (1H, t), 3.23 (2H, d), 2.41 (3H, s)	MS: [M+H] ⁺ 357

Example No.	Chemical structure	Chemical name	Method of preparation	NMR characterisation data	MS
28		[2-(4-Methoxy-3-pyridin-4-yl-phenyl)-2-(4-pyridin-4-yl-phenyl)-ethyl]-methyl-amine	Method 16 using 2-chloroanisole. Then method 6 using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyridine	¹ H NMR (Me-d ₃ -OD) 8.51 (4H, dd), 7.70 (2H, d), 7.65 (2H, d), 7.56 (2H, d), 7.48 (2H, d), 7.39 (1H, dd), 7.32 (1H, d), 7.10 (1H, d), 4.28 (1H, t), 3.80 (3H, s), 3.25 (2H, d), 2.41 (3H, s)	MS: [M+H] ⁺ 396
29		[2-(3-Chloro-4-methoxy-phenyl)-2-(4-pyridin-4-yl-phenyl)-ethyl]-methyl-amine	Method 16 using 2-chloroanisole. Then method 6 using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyridine	¹ H NMR (Me-d ₃ -OD) 8.55 (2H, d), 7.73 (2H, d), 7.68 (2H, d), 7.45 (2H, d), 7.32 (1H, d), 7.25 (1H, dd), 7.03 (1H, d), 4.20 (1H, t), 3.85 (3H, s), 3.21 (2H, d), 2.42 (3H, s)	MS: [M+H] ⁺ 353
30		2-(4-Chlorophenyl)-2-(4-pyridin-4-yl-phenyl)-ethylamine	Method 16 using 1-(4-bromo-phenyl)-2-amino-ethanol. Then method 6 using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyridine	¹ H NMR (Me-d ₃ -OD) 8.45 (2H, d), 7.61 (2H, d), 7.58 (2H, d), 7.32 (2H, d), 7.20 (4H, s), 4.00 (1H, t), 3.15 (2H, d)	MS: [M+H] ⁺ 309

Example No.	Chemical structure	Chemical name	Method of preparation	NMR characterisation data	MS
31		4-{4-[4-(4-Chloro-3-fluoro-phenyl)-piperidin-4-yl]-phenyl}-pyridine	Method 23. Then Method 6 using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyridine	¹ H NMR (Me- <i>d</i> ₃ -OD) 8.60 (2H, d), 7.80 (2H, d), 7.72 (2H, d), 7.55 (2H, d), 7.45 (1H, t), 7.32 (1H, d), 7.23 (1H, d), 3.22 (4H, m), 2.73 (2H, m), 2.68 (2H, m), 1.95 (3H, s)	MS: [M+H] ⁺ 367
32		4-{4-[4-(3,4-Dichloro-phenyl)-piperidin-4-yl]-phenyl}-pyridine	Method 7 using 1,2-dichlorobenzene. Then Method 6 using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyridine	¹ H NMR (Me- <i>d</i> ₃ -OD) 8.60 (2H, d), 7.81 (2H, d), 7.72 (2H, d), 7.68 (3H, m), 7.52 (1H, d), 7.35 (1H, d), 3.21 (4H, m), 2.78 (2H, m), 2.68 (2H, m), 1.92 (5H, s)	MS: [M+H] ⁺ 383
33		4-{4-[4-(3-Chloro-4-methoxy-phenyl)-piperidin-4-yl]-phenyl}-pyridine	Method 7 using orthochloroanisole. Then Method 6 using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-pyridine	¹ H NMR (Me- <i>d</i> ₃ -OD) 8.59 (2H, d), 8.32 (2H, s), 7.78 (2H, d), 7.71 (2H, d), 7.51 (2H, d), 7.39 (1H, s), 7.31 (1H, d), 7.08 (1H, d), 3.86 (3H, s), 3.25 (4H, m), 2.80 (4H, m)	MS: [M+H] ⁺ 379

BIOLOGICAL ACTIVITY

EXAMPLE 34Measurement of PKA Kinase Inhibitory Activity (IC_{50})

Compounds of the invention can be tested for PK inhibitory activity using the PKA catalytic domain from Upstate Biotechnology (#14-440) and the 9 residue PKA specific peptide (GRTGRRNSI), also from Upstate Biotechnology (#12-257), as the substrate. A final concentration of 1 nM enzyme is used in a buffer that includes 20 mM MOPS pH 7.2, 40 μ M ATP/ γ^{33} P-ATP and 5 μ M substrate. Compounds are added in dimethylsulphoxide (DMSO) solution to a final DMSO concentration of 2.5%. The reaction is allowed to proceed for 20 minutes before addition of excess orthophosphoric acid to quench activity. Unincorporated γ^{33} P-ATP is then separated from phosphorylated proteins on a Millipore MAPH filter plate. The plates are washed, scintillant is added and the plates are then subjected to counting on a Packard Topcount.

The % inhibition of the PKA activity is calculated and plotted in order to determine the concentration of test compound required to inhibit 50% of the PKB activity (IC_{50}).

The compounds of Examples 25, 26, 27, 29, 30, 31 and 32 have IC_{50} values of less than 1 μ M.

EXAMPLE 35Measurement of PKB Kinase Inhibitory Activity (IC_{50})

The inhibition of protein kinase B (PKB) activity by compounds can be determined determined essentially as described by Andjelkovic *et al.* (Mol. Cell. Biol. 19, 5061-5072 (1999)) but using a fusion protein described as PKB-PIF and described in full by Yang *et al.* (Nature Structural Biology 9, 940 – 944 (2002)). The protein is purified and activated with PDK1 as described by Yang *et al.* The peptide AKTide-2T (H-A-R-K-R-E-R-T-Y-S-F-G-H-H-A-OH) obtained from Calbiochem (#123900) is used as a substrate. A final concentration of 0.6 nM enzyme is used in a buffer that includes 20 mM MOPS pH 7.2, 30 μ M ATP/ γ^{33} P-ATP and 25 μ M substrate. Compounds are added in DMSO solution to a final DMSO concentration of 2.5%. The reaction is allowed to proceed for 20 minutes before addition of excess orthophosphoric acid to quench activity. The reaction mixture is transferred to a phosphocellulose filter plate where the peptide binds and the unused ATP is washed away. After washing, scintillant is added and the incorporated activity measured by scintillation counting.

The % inhibition of the PKB activity is calculated and plotted in order to determine the concentration of test compound required to inhibit 50% of the PKB activity (IC_{50}).

The compounds of Examples 1, 3, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16, 21, 25, 26, 29, 30, 31 and 32 have IC_{50} values of less than 1 μ M, whereas the compounds of Examples 2, 4, 9, 10, 17, 18, 19, 20, 23, 24 and 28 have IC_{50} values of less than 10 μ M, and the compound of Example 22 has an IC_{50} value of less than 20 μ M.

PHARMACEUTICAL FORMULATIONS

EXAMPLE 36

(i) Tablet Formulation

10 A tablet composition containing a compound of the formula (I) is prepared by mixing 50 mg of the compound with 197mg of lactose (BP) as diluent, and 3 mg magnesium stearate as a lubricant and compressing to form a tablet in known manner.

(ii) Capsule Formulation

15 A capsule formulation is prepared by mixing 100mg of a compound of the formula (I) with 100mg lactose and filling the resulting mixture into standard opaque hard gelatin capsules.

(iii) Injectable Formulation I

A parenteral composition for administration by injection can be prepared by dissolving a compound of the formula (I) (e.g. in a salt form) in water containing 10% propylene glycol to give a concentration of active compound of 1.5 % by weight. The solution is then
20 sterilised by filtration, filled into an ampoule and sealed.

(iv) Injectable Formulation II

A parenteral composition for injection is prepared by dissolving in water a compound of the formula (I) (e.g. in salt form) (2 mg/ml) and mannitol (50 mg/ml), sterile filtering the solution and filling into sealable 1 ml vials or ampoules.

25 (v) Injectable formulation III

A formulation for i.v. delivery by injection or infusion can be prepared by dissolving the compound of formula (I) (e.g. in a salt form) in water at 20 mg/ml. The vial is then sealed and sterilised by autoclaving.

(vi) Injectable formulation IV

A formulation for i.v. delivery by injection or infusion can be prepared by dissolving the compound of formula (I) (e.g. in a salt form) in water containing a buffer (e.g. 0.2 M acetate pH 4.6) at 20mg/ml. The vial is then sealed and sterilised by autoclaving.

5 (vii) Subcutaneous Injection Formulation

A composition for sub-cutaneous administration is prepared by mixing a compound of the formula (I) with pharmaceutical grade corn oil to give a concentration of 5 mg/ml. The composition is sterilised and filled into a suitable container.

(viii) Lyophilised formulation


- 10 Aliquots of formulated compound of formula (I) are put into 50 ml vials and lyophilized. During lyophilisation, the compositions are frozen using a one-step freezing protocol at (–45 °C). The temperature is raised to –10 °C for annealing, then lowered to freezing at –45 °C, followed by primary drying at +25 °C for approximately 3400 minutes, followed by a secondary drying with increased steps if temperature to 50 °C. The pressure during primary
15 and secondary drying is set at 80 millitor.

Equivalents

- The foregoing examples are presented for the purpose of illustrating the invention and should not be construed as imposing any limitation on the scope of the invention. It will readily be apparent that numerous modifications and alterations may be made to the
20 specific embodiments of the invention described above and illustrated in the examples without departing from the principles underlying the invention. All such modifications and alterations are intended to be embraced by this application.

CLAIMS

1. A compound for use in the prophylaxis or treatment of a disease state or condition mediated by protein kinase B, the compound being a compound of the formula (I):



- 5 or a salt, solvate, tautomer or N-oxide thereof;
 wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R¹ and NR²R³ and a maximum chain length of 4 atoms extending between E and NR²R³, wherein one of the carbon atoms in the linker group may optionally
 10 be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom α with respect to the NR²R³ group and provided that the oxo group when present is located at a carbon atom α with respect to the NR²R³ group;
 15 E is a monocyclic or bicyclic carbocyclic or heterocyclic group;
 HET is a monocyclic heterocyclic group having 4 to 7 ring members of which up to 4 are heteroatoms selected from O, N and S;
 R¹ is an aryl or heteroaryl group;
 R² and R³ are independently selected from hydrogen, C₁₋₄ hydrocarbyl and
 20 C₁₋₄ acyl wherein the hydrocarbyl and acyl moieties are optionally substituted by one or more substituents selected from fluorine, hydroxy, amino, methylamino, dimethylamino and methoxy;
 or R² and R³ together with the nitrogen atom to which they are attached form a cyclic group selected from an imidazole group and a saturated monocyclic heterocyclic group having 4-7 ring members and optionally containing a second
 25 heteroatom ring member selected from O and N;

or one of R^2 and R^3 together with the nitrogen atom to which they are attached and one or more atoms from the linker group A form a saturated monocyclic heterocyclic group having 4-7 ring members and optionally containing a second heteroatom ring member selected from O and N;

5 or NR^2R^3 and the carbon atom of linker group A to which it is attached together form a cyano group;

n is 0 to 4;

each R^4 is independently selected from oxo; halogen; C_{1-6} hydrocarbyl optionally substituted by halogen, hydroxy or C_{1-2} alkoxy; cyano; C_{1-6} hydrocarbyloxy optionally substituted by halogen, hydroxy or C_{1-2} alkoxy; $CONH_2$; $CONHR^9$; CF_3 ; NH_2 ; $NHCOR^9$; $NHCONHR^9$; and NHR^9 ;

R^9 is a group R^{9a} or $(CH_2)R^{9a}$, wherein R^{9a} is a monocyclic or bicyclic group which may be carbocyclic or heterocyclic;

15 the carbocyclic group or heterocyclic group R^{9a} being optionally substituted by one or more substituents selected from halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, mono- or di- C_{1-4} hydrocarbylamino; a group R^a-R^b wherein R^a is a bond, O, CO, $X^1C(X^2)$, $C(X^2)X^1$, $X^1C(X^2)X^1$, S, SO, SO_2 , NR^c , SO_2NR^c or NR^cSO_2 ; and R^b is selected from hydrogen, heterocyclic groups having from 3 to 12 ring members, and a C_{1-8} hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, carboxy, amino, mono- or di- C_{1-4} hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C_{1-8} hydrocarbyl group may optionally be replaced by O, S, SO, SO_2 , NR^c , $X^1C(X^2)$, $C(X^2)X^1$ or $X^1C(X^2)X^1$;


25 R^c is selected from hydrogen and C_{1-4} hydrocarbyl; and

X^1 is O, S or NR^c and X^2 is =O, =S or = NR^c ;

provided that:

(a-1) HET is other than an unsubstituted or substituted pyrazole-4-yl group.

2. A compound for use in medicine having the formula (Ia):



or a salt, solvate, tautomer or N-oxide thereof;

wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R¹ and NR²R³ and a maximum chain length of 4 atoms extending between E and NR²R³, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom α with respect to the NR²R³ group and provided that the oxo group when present is located at a carbon atom α with respect to the NR²R³ group;

E is a monocyclic or bicyclic carbocyclic or heterocyclic group;

HET is a monocyclic heterocyclic group having 4 to 7 ring members of which up to 4 are heteroatoms selected from O, N and S;

R¹ is an aryl or heteroaryl group;

R² and R³ are independently selected from hydrogen, C₁₋₄ hydrocarbyl and C₁₋₄ acyl wherein the hydrocarbyl and acyl moieties are optionally substituted by one or more substituents selected from fluorine, hydroxy, amino, methylamino, dimethylamino and methoxy;

or R² and R³ together with the nitrogen atom to which they are attached form a cyclic group selected from an imidazole group and a saturated monocyclic heterocyclic group having 4-7 ring members and optionally containing a second heteroatom ring member selected from O and N;

or one of R² and R³ together with the nitrogen atom to which they are attached and one or more atoms from the linker group A form a saturated monocyclic heterocyclic group having 4-7 ring members and optionally containing a second heteroatom ring member selected from O and N;

or NR²R³ and the carbon atom of linker group A to which it is attached together form a cyano group;

n is 0 to 4;

each R⁴ is independently selected from oxo; halogen; C₁₋₆ hydrocarbyl optionally substituted by halogen, hydroxy or C₁₋₂ alkoxy; cyano; C₁₋₆ hydrocarbyloxy optionally substituted by halogen, hydroxy or C₁₋₂ alkoxy; CONH₂; CONHR⁹; CF₃; NH₂; NHCOR⁹; NHCONHR⁹; and NHR⁹;

R⁹ is a group R^{9a} or (CH₂)R^{9a}, wherein R^{9a} is a monocyclic or bicyclic group which may be carbocyclic or heterocyclic;

the carbocyclic group or heterocyclic group R^{9a} being optionally substituted by one or more substituents selected from halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, mono- or di-C₁₋₄ hydrocarbylamino; a group R^a-R^b wherein R^a is a bond, O, CO, X¹C(X²), C(X²)X¹, X¹C(X²)X¹, S, SO, SO₂, NR^c, SO₂NR^c or NR^cSO₂; and R^b is selected from hydrogen, heterocyclic groups having from 3 to 12 ring members, and a C₁₋₈ hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, carboxy, amino, mono- or di-C₁₋₄ hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C₁₋₈ hydrocarbyl group may optionally be replaced by O, S, SO, SO₂, NR^c, X¹C(X²), C(X²)X¹ or X¹C(X²)X¹;

R^c is selected from hydrogen and C₁₋₄ hydrocarbyl; and

X¹ is O, S or NR^c and X² is =O, =S or =NR^c;


provided that:

(a-1) HET is other than a substituted or unsubstituted pyrazole-4-yl group;

(b-1) when E is phenyl, A is a saturated hydrocarbyl group bearing a hydroxy substituent and NR²R³ forms an imidazolyl group, then HET is other than a pyridyl group; and

(b-2) when HET is a thienyl group, E is an optionally substituted phenyl group and the moiety ANR²R³ forms an optionally substituted piperidine group, then R¹ is other than a phenyl group bearing a substituent at the *meta* position thereof and optionally a second substituent.

3. A compound the formula (Ib):



or a salt, solvate, tautomer or N-oxide thereof;

wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R^1 and NR^2R^3 and a maximum chain length of 4 atoms extending between E and NR^2R^3 , wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom; and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom α with respect to the NR^2R^3 group and provided that the oxo group when present is located at a carbon atom α with respect to the NR^2R^3 group;

E is a monocyclic or bicyclic carbocyclic or heterocyclic group;

HET is a monocyclic heterocyclic group having 4 to 7 ring members of which up to 4 are heteroatoms selected from O, N and S;

R^1 is an aryl or heteroaryl group;

R^2 and R^3 are independently selected from hydrogen, C_{1-4} hydrocarbyl and C_{1-4} acyl wherein the hydrocarbyl and acyl moieties are optionally substituted by one or more substituents selected from fluorine, hydroxy, amino, methylamino, dimethylamino and methoxy;

or R^2 and R^3 together with the nitrogen atom to which they are attached form a cyclic group selected from an imidazole group and a saturated monocyclic heterocyclic group having 4-7 ring members and optionally containing a second heteroatom ring member selected from O and N;

or one of R^2 and R^3 together with the nitrogen atom to which they are attached and one or more atoms from the linker group A form a saturated monocyclic heterocyclic group having 4-7 ring members and optionally containing a second heteroatom ring member selected from O and N;

or NR^2R^3 and the carbon atom of linker group A to which it is attached together form a cyano group;

n is 0 to 4;

each R⁴ is independently selected from oxo; halogen; C₁₋₆ hydrocarbyl optionally substituted by halogen, hydroxy or C₁₋₂ alkoxy; cyano; C₁₋₆ hydrocarbyloxy optionally substituted by halogen, hydroxy or C₁₋₂ alkoxy; CONH₂; CONHR⁹; CF₃; NH₂; NHCOR⁹; NHCONHR⁹; and NHR⁹;

R⁹ is a group R^{9a} or (CH₂)R^{9a}, wherein R^{9a} is a monocyclic or bicyclic group which may be carbocyclic or heterocyclic;

the carbocyclic group or heterocyclic group R^{9a} being optionally substituted by one or more substituents selected from halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, mono- or di-C₁₋₄ hydrocarbylamino; a group R^a-R^b wherein R^a is a bond, O, CO, X¹C(X²), C(X²)X¹, X¹C(X²)X¹, S, SO, SO₂, NR^c, SO₂NR^c or NR^cSO₂; and R^b is selected from hydrogen, heterocyclic groups having from 3 to 12 ring members, and a C₁₋₈ hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, carboxy, amino, mono- or di-C₁₋₄ hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C₁₋₈ hydrocarbyl group may optionally be replaced by O, S, SO, SO₂, NR^c, X¹C(X²), C(X²)X¹ or X¹C(X²)X¹;

R^c is selected from hydrogen and C₁₋₄ hydrocarbyl; and

X¹ is O, S or NR^c and X² is =O, =S or =NR^c;

provided that:

(a-1) HET is other than a substituted or unsubstituted pyrazole-4-yl group;

(b-1) when E is phenyl, A is a saturated hydrocarbyl group bearing a hydroxy substituent and NR²R³ forms an imidazolyl group, then HET is other than a pyridyl group;


(b-2) when HET is a thienyl group, E is an optionally substituted phenyl group and the moiety ANR²R³ forms an optionally substituted piperidine group, then R¹ is other than a phenyl group bearing a substituent at the *meta* position thereof and optionally a second substituent; and

(c-1) when E is phenyl and the moiety R¹ANR²R³ is an N-monosubstituted or N,N-disubstituted phenylacetamide group, then HET is other than a morpholine or N-methylpiperazine group.

4. A compound according to claim 3 wherein the linker group A has a maximum chain length of 3 atoms (more preferably 1 or 2 atoms, and most preferably 2 atoms) extending between R^1 and NR^2R^3 .
5. A compound according to claim 4 wherein the linker group A has a maximum chain length of 3 atoms extending between E and NR^2R^3 .
6. A compound according to claim 5 wherein the linker group A has a chain length of 2 or 3 atoms extending between R^1 and NR^2R^3 and a chain length of 2 or 3 atoms extending between E and NR^2R^3 .
7. A compound according to any one of claims 3 to 6 wherein the linker group atom linked directly to the group E is a carbon atom and the linker group A has an all-carbon skeleton.
8. A compound according to any one of claims 3 to 6 wherein the portion R^1 -A- NR^2R^3 of the compound is represented by the formula R^1 -(G)_k-(CH₂)_m-W-O_b-(CH₂)_n-(CR⁶R⁷)_p- NR^2R^3 wherein G is NH, NMe or O; W is attached to the group E and is selected from (CH₂)_j-CR²⁰, (CH₂)_j-N and (NH)_j-CH; b is 0 or 1, j is 0 or 1, k is 0 or 1, m is 0 or 1, n is 0, 1, 2, or 3 and p is 0 or 1; the sum of b and k is 0 or 1; the sum of j, k, m, n and p does not exceed 4; R⁶ and R⁷ are the same or different and are selected from methyl and ethyl, or CR⁶R⁷ forms a cyclopropyl group; and R²⁰ is selected from hydrogen, methyl, hydroxy and fluorine.
9. A compound according to claim 8 wherein k is 0, m is 0 or 1, n is 0, 1, 2 or 3 and p is 0.
10. A compound according to claim 8 wherein k is 0, m is 0 or 1, n is 0, 1 or 2 and p is 1.
11. A compound according to claim 8 wherein X is (CH₂)_j-CH, k is 1, m is 0, n is 0, 1, 2 or 3 and p is 0.
12. A compound according to claim 8 wherein X is (CH₂)_j-CH, k is 1, m is 0, n is 0, 1 or 2 and p is 1.
13. A compound according to any one of claims 8, 11 and 12 wherein j is 0.

14. A compound according to any one of claims 8, 11 and 12 wherein j is 1.
15. A compound according to any one of claims 8, 11 and 12 wherein CR^6R^7 is $\text{C}(\text{CH}_3)_2$.
- 5 16. A compound according to claim 8 wherein the portion $\text{R}^1\text{-A-NR}^2\text{R}^3$ of the compound is represented by the formula $\text{R}^1\text{-X-(CH}_2)_n\text{-NR}^2\text{R}^3$ where X is attached to the group E and is a group CH, and n is 2.
17. A compound according to any one of the preceding claims wherein $\text{R}^1\text{-A(E)-NR}^2\text{R}^3$ is a group selected from the groups A1 to A11 set out in Table 1 herein.
- 10 18. A compound according to claim 15 wherein $\text{R}^1\text{-A(E)-NR}^2\text{R}^3$ is selected from groups A1, A2, A3 and A10 in Table 1.
19. A compound according to claim 16 wherein $\text{R}^1\text{-A(E)-NR}^2\text{R}^3$ is the group A10 in Table 1.
20. A compound according to any one of the preceding claims wherein E is a monocyclic group.
- 15 21. A compound according to any one of claims 3 to 20 wherein E is an aryl or heteroaryl group.
22. A compound according to claim 21 wherein E is selected from optionally substituted phenyl, thiophene, furan, pyrimidine and pyridine groups.
23. A compound according to claim 22 wherein E is a phenyl group.
- 20 24. A compound according to any one of claims 3 to 20 wherein E is a non-aromatic monocyclic group selected from cycloalkanes such as cyclohexane and cyclopentane, and nitrogen-containing rings such as piperazine and piperazone.
- 25 25. A compound according to any one of claims 3 to 24 wherein the group A and the pyrazole group are attached to the group E in a *meta* or *para* relative orientation; i.e. A and the pyrazole group are not attached to adjacent ring members of the group E.

26. A compound according to claim 25 wherein E is selected from 1,4-phenylene, 1,3-phenylene, 2,5-pyridylene and 2,4-pyridylene, 1,4-piperazinyl, and 1,4-piperazonyl.
27. A compound according to any one of claims 3 to 24 wherein E is unsubstituted or has up to 4 substituents R^8 selected from hydroxy, oxo (when E is non-aromatic), chlorine, bromine, trifluoromethyl, cyano, C_{1-4} hydrocarbyloxy and C_{1-4} hydrocarbyl optionally substituted by C_{1-2} alkoxy or hydroxy.
28. A compound according to claim 27 wherein E has 0-3 substituents, more preferably 0-2 substituents, for example 0 or 1 substituent.
29. A compound according to claim 28 wherein E is unsubstituted.
30. A compound according to any one of claims 3 to 29 wherein the group E is an aryl or heteroaryl group having five or six members and containing up to three heteroatoms selected from O, N and S, the group E being represented by the formula:



15

where * denotes the point of attachment to the pyrazole group, and "a" denotes the attachment of the group A;

r is 0, 1 or 2;

U is selected from N and CR^{12a} ; and


- 20 V is selected from N and CR^{12b} ; where R^{12a} and R^{12b} are the same or different and each is hydrogen or a substituent containing up to ten atoms selected from C, N, O, F, Cl and S provided that the total number of non-hydrogen atoms present in R^{12a} and R^{12b} together does not exceed ten;
- 25 or R^{12a} and R^{12b} together with the carbon atoms to which they are attached form an unsubstituted five or six membered saturated or unsaturated ring containing up to two heteroatoms selected from O and N; and

- 5 R^{10} is selected from halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, mono- or di- C_{1-4} hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members; a group R^a-R^b wherein R^a is a bond, O, CO, $X^1C(X^2)$, $C(X^2)X^1$, $X^1C(X^2)X^1$, S, SO, SO_2 , NR^c , SO_2NR^c or NR^cSO_2 ; and R^b is selected from hydrogen, carbocyclic and heterocyclic groups having from 3 to 12 ring members, and a C_{1-8} hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, carboxy, amino, mono- or di- C_{1-4} hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C_{1-8} hydrocarbyl group may optionally be replaced by O, S, SO, SO_2 , NR^c , $X^1C(X^2)$, $C(X^2)X^1$ or $X^1C(X^2)X^1$;

R^c is selected from hydrogen and C_{1-4} hydrocarbyl; and

X^1 is O, S or NR^c and X^2 is =O, =S or = NR^c .

31. A compound according to claim 30 wherein E is represented by the formula:




15

where P, Q and T are the same or different and are selected from N, CH and NCR^{10} , provided that the group A is attached to a carbon atom.

32. A compound according to claim 31 wherein the group E is selected from groups B1 to B13 in Table 2.
- 20 33. A compound according to any one of claims 3 to 31 wherein R^1 is selected from optionally substituted phenyl, naphthyl, thienyl, furan, pyrimidine and pyridine.
34. A compound according to claim 33 wherein R^1 is optionally substituted phenyl.
35. A compound according to any one of claims 3 to 31, 33 and 34 wherein R^1 is unsubstituted or bears one or more substituents selected from hydroxy; C_{1-4} acyloxy; fluorine; chlorine; bromine; trifluoromethyl; cyano; $CONH_2$; nitro; C_{1-4} hydrocarbyloxy and C_{1-4} hydrocarbyl each optionally substituted by C_{1-2} alkoxy, carboxy or hydroxy; C_{1-4} acylamino; benzoylamino; pyrrolidinocarbonyl;
- 25

- piperidinocarbonyl; morpholinocarbonyl; piperazinocarbonyl; five and six membered heteroaryl and heteroaryloxy groups containing one or two heteroatoms selected from N, O and S; phenyl; phenyl-C₁₋₄ alkyl; phenyl-C₁₋₄ alkoxy; heteroaryl-C₁₋₄ alkyl; heteroaryl-C₁₋₄ alkoxy and phenoxy, wherein the heteroaryl, heteroaryloxy, phenyl, phenyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkoxy, heteroaryl-C₁₋₄ alkyl, heteroaryl-C₁₋₄ alkoxy and phenoxy groups are each optionally substituted with 1, 2 or 3 substituents selected from C₁₋₂ acyloxy, fluorine, chlorine, bromine, trifluoromethyl, cyano, CONH₂, C₁₋₂ hydrocarbyloxy and C₁₋₂ hydrocarbyl each optionally substituted by methoxy or hydroxy.
- 5
- 10 36. A compound according to claim 35 wherein R¹ is unsubstituted or is substituted by up to 5 substituents selected from hydroxy; C₁₋₄ acyloxy; fluorine; chlorine; bromine; trifluoromethyl; cyano; C₁₋₄ hydrocarbyloxy and C₁₋₄ hydrocarbyl optionally substituted by C₁₋₂ alkoxy or hydroxy; and five membered heteroaryl groups containing one or two heteroatoms selected from N, O and S, the heteroaryl groups being optionally substituted by one or more C₁₋₄ alkyl substituents.
- 15
37. A compound according to claim 36 wherein R¹ is unsubstituted or is substituted by up to 5 substituents selected from hydroxy, C₁₋₄ acyloxy, fluorine, chlorine, bromine, trifluoromethyl, cyano, C₁₋₄ hydrocarbyloxy and C₁₋₄ hydrocarbyl optionally substituted by C₁₋₂ alkoxy or hydroxy.
- 20 38. A compound according to claim 36 or claim 37 wherein R¹ is unsubstituted or is substituted by 0, 1, 2, 3 or 4 substituents, preferably 0, 1, 2 or 3, and more preferably 0, 1 or 2 substituents.
39. A compound according to claim 38 wherein the group R¹ has one or two substituents selected from fluorine, chlorine, trifluoromethyl, methyl and methoxy.
- 25 40. A compound according to claim 39 wherein R¹ is a mono-chlorophenyl or dichlorophenyl group.
41. A compound according to any one of claims 3 to 40 wherein R² and R³ are independently selected from hydrogen, C₁₋₄ hydrocarbyl and C₁₋₄ acyl.
42. A compound according to claim 41 wherein R² and R³ are independently selected from hydrogen and methyl.
- 30


43. A compound according to claim 42 wherein R^2 and R^3 are both hydrogen.
44. A compound according to any one of claims 3 to 43 wherein the cyclic group HET has 4 to 6 ring members, for example 5 or 6 ring members.
45. A compound according to claim 44 wherein the cyclic group HET is an optionally substituted monocyclic heteroaryl group.
46. A compound according to claim 45 wherein the monocyclic heteroaryl group is selected from pyridine, pyrimidine, pyrazine, thiophene, furan, oxazole, triazole and imidazole, with pyridine being particularly preferred.
47. A compound according to any one of claims 3 to 46 wherein the cyclic group HET takes the form:



where Q^x is a hydrogen bond acceptor atom or group.

48. A compound according to claim 47 wherein the cyclic group HET is as defined in Table 3 herein.


49. A compound according to claim 47 or claim 48 wherein the cyclic group HET contains a hydrogen bond donor group adjacent the group G and hence the cyclic group HET takes the form:



where Q^x is a hydrogen bond acceptor atom or group and D is a hydrogen bond donor group.


50. A compound according to claim 49 wherein the hydrogen bond donor group is selected from NH , $C-NH_2$, $C-NH$, $C-OH$, $C-SH$ and $C-H$.
51. A compound according to any one of claims 3 to 50 wherein R^4 is selected from hydrogen and methyl.

52. A compound according to any one of claims 3 to 51 wherein R^5 is selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, hydroxyethyl, methoxymethyl, cyano, CF_3 , NH_2 , $NHCOR^{9b}$ and $NHCONHR^{9b}$ where R^{9b} is phenyl or benzyl optionally substituted by hydroxy, C_{1-4} acyloxy, fluorine, chlorine, bromine, trifluoromethyl, cyano, C_{1-4} hydrocarbyloxy and C_{1-4} hydrocarbyl optionally substituted by C_{1-2} alkoxy or hydroxy.
53. A compound according to claim 3 having the general formula (II):




wherein the group A is attached to the *meta* or *para* position of the benzene ring, q is 0-4; R^1 , R^2 , R^3 , R^4 , R^5 and R^8 are as defined in any one of the preceding claims.

54. A compound according to claim 52 wherein q is 0, 1 or 2, more preferably 0 or 1 and most preferably 0.
55. A compound according to claim 53 or 54 wherein the group A is attached to the *para* position of the benzene ring.
56. A compound according to any one of claims 53 to 55 having the formula (III):




where A' is the residue of the group A and R¹ to R⁴ are as defined in any one of the preceding claims.

57. A compound according to claim 56 having the formula (IV):




- 5 wherein z is 0, 1 or 2, R²⁰ is selected from hydrogen, methyl, hydroxy and fluorine and R¹ to R⁴ are as defined in any one of the preceding claims, provided that when z is 0, R²⁰ is other than hydroxy.

58. A compound according to claim 56 having the formula (V):




- 10 wherein R¹ and R³ to R⁴ are as defined in any one of the preceding claims.

59. A compound according to claim 58 wherein R³ is selected from hydrogen and C₁₋₄ hydrocarbyl, for example C₁₋₄ alkyl such as methyl, ethyl and isopropyl.
60. A compound according to claim 59 wherein R³ is hydrogen.
61. A compound according to claim 3 having the formula (VI):



wherein T is N or CH, n is 0, 1 or 2 (preferably 0 or 1, and more preferably 0), R¹⁶ is selected from hydrogen and amino; and A, E and R¹ to R⁴ are as defined in any one of the preceding claims.

- 5 62. A compound according to claim 60 wherein E is a phenyl group.
63. A compound according to claim 59 or claim 60 wherein R⁴ is absent (i.e. n is 0).
64. A compound according to any one of claims 60 to 62 which is represented by the formula (VII);



- 10 65. A compound according to claim 64 wherein T is CH and R¹⁶ is hydrogen.
66. A compound according to claim 64 wherein T is N.
67. A compound according to claim 66 wherein R¹⁶ is amino.
68. A compound according to any one of claims 3 to 67 having a molecular weight no greater than 1000, more usually less than 750, for example less than 700, or less than 650, or less than 600, or less than 550.
- 15


69. A compound according to claim 68 wherein the molecular weight is less than 525 and, for example, is 500 or less.
70. A compound according to any one of claims 3 to 69 in the form of a salt, solvate (such as a hydrate), ester or N-oxide.
- 5 71. A compound as defined in any one of claims 3 to 70 for use in medicine.
72. A compound as defined in any one of claims 1 to 70 for use in the prophylaxis or treatment of a disease state or condition mediated by protein kinase B.
73. The use of a compound as defined in any one of claims 1 to 70 for the manufacture of a medicament for the prophylaxis or treatment of a disease state or condition
10 mediated by protein kinase B.
74. A method for the prophylaxis or treatment of a disease state or condition mediated by protein kinase B, which method comprises administering to a subject in need thereof a compound as defined in any one of claims 1 to 70.
75. A method for treating a disease or condition comprising or arising from abnormal
15 cell growth in a mammal, which method comprises administering to the mammal a compound as defined in any one of claims 1 to 70 in an amount effective in inhibiting abnormal cell growth.
76. A method for treating a disease or condition comprising or arising from abnormal
20 cell growth in a mammal, the method comprising administering to the mammal a compound as defined in any one of claims 1 to 70 in an amount effective to inhibit PKB activity.
77. A method of inhibiting a protein kinase B, which method comprises contacting the kinase with a kinase-inhibiting compound as defined in any one of claims 1 to 70.
78. A method of modulating a cellular process by inhibiting the activity of a protein
25 kinase B using a compound as defined in any one of claims 1 to 70.
79. A method for treating an immune disorder in a mammal, the method comprising administering to the mammal a compound as defined in any one of claims 1 to 70 in an amount effective to inhibit PKB activity.

80. A compound as defined in any one of claims 1 to 70 for use in the prophylaxis or treatment of a disease state or condition mediated by protein kinase A.
- 5 81. The use of a compound as defined in any one of claims 1 to 70 for the manufacture of a medicament for the prophylaxis or treatment of a disease state or condition mediated by protein kinase A.
82. The use of a compound of the formula (I) as defined in any one of claims 1 to 70 for the manufacture of a medicament for the prophylaxis or treatment of a disease state or condition arising from abnormal cell growth.
- 10 83. The use of a compound of the formula (I) as defined in any one of claims 1 to 70 for the manufacture of a medicament for the prophylaxis or treatment of a disease in which there is a disorder of proliferation, apoptosis or differentiation.
84. A method for the prophylaxis or treatment of a disease state or condition mediated by protein kinase A, which method comprises administering to a subject in need thereof a compound as defined in any one of claims 1 to 70.
- 15 85. A method for treating a disease or condition comprising or arising from abnormal cell growth in a mammal, the method comprising administering to the mammal a compound as defined in any one of claims 1 to 70 in an amount effective to inhibit PKA.
- 20 86. A method of inhibiting a protein kinase A, which method comprises contacting the kinase with a kinase-inhibiting compound as defined in any one of claims 1 to 70.
87. A method of modulating a cellular process by inhibiting the activity of a protein kinase A using a compound as defined in any one of claims 1 to 70.
- 25 88. A method for treating an immune disorder in a mammal, the method comprising administering to the mammal a compound as defined in any one of claims 1 to 70 in an amount effective to inhibit PKA activity.
89. A method of inducing apoptosis in a cancer cell, which method comprises contacting the cancer cell with a compound as defined in any one of claims 1 to 70.


90. A pharmaceutical composition comprising a novel compound as defined in any one of claims 1 to 70 and a pharmaceutically acceptable carrier.
91. A compound as defined in any one of claims 1 to 70 for use in medicine.
92. A process for the preparation of a compound of the formula (I) as defined in any one of claims 1 to 70, which process comprises:
- 5 (a) the reaction of a compound of the formula (X) with a compound of the formula (XI) or an N-protected derivative thereof:



- wherein A, E, and R^1 to R^4 are as defined in any one of the preceding claims, one of the groups X and Y is selected from chlorine, bromine, iodine and trifluoromethanesulphonate, and the other one of the groups X and Y is a boronate residue, for example a boronate ester or boronic acid residue, in the presence of a palladium catalyst and a base;
- 10 (b) the reductive amination of a compound of the formula (XXXVI):



- 15 with HNR^2R^3 in the presence of a reducing agent; and optionally
- (c) the conversion of one compound of the formula (I) into another compound of the formula (I).
93. A process according to claim 92, variant (a) wherein the compound of the formula (X) is prepared by the reaction of a compound of the formula (LXX):



with a compound of the formula $\text{R}^1\text{-H}$ under Friedel Crafts alkylation conditions, for example in the presence of an aluminium, halide (e.g. AlCl_3).

INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2006/002278

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D333/20 C07D401/10 A61K31/381 A61K31/4409 A61K31/506
C07D307/52 A61K31/341 C07D249/08 A61K31/4196 C07D213/38
A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00/14066 A (PFIZER PRODUCTS INC; LIRAS, SPIROS) 16 March 2000 (2000-03-16) cited in the application compounds 20, 23 and 27 (pages 19, 21 and 24)	3,57
X	WO 00/39091 A (PFIZER PRODUCTS INC; LIRAS, SPIROS; ALLEN, MARTIN, PATRICK; SEGELSTEIN) 6 July 2000 (2000-07-06) cited in the application	3
A	claim 1	57
A	WO 91/11445 A (THE DU PONT MERCK PHARMACEUTICAL COMPANY) 8 August 1991 (1991-08-08) cited in the application claim 1	3,60
	----- -/-- -----	

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

9 October 2006

Date of mailing of the international search report

19/10/2006

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

SAHAGUN KRAUSE, H

INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2006/002278

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 03/011855 A (VERTEX PHARMACEUTICALS INCORPORATED; HALE, MICHAEL, ROBIN; JANETKA, JA) 13 February 2003 (2003-02-13) page 56 - page 57; claim 1 -----	1
P,A	WO 2005/061463 A (ASTEX TECHNOLOGY LIMITED; CANCER RESEARCH TECHNOLOGY LIMITED; THE INST) 7 July 2005 (2005-07-07) claim 1 -----	1
A	US 6 200 978 B1 (MAW GRAHAM NIGEL ET AL) 13 March 2001 (2001-03-13) the whole document, especially preparations 73 and 74 -----	3

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Although claims 73-78 and 83-88 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box II.2

Claims Nos.: 1-92 (part)

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claims 1-92 may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, the search was performed taking into consideration the non-compliance in determining the extent of the search of claims 1-92 .

The search of claims 1-92 was restricted to: 57, 60 and its dependent claims (including use).

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB2006/002278

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-92 (part)
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 73-78 and 83-88 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 1-92 (part)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2006/002278

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0014066	A	16-03-2000	AT 312819 T	15-12-2005
			AU 749096 B2	20-06-2002
			AU 5383799 A	27-03-2000
			BG 105411 A	31-12-2001
			BR 9913512 A	05-06-2001
			CA 2343236 A1	16-03-2000
			CN 1316993 A	10-10-2001
			CZ 20010850 A3	12-12-2001
			DE 69928945 T2	27-07-2006
			EE 200100145 A	17-06-2002
			EP 1112255 A1	04-07-2001
			ES 2252960 T3	16-05-2006
			HR 20010167 A2	28-02-2002
			HU 0103542 A2	28-01-2002
			ID 29129 A	02-08-2001
			JP 2002524445 T	06-08-2002
			MA 26686 A1	20-12-2004
			NO 20011183 A	04-05-2001
			NZ 509841 A	29-08-2003
			OA 11648 A	08-12-2004
			PL 346648 A1	25-02-2002
			SK 3032001 A3	04-04-2002
			TR 200100694 T2	22-10-2001
			ZA 200101744 A	03-06-2002
WO 0039091	A	06-07-2000	AT 266637 T	15-05-2004
			AU 760874 B2	22-05-2003
			AU 1290500 A	31-07-2000
			BG 105731 A	28-02-2002
			BR 9916680 A	13-11-2001
			CA 2350589 A1	06-07-2000
			CN 1332727 A	23-01-2002
			CZ 20012388 A3	11-09-2002
			DE 69917327 D1	17-06-2004
			DE 69917327 T2	04-05-2005
			DK 1140835 T3	09-08-2004
			EE 200100347 A	16-12-2002
			EP 1140835 A1	10-10-2001
			ES 2220127 T3	01-12-2004
			HR 20010491 A2	31-08-2002
			HU 0105075 A2	29-04-2002
			ID 29052 A	26-07-2001
			JP 2002538083 T	12-11-2002
			MA 26716 A1	20-12-2004
			NO 20013237 A	28-08-2001
			NZ 511791 A	29-08-2003
			OA 11743 A	13-05-2005
			PL 348668 A1	03-06-2002
			PT 1140835 T	30-07-2004
			SK 9012001 A3	03-12-2002
			TR 200101978 T2	21-12-2001
			ZA 200104255 A	24-06-2002
WO 9111445	A	08-08-1991	AT 131475 T	15-12-1995
			AU 632905 B2	14-01-1993
			AU 7222891 A	21-08-1991
			CA 2074723 A1	24-07-1991
			DE 69115468 D1	25-01-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/GB2006/002278

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9111445	A		DE 69115468 T2	23-05-1996
			EP 0513149 A1	19-11-1992
			GR 3019121 T3	31-05-1996
			HK 1006840 A1	19-03-1999
			IE 910207 A1	31-07-1991
			JP 3053428 B2	19-06-2000
			JP 5507904 T	11-11-1993
			NZ 236850 A	26-01-1994
			US 5049570 A	17-09-1991
			ZA 9100490 A	30-09-1992
WO 03011855	A	13-02-2003	AU 2002321910 A1	17-02-2003
			CA 2456192 A1	13-02-2003
			EP 1423382 A2	02-06-2004
			JP 2005500353 T	06-01-2005
			MX PA04001087 A	08-07-2004
WO 2005061463	A	07-07-2005	AU 2004303602 A1	07-07-2005
			CA 2548374 A1	07-07-2005
			EP 1706385 A1	04-10-2006
US 6200978	B1	13-03-2001	BR 9917527 A	23-07-2002
			CA 2263957 A1	05-09-1999
			JP 3416069 B2	16-06-2003
			JP 2000016984 A	18-01-2000